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Is life just a game where we make up the rules, 
While we're searching for something to say, 
Or are we just simply spiralling coils, 
Of self-replicating DNA? 
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(Different sections of the introduction and discussion are based on the chapter “Detecting copy 
number changes in genomic DNA - MAPH and MLPA”, White S.J., Breuning M.H., and den 
Dunnen J.T.  In Cytometry 4ed, Volume 75 of the Methods in Cell Biology, in press). 
 
 
It has long been recognized that some diseases run in the family. A classic example of this is 
hemophilia, which affected several European royal families descended from the English monarch 
Queen Victoria.  Following the discovery of DNA as the hereditary material it became clear that 
it was changes in DNA that were responsible for many diseases, some inherited and some that 
appeared to have arisen spontaneously.  
In principle there are 3 ways that the DNA within a genome can be changed. Qualitative 
alterations involve changes of one or more nucleotides in a given stretch of DNA, either by 
substitution or chemical modification. Positional rearrangements occur when a sequence moves 
from one specific location to another, for example translocations and inversions. The last class of 
changes are the quantitative rearrangements, involving the gain or loss of segments of DNA. 
The purpose of the research described in this thesis is the development and optimization of 
techniques for detecting such duplications and deletions in genomic DNA. Many different 
methods for detecting copy number changes have been described (reviewed in (1)). The most 
commonly applied techniques to date have been FISH (Fluorescent In Situ Hybridization), 
Southern blotting (sometimes combined with Pulse-Field Gel Electrophoresis (PFGE)), and 
quantitative PCR. FISH combines hybridization of a fluorescently labeled probe with microscopic 
analysis of genomic DNA (2-4). Because of its relative reliability and ease of analysis, the 
technique has been widely used in diagnostic laboratories. Its main disadvantages are the 
workload involved, i.e. culturing cells, making chromosome preparations and performing 
hybridizations, and the fact that deletions smaller than ~40 kb cannot be routinely detected.  
As an alternative, Southern blotting has also been broadly applied for the detection of deletions 
and duplications (5,6). In addition one has the possibility to scan for the unique junction 
fragments of the rearrangements and use these for diagnosis (7). Although this latter possibility 
requires some effort to identify a junction fragment, when found it does provide a powerful 
diagnostic tool. In this respect, the combination of PFGE and Southern blotting can be very 




(7,8). The problem with Southern blotting is that it is time consuming, and producing blots of the 
necessary quality is technically demanding. 
Quantitative PCR has been tried by many (9,10) but has also turned out to be challenging and 
difficult to implement. Recently, the development of real-time PCR technology revived the 
diagnostic application of quantitative PCR (11-13) but it failed to take away another drawback, 
the difficulty of multiplexing, i.e. measuring copy number changes of several DNA sequences in 
parallel. 
The development of new diagnostic methods is made easier by having a series of samples with 
known mutations to test. Within the department of Human and Clinical Genetics in Leiden 
several hundred DNA samples from patients suffering from Duchenne Muscular Dystrophy have 
been collected over the years.   As is made clear in the next section, there are several features of 




A. Duchenne Muscular Dystrophy 
 
In 1852 the English physician Meryon described nine boys affected by muscle wasting and 
weakness (14).  He noted that it appeared to be of muscular rather than nervous origin, and 
described the degeneration of the voluntary muscular tissue. The same form of disease was 
discussed further by Duchenne in 1868 (described in (15)). He wrote about a disorder affecting 
primarily males, often familial and characterized by weakness of the lower musculature from an 
early age. This would spread to the upper body, and death from cardiac or respiratory failure 
usually occurred before the age of 20. This disease is now known as Duchenne Muscular 
Dystrophy (DMD). 
The fact that it affected almost exclusively males meant that the causative gene was probably on 
the X chromosome. Ironically enough it was the extremely rare cases affecting females that first 
provided the clue as to where the gene was on the X chromosome.  If a female had a translocation 
disrupting the gene affected in muscular dystrophy, the unaffected X-chromosome becomes 
inactivated and there will be no product from the DMD gene. This individual would then show all 
the manifestations of DMD. Combined analysis of such translocation cases (16-18), along with a 
cytogenetically visible deletion in a male patient (19), and restriction fragment length 
polymorphisms (RFLPs) (20,21) defined the breakpoint to a region on the short arm of the X 
chromosome, within the band Xp21.  Further mapping defined the location of the gene more 




The gene remains the largest known, covering ~2.4 Mbases (24,25). It is composed of 79 exons 
(26), and there are at least 7 alternative promoters, leading to a number of different isoforms 
(Figure 1). The exons make up <1% of the total gene size, and the introns vary greatly in size, 




The protein product of the DMD gene is known as dystrophin. The full-length product from the 
muscle promoter has a molecular weight of 427 kDa (27), and is found primarily in skeletal and 
cardiac muscle. Other isoforms also show specific patterns of expression, and can be found in 
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Figure 1.  The DMD gene. In this diagram the promoter for the muscle isoform (Dp427m) is shown as exon 1, and the 
locations of the other  promoters are indicated with arrows. Every 10th exon is numbered.  
 
The amino terminal domain shows homology to the amino terminus of alpha-actin, and binds to 
the actin cytoskeleton (32). The central rod domain is the largest part of the protein, and is 
composed of a series of coiled-coil repeats.  This is followed by a cystein-rich domain, and finally 
a carboxy terminal domain that interacts with several different proteins in the dystrophin-
glycoprotein complex (33). The primary function of the protein appears to be structural, linking 
the cytoskeleton with the extracellular matrix. There is recent evidence that dystrophin may also 
be involved in different cell signalling pathways (34,35). 
 
Deletion/duplication detection in patients 
 
Cytogenetically invisible deletions were first detected with probes derived either randomly (36), 
from a region known to be missing in a patient (37), or a translocation breakpoint (38,39). Prior to 
the cloning of the cDNA it was shown by Pulse-Field Gel Electrophoresis (PFGE) that gross 
deletions and duplications could be found in >50% of DMD cases (7). By using cDNA fragments 
as a probe it was possible to examine the entire gene for both deletions and duplications using 
Southern blotting (40).  This and other work showed that a deletion of one or more exons 
occurred in  ~65% of cases, with the duplication frequency being estimated at 6% (41,42). The 
deletions clustered in 2 regions; a major hotspot between exons 45-52 and a minor hotspot 
between exons 2-19 (41,43,44). This clustering allowed for ~95% of all deletions in patients to be 
detected using 2 multiplex PCR kits, each amplifying 9 exons (45,46). These primer sets were 
later expanded and modified using fluorescently-labelled primers and dosage analysis, allowing 
duplications to be detected as well (9,10). 
More recently, MAPH probe sets have been developed covering each of the 79 exons (47) 




that had not been previously detected using other techniques.  Noteworthy here is that a 
duplication of exon 2 was the most common duplication found, yet had never been reported using 
alternative methods e.g. Southern blotting.   
The ability to precisely determine the breakpoints led to an explanation for the difference in 
severity seen between DMD and Becker Muscular Dystrophy (BMD). BMD is milder, with the 
patients generally showing a later age of onset, slower disease progression and increased life 
expectancy. There are many cases where the deletion of a single exon is sufficient to cause DMD, 
whereas deletions of nearly half the gene have been found in BMD patients (48,49). Analysis of 
the breakpoints of the deletions lead to the development of the reading frame hypothesis (50).  
The theory was that mutations that disrupted the reading frame lead to a truncated protein, which 
could not carry out its physiological role of connecting the intracellular skeleton with the 
extracellular matrix.  This destabilized the muscle cell, leading to all the symptoms of the disease. 
In contrast, an in-frame deletion would shorten the protein, but the presence of both the N-
terminus and C-terminus would ensure that the protein would be at least partly functional, 
connecting the cytoskeleton and extra-cellular matrix.  
Based on DNA analysis only, this theory is valid in about 90% of cases. Exceptions have been 
described, both for DMD patients with in-frame deletions and BMD with out-of-frame deletions. 
These are most commonly found at the 5' end of the gene (51). In-frame mutations causing DMD 
are either large or remove a domain essential for dystrophin function, whereas out-of-frame 
mutations causing BMD are presumably compensated for, either by the use of an alternative start 




In ~30% of cases no exonic deletion or duplication can be detected.  The most common mutation 
in this subset of patients are changes of one or a few nucleotides leading to a truncated transcript, 
either via a premature stop codon or the disruption of the reading frame. Missense mutations have 
been rarely described (55-57). Given the large size of the gene and the fact that there are no 
apparent hot spots for point mutations, finding them is a time-consuming process. Screening for 
these changes has been performed by a number of different techniques, including heteroduplex 
analysis (58,59), denaturing high-performance liquid chromatography (DHPLC) (60), single 
strand conformation polymorphism (SSCP) (61), denaturing gradient gel electrophoresis (DGGE) 




With the advances in screening technology it is now possible to detect the causative mutation in 
~96% of patients by screening at the DNA level (64). The use of RNA-based techniques, such as 
RT-PCR and the protein truncation test (PTT) (65,66), afford the possibility of detecting changes 
located deep within introns that activate cryptic splice sites (67,68), further increasing the 
detection rate. The disadvantages of using RNA relate primarily to the source. The amount of the 
dystrophin transcript within lymphocytes is very low, while the best mRNA source, a muscle 
biopsy,  is not always easy to obtain. 
There are several possible reasons as to why no mutations are found in the remainder of the 
patients. It may be that some patients do not have DMD, but instead suffer from another 
neuromuscular disorder. If the absence of dystrophin has not been confirmed it may be difficult to 
distinguish DMD from a severe form of limb-girdle muscular dystrophy purely on the clinical 
symptoms. Another, less likely, possibility is that there is a mutation in another gene that 
influences the regulation of dystrophin expression. 
Knowing the mutation is not only important for confirming the diagnosis, but may also be a 
critical first step towards therapeutic intervention. Several different gene therapy strategies have 
been described for DMD (reviewed in (69)).  For the mutation-specific approaches e.g. exon 




Finding the mutation is not only of importance for the patient. It also facilitates the genetic 
counseling of relatives who may be carriers. Prior to genetic testing this was primarily based on 
biochemical assays, of which elevated serum creatine kinase was the most common (72). The 
discovery of the DMD gene meant that a DNA-based test was possible, and most of the 
techniques applied for mutation screening in males are also applicable for testing females (73). In 
the early years of genetic testing it was not always possible to find the causative mutation in the 
patient.  This made the determination of carrier status particularly difficult, often relying on 
haplotype analysis (74-77). 
Identifying the mutation in the index patient simplifies carrier detection, as the entire gene no 
longer needs to be screened. Heterozygosity for a point mutation can be determined by 
sequencing. Different approaches have been described for determining the carrier status in cases 
involving a deletion or duplication (78,79). They are based around the analysis in the maternal 
DNA of an exon or exons known to be affected in the patient, and comparing these with a region 




An important point to be considered in carrier testing is the possibility of somatic or germ line 
mosaicism (80-83). In a somatic mosaic case the mutation may be present in only a percentage of 
maternal cells. A negative result may be concluded, as the normal cells have masked the mutation 
present in the affected cells.  Germ-line mosaicism will not be detectable in DNA isolated from 
blood cells. The frequency of mosaic cases has been estimated to be up to 14% (84). The high 
recurrence risk for apparently de novo mutations means that prenatal screening is still offered for 
females that have tested negative for carrier status. 
 
How do deletions and duplications occur? 
 
DMD is an unusual disease in that the majority of mutations found are deletions or duplications 
of one or more exons. Such rearrangements are also found in other diseases, but at a lower 
frequency. A great deal of effort has therefore gone into studying the mechanisms involved in 
these aberrant recombination events. It is known that the precursor for recombination is the 
double stranded break, or DSB. This occurs during normal cellular processes, for example 
recombination in meiosis (85,86) and V(D)J recombination in antibody processing (87). Less 
beneficially, it can also be caused by damaging environmental factors, such as ionizing radiation 
or free radicals. 
When a DSB occurs, an attempt will be made by the cell to rejoin the free ends of the DNA 
molecule. Two main pathways are known to be involved (88,89), namely homologous 
recombination and non-homologous end joining. Both pathways are highly conserved from 
bacteria to humans, indicating the fundamental importance of the process (90,91).  
 
Homologous recombination  
 
Homologous recombination (HR) is a process that uses an intact template for the repair of a DSB. 
Once a DSB is recognized, a protein complex at the site is formed, and there is a partial 5' to 3' 
resection at the ends.  Following strand invasion into an intact, homologous DNA molecule, an 
extension reaction by a DNA Polymerase fills in the gap. Precisely how the different strands are 
resolved will determine whether or not crossing over and/or gene conversion will occur (88). 
Non-allelic homologous recombination (NAHR) can occur when two highly similar sequences 
misalign. Following a DSB the two homologous sequences are aligned, and crossing over occurs.  
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specific (100), and can be divided into different groups on the basis of evolutionary age.  These 
are present in ~1 million copies in each genome (92), or on average once every 3 kb. In contrast 




Segmental duplications, also known as low copy repeats (LCRs), are defined as stretches of 
DNA, usually between 1-500 kb and with a high degree of homology (>90%), which are present 
in at least two copies within the genome (103).  Such duplicated blocks have not been found in 
invertebrates, and occur more frequently in humans than lower mammals, for example the rat 
(104) or mouse (105). In total they comprise ~5 % of the human genome (103,106,107). A 
notable feature of LCR sequences in humans is the high frequency of Alu sequences found at the 
boundaries of segmental duplications (108). As it was predominantly the younger Alu sequences 
that were detected it was suggested that a large increase of Alu retroposition approximately 35 
million years ago was the initial trigger for widespread, primate specific, duplication events 
(109). LCRs are found both interchromosomally and intrachromosomally. 
 
Interchromosomal LCRs  
 
Although these repeats are distributed throughout the genome, they predominate in the 
subtelomeric and pericentromeric regions. The reason for this is not known, but it has been 
suggested that such regions show an increased propensity for repeat accumulation (110), or that 
they are simply more tolerant for rearrangements. 
These areas show high rates of recombination, with blocks of repeat units being duplicated and 
exchanged between multiple chromosomes. An example of such plasticity is found in the 
subtelomeric regions of the long arms of chromosomes 4 and 10, where swapping of repeat arrays 
between 4q and 10q has been reported to occur in 20% of the Dutch population (111,112). In 
addition, subtelomeric screening using FISH probes has shown a high degree of cross-
hybridization across different chromosomes (113). The degree of recombination and sequence 
similarity of such regions has significantly hampered the sequencing of these areas, and it is 
noticeable that it is often these areas that remain as gaps in the “completed” human genome draft 
sequence (114).  
Repeats on different chromosomes can lead to translocations, and there have been several 




the chromosomal rearrangements that have occurred during speciation are also mediated by 
LCRs, as studies have shown a correlation between such sequences and syntenic breakpoints 




Intrachromosomal LCRs, also known as chromosome-specific duplications, are usually found on 
the same chromosome arm (106,120). Although there is a pericentric bias in localization for 
several chromosomes, in general such duplicons appear to be more evenly distributed throughout 
the chromosome than the interchromosomal repeats (103,106).   
Several regions between the repeats show a recombination rate higher than would be expected 
due to random events, and many different disorders are known to be caused by NAHR between 
flanking LCRs (Table 1). Bailey et al. found 169 regions between 50 kb and 10 Mb flanked by 
low copy repeats (106), with rearrangements of 24 of these found in locations associated with 
specific disorders. It remains to be seen whether any of the remaining regions are also rearranged 
in other diseases. 
Despite the fact that the LCR duplicons are often several hundreds of kilobases in length, the 
exact position of the breakpoints in different patients often shows a preference for a smaller, 
defined region (121). An explanation for this could be that the increased length of the duplicons 
allows (mis)alignment to take place, yet more specific sequences within the LCRs are actually 
involved in the recombination.  It has been proposed that at least 200-500 bp of almost complete 
homology (minimal efficient processing segment; MEPS) is required for recombination 
(122,123). Additional factors are also involved in influencing the probability of recombination. 
For example, inversion polymorphisms can increase the chance of a rearrangement occurring 
between 2 repeats. This has been shown to be the case in the region affected in Williams-Beuren 
Syndrome (124,125), as well as between olfactory repeat genes in 8p23.1 (126,127). 
To date all of the LCRs associated with human disease have been shown to be primate specific 
(110), and it is possible to give an approximate date to the origin of different LCRs with 
interspecies comparison. It has been suggested that some primate-specific characteristics have 








Disorder Locus Size of 
LCR 
(kb) 






Sotos 5q35 140 1300-2700 deletion (128-130) 
Williams-Beuren 7q11.23 320 1600 deletion (125,131-134) 
Angelman/Praeder-
Willi 
15q12 500 3500 deletion (135,136) 
Smith-Magenis 17p11.2 200 3700 deletion (121,137-139) 
HNPP 17p12 24 1400 deletion (122,140,141) 
Charcot Marie 
Tooth 
17p12 24 1400 duplication (141-144) 
Neurofibromatosis 
Type 1 
17q11 85 1500 deletion (145-148) 
Di George 22q11.2 200-
400 
1500-3000 deletion (149-151) 
Emery Muscular 
Dystrophy 




Haemophilia A Xq28 10 300-500 inversion (155-157) 
 
Table 1.  A selection of regions known to be altered via recombination between specific Low Copy Repeats (LCRs). 
Described are the rearrangements that occur, the size of such rearrangements and the associated LCRs, and the 
corresponding disorder.  
 
Non-homologous end joining  
 
Non-homologous end joining (NHEJ) is a poorly understood process, where two DNA ends 
without significant sequence homology are joined. As the repair is not template based errors 
frequently occur, and deletions and insertions are often found at the junction. Breakpoints within 
a given region show less clustering compared to HR, although several sequences have been 
implicated in increasing the probability of a DSB (158).  An example of such is the Chi sequence, 
which is a nonamer involved with recombination in prokaryotes (159) and has been linked with 
deletions in several different human disease genes (160-163). Alu sequences also have a 26 bp 




in both HR and NHEJ. Detailed analysis of a series of deletion breakpoints showed that the 
presence of inverted repeats was a common motif in deletions, especially those suggestive of 
NHEJ i.e. deletions plus small insertions (165). It was proposed that stem-loop formation was 
responsible for the DSB.  
NHEJ is a faster process than HR, which may explain why the majority of DSBs in mammalian 
cells are repaired by NHEJ (166). Which of the two repair pathways is used is presumably at least 
partially dependent on the position within the cell cycle, with HR being preferred when a sister 
chromatid is present (167). 
 
Rearrangements within the DMD gene. 
 
Given the above information, what can be said about the cause of the rearrangements found 
within the DMD gene? Although deletions can be found throughout the entire gene, they cluster 
within 2 areas.  These regions also correspond to the location of the largest introns, and the larger 
introns do tend to show an increased number of breakpoints. Intron 44 is the largest intron within 
the gene, at ~248 kb, and 35% of all deletions have one of the breakpoints within this intron.  
Analysis of the position of the breakpoints, however, reveals that any correlation between length 
and breakpoint frequency only holds for the 5' end of the breakpoint (figure 3). This is primarily 
due to a reduction in the number of 3' breaks in the two largest introns (only 15% of breakpoints 
in intron 44 are at the 3' end of a deletion, and in the case of intron 2 there are no 3' deletion 
breakpoints described) (Figure 4). The bias between 5' and 3' breakpoints suggests a directional 
influence in deletion formation, although it is unclear what causes the initial DSB. A direct 
association between meiotic DNA replication and DSB formation has been described in yeast 
(86), and the two recombination hotspots within the DMD gene colocalize with two of the most 
common deletion breakpoints, namely intron 7 and intron 44 (43).  
Pozzoli and colleagues have performed a detailed analysis of the repeat content of the introns, and 
found that 37% of the intronic sequences are repetitive elements (168,169).  A significant 
correlation between intron length and repeat content was found, suggesting that repeat expansion 
was at least part of the reason for the large introns found in the DMD gene. As repetitive 
sequences have been associated with recombination events, studies have been carried out to 
determine the exact sequences involved at the breakpoints (170-173).  In the majority of cases no 
































































ure 3.  The relationship between intron size and breakpoint frequency for deletions within the DMD gene.  
5' breakpoint frequency. B. 3' breakpoint frequency. The correlations are A; r=0.75, B; r=0.29. 
tween repetitive elements is not the predominant cause of rearrangements within the DMD 
ne.   
her factors may be involved that influence DNA conformation, increasing the probability of a 
B. Matrix attachment regions (MARs) are sequences of DNA that are involved in DNA 
ping and attachment to the protein scaffold (174). It has been proposed  that a relative paucity 
MAR sites might lead to greater torsional stress within these regions (171). This would then 
d to an increased probability of DNA breakage, which in turn would lead to an increased 
ance of a rearrangement. Correlations between Loop Anchorage Regions (LARs) and 
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re 4. The distinction between (A) 5' and (B)  3' deletion breakpoints. The reduction in 3' breakpoints of the two 
est introns (intron 2 and intron 44) is indicated by the arrows. 
tudy of DNA replication showed 6 origin of replication sites (oris) in the DMD gene (176), 
 ori sites have been associated with chromosomal fragility (177). One of the replication 
ination sites was within the major deletion hotspot, in intron 44. As this intron makes up 
% of the gene this could be coincidental, but it is known from studies in prokaryotes that such  
ination sites are also deletion hot spots (178). It has been shown in E. coli that in at least 
e cases this activity is also dependent on the presence of the Chi sequence (179) . A recent 
ort (180) also showed a co-localization of MARs and oris within the DMD gene, with one 
R falling within the major deletion hotspot.  
 argument for the importance of chromatin structure is strengthened by the findings of Passos-
no and colleagues (181). In their study on deletion distribution in mosaic cases they found 
 
  
that distal deletions were found in 72% of isolated cases, with 28% of the deletions occurring in 
the proximal region. Conversely the distribution between the proximal and distal regions amongst 
inherited cases was virtually identical (47% and 53% respectively). This suggested that proximal 
deletions were more likely to occur early in development during mitosis, with a corresponding 
increased risk of recurrence. It is known that transcription is coupled with changes in chromatin 
structure, which in turn may alter the chances of recombination (85). This may lead to certain 
regions becoming more accessible/vulnerable during different stages of development. It is 
probable therefore that the combination of specific sequence interactions and chromatin structure 
also underlie the disparity seen between the 2 hotspots.   
Fewer studies have been carried out looking at the mechanisms involved in duplications. Analysis 
of 8 families showed that in each case the duplication originated from a single X chromosome, 
and unequal sister chromatid exchange was thought to be the mechanism responsible.  In 7 of the 
8 cases the results suggested that the mutation had occurred in the germline of the maternal 
grandfather (182,183).  It was proposed that, as spermatogenesis needs several hundred cell 
divisions and oogenesis as few as 23, mutations will occur more frequently in the male germline. 
This theory, however, is not supported by analysis of deletions, where the orginal mutational 
event has been traced to a female in the majority of cases (184,185). This bias in parental origin 
of different types of mutations has also been observed for other genes on the X chromosome 
(186,187). 
A more detailed study of three duplications showed that they were all duplicated in tandem (188). 
One case involved NAHR between two Alu sequences, whereas the other cases appeared to be 
derived from NHEJ, perhaps involving cleavage sites for DNA Topoisomerase enzymes. These 
proteins are known to be involved in DNA replication and transcription, breaking DNA 
molecules and altering chromatin conformation to allow these biological processes to take place 
(189,190).  
It was noted by den Dunnen et al (41) that duplications were more commonly found in the 
proximal region than in the distal region. A survey of the Leiden DMD database www.dmd.nl  
(26 October 2004) shows that 59% of all duplications have at least one breakpoint within the  
proximal region (delineated by exons 2-19), compared with only 20% of the deletions. The 
locations of the most frequently occurring duplications are significantly different to those of the 
most common deletions (table 2), again suggesting a fundamental difference in mutation 
mechanism and/or timing of the different rearrangements.  
Along with the differences in distribution, the relative frequency of specific regions being deleted 




single most common duplication seen, yet there has not been a single report of a deletion of  
exon2 only. Precisely why this is remains unclear. It may be that such a deletion is embryonically 
lethal, that a deletion of exon 2 is not disease causing, or that structural restraints greatly reduce 
the probability of such a rearrangement. Alternatively, the mechanism responsible for the 
duplications may not involve unequal crossing over. Our analysis (chapter 2.2) suggests that the 




ranking deleted exon(s) % ranking duplicated exon(s) % 
1 45-47 7.0 1 2* 8.5 
2 45 5.3 2= 3-7 3.5 
3 48-50 5.1 2= 8-9 3.5 
4 45-48 4.3 4= 2-7 3.0 
5 45-50 4.0 4= 51 3.0 
6 51 3.9 6= 3-11 2.0 
7 44 3.5 6= 8-13 2.0 
8 49-50 2.8 8= 3-4 1.5 
9= 3-7 2.3 8= 9-14* 1.5 
9= 45-52 2.3 8= 17 1.5 
11 46-47 2.3 8= 22-25* 1.5 
12 50 2.2 8= 43 1.5 
13 45-49 2.0 8= 44 1.5 
 
Table 2. The most frequently occurring deletions and duplications. It is clear that the region most commonly deleted is 
between exons 45-52; in contrast the duplications occur more frequently in the 5' end of the gene. A * indicates a 
duplication that has not been described as a deletion. 
 
In conclusion therefore, although repetitive sequences are undoubtedly involved in some 
recombination events, these cannot be the predominant reason for the rearrangements seen in the 
DMD gene. The evidence suggests that other features, such as structural and functional domains, 
as well as changes in chromatin and DNA topology during replication and transcription, also 
influence the probability of DNA breakage and subsequent recombination. These factors, along 
with the repair mechanisms involved, are likely to be cell type dependent, which may underly the 




B. MAPH and MLPA 
 
“The art of research [is] the art of making difficult problems soluble by devising means of getting 
at them” 
-Sir Peter Medawar 
 




The MAPH assay is based upon the quantitative recovery of probes following hybridization to 
immobilized genomic DNA. Probes for MAPH analysis were initially created by cloning small 
DNA fragments into a vector (191).  These fragments were generated either by PCR or restriction 
digestion of larger DNA constructs (e.g. PACs or BACs). The specific probes were then prepared 
by amplification from the vector using primers specific for the vector sequence.  The drawback of 
the cloning approach is that the preparation of a large number of probes is arduous and time 
consuming. 
An alternative method of probe preparation is to design primers to consist of two parts (192).  A 
unique section, which is used for the amplification from genomic DNA, and an identical 5' 
priming sequence, which is the same for each probe. Once each probe is amplified from genomic 
DNA the products can then be combined into a probe mix.  Because they all have the same ends 
the subsequent amplification can take place in exactly the same manner as for cloned probes. 
A potential disadvantage of this approach is that during the original PCR amplification from 
genomic DNA, more than one PCR product could be amplified. These extra products would then 
be present in the probe mix, and the extra peaks would appear on any subsequent trace.  In 
practice, however, we have not seen this as a common problem, and any problematical probes 
could be cloned and/or gel purified if necessary. 
There are several criteria that the probes need to conform to. First, each sequence must be unique. 
This can be tested using the BLAST (193) or BLAT (194) program to check the sequence against 
the genomic database.  Second, the hybridizing segment of each probe should ideally have a GC-
content of between 40% and 60%.  Some regions of the genome do not fall within these limits, 
and the probe length should be adjusted accordingly.  Probes for regions with a GC-content as 




For difficult regions of the genome it may be necessary to try several different sequences before a 
good probe is found. Third, it is essential that each probe is of a different length, allowing the 
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need to be marked in such a way that they can be easily distinguished from each other. It is 
possible to cut the filters into different shapes, but the most convenient method is to number each 
filter with a sharp pencil.  This mark will remain visible after all the washing steps. 
We have found that the easiest way of applying the DNA to the filter is to pipette each DNA 
sample into a well of micotiter plate, already containing the NaOH.  Each filter can then be put 






















Figure 6.  The use of a microtiter plate for applying denatured genomic DNA to the filters. The number on the filter 
held in the forceps can be clearly seen; this will remain easily visible after all the washing steps. 
 
After the filters are dry the DNA is fixed to the filter, either by UV cross-linking, or by heating 
the filters at 80 oC for 1 hour.  The filters are then combined in a prehybridization mixture for 2 
hours to overnight, followed by addition of the hybridization mix.  This mixture contains the 
probes of interest along with competitive DNA (e.g. Cot1, fragmented E. coli or herring sperm 
DNA as well as sequences that block any interactions between the common ends of the probes).  
After overnight incubation the hybridization mixture is removed, followed by stringent washing.  




beaker, as it is easier to recover filters from this than the U-bend of a sink.  Alternatively, a tea 
strainer or something similar can be used. 
Following the washing steps each filter is placed individually into a PCR tube containing 1x PCR 
buffer.  After heating to 95 oC for 5 minutes the previously bound probes are released into 
solution, and an aliquot of this is added to a PCR mix.   Optimization of the PCR reaction 





MLPA (195) is based upon the ligation of two adjacently-annealing oligonucleotides, followed by 
a quantitative PCR amplification of the ligated products. The left hand half-probe is usually the 
shorter of the two probes (typically 45-70 nt), and is chemically synthesized. This half-probe is 
composed of two sections, a unique, annealing sequence and terminal priming sequences 
common to all probes. The right hand half-probe can be up to 440 nt, which cannot be routinely 
synthesized.  Instead, a series of M13 vectors has been created, each with a “spacer” sequence of 
a different length (195). Two complementary oligonucleotides are annealed to each other, 
followed by ligation into the modified M13 vector. It is the spacer which determines the final 
length of the half probe. The resulting M13 construct containing the annealed oligonucleotides is 
isolated in single-stranded form, and the cloned sequence, including the spacer and priming 
sequence can be isolated from the vector by restriction digestion.  
It is also possible to use chemically synthesized oligos for the right hand half-probe as well, but to 
facilitate ligation it is necessary that this sequence is 5' phosphorylated.  Although chemically 
synthesizing both probes greatly accelerates the probe production process, due to length 
constraints during synthesis the number of probes that can be subsequently combined within a 
single set is limited. 
The MLPA protocol is described in full in Schouten et al., 2002 (193), and is also available at the 
following web site (http://www.mrc-holland.com/).  As outlined in the notes of the protocol, 
several modifications are possible.  To save on reagents the PCR volume can be reduced from 50 
µl to 25 µl without influencing the results.  Combining the two pre-PCR mixes together and 
adding 5 µl of the ligated products on ice makes the overall procedure easier, particularly when 
working with many samples.  As with MAPH, it may be necessary to adjust the number of PCR 






For both MAPH and MLPA the methods of data analysis are effectively identical.  The PCR 
products are usually separated by electrophoresis and each probe is quantified, with the relative 
amount of each product being proportional to the copy number of the locus being tested.  In the 
original MAPH protocol (191) the probes were labeled with a 33P-5'-end-labelled  primer and 
separated on a polyacrylamide gel, with the bands being quantified using a phosphoimager 
screen. A faster and easier method is to use a fluorescently labeled primer during the PCR 
amplification (47) and separate the products on a sequencing system, either a polyacrylamide gel 
or through polymer-filled capillaries (Figure 7).  This approach also simplifies the analysis of the 
products, as software (e.g. GeneScan and Genotyper from Applied Biosystems) has been 
integrated into these systems. To obtain sufficient signal it may be necessary to concentrate the 
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Several different methods have been described for data analysis. At the most basic level peaks 
can be visually compared (195), e.g. by overlaying control and test traces.  In theory any deletion 
or duplication should be sufficiently obvious without any calculations being performed.  Whilst 
this is usually true for deletions, especially single exon duplications will not always be obvious.  






Figure 8. An example of traces obtained by analyzing MAPH products on the Lab-on-a-chip from Agilent. In this 
example the probes have a spacing of 30-40 base pairs.  As can be seen, this spacing could be reduced if necessary to 
allow more probes to be used. A typical pattern from an unaffected individual is shown in trace A, a single locus 
duplication is indicated by an asterisk in trace B. 
 
Software such as GeneScan provides data about the peak height and peak area, both of which 
have been used in different reports (47,196-198) with equivalent results. Most methods of 
calculation described have been based on dividing the value of a given probe by the sum of 2 or 
more other probes to obtain a ratio.  These are preferably control probes that are unlinked to the 
loci in question. The "nearest neighbor" method can be used, where the values of the four nearest 
peaks are added together.  This means that each probe will be normalized against a different 
group of probes.  It is also possible to add up the values of all probes in a trace (a global 
approach), and divide each probe by that value.  Exactly which method is used is dependent on 




subtelomeric rearrangements are found in about 5% of mentally retarded patients, and it is 
unlikely that more than two probes would be affected.  It should therefore be no problem to use 
the nearest neighbor or global approach, as the vast majority of probes and samples will be 
unaffected. In contrast, sets composed of probes for all exons within one gene should be analyzed 
by another method.  It is possible that most if not all of the exons within a gene are deleted, which 
mean that none of these probes should be used for normalization purposes.  It is therefore 
essential to add control probes for loci elsewhere in the genome. 
The ratio obtained for each probe is averaged across a series of samples to obtain a normalized 
value, usually corresponding to a copy number of 2 (1 for X-linked probes in a male). The 
original ratio for each sample is then divided by the normalized value, and in an unaffected 
situation should give a number distributed around 1.  Under ideal circumstances a deletion (1:2) 
would give a value 50% lower, i.e. 0.5, and a duplication (3:2) a value 50% higher i.e. 1.5 (Figure 
9).  Of course each probe will show a certain level of variation, and it is this variation that 
determines the degree of certainty of each measurement.  The variation is dependent on several 
factors.  Amplification by PCR will introduce a certain level of variability; this can be determined 
by performing several amplifications from a single pre-MAPH/MLPA.  Each probe itself will 
have a certain amount of variance, depending on several factors such as GC-content, degree of 
homology with other regions in the genome, possible interactions with other probes, amplification 
efficiency, etc.  These influences can be estimated by calculating the standard deviation for each 
probe over a series of control samples.  The accuracy of each probe in detecting a true copy 
number change is also important.  For this reason it is desirable to be able to test each probe on 
samples with known mutations.  
Different criteria can be applied for deciding whether a given result is significant or not. At the 
most basic level thresholds can be set, usually at 0.75 and 1.25. A more statistical approach can 
be used by calculating the standard deviation either for each probe across all samples, or for all 
probes within a sample.  As the variation of each probe also depends on the quality of the DNA 
being tested, it does not always follow that the standard deviation seen on control samples will be 
the same as that seen on test samples.  This usually, however, provides a good estimate as to the 
overall reliability of any given probe.  The use of bivariate analysis has also been described (196). 
This relies on duplicate testing of each sample, and allows the user to decide beforehand what the 
false negative rate will be. A full explanation is provided at the following web site 
(http://www.nottingham.ac.uk/~pdzjala/maph/ststats.pdf).
The exact criteria that are used for determining a significant result, be it a fixed figure or a certain 




the thresholds at a relatively low level will lead to a correspondingly low false negative rate.  This 
will however lead to a relatively higher false positive rate. One of the strengths of both MAPH 
















































 Bure 9.  Analysis of MLPA reactions with 2 DMD probe sets following normalization.  Under normal circumstances  
 ratios of all probes clustered around 1.0, indicating an unaffected individual.  Graph A shows a single probe with a 
o around 1.5, this is from a female carrier of an exon 61 duplication. In graph B there are seven probes with ratios  
und 2.0, corresponding to a duplication of exons 37-43 in a male patient.  
ples. Thus it should be easy to test all samples twice, and only probes that deviate in a 
nificant manner in both duplicates should then be retested with another technique.  If the 
jority of samples do not show any changes, however, then it can be argued that routine 
plicate testing, at least on the same DNA isolate, is not necessary.  If both tests need to show 
 same deviation, and the first is normal, then the second test is not going to change the 
nclusion.  Therefore only samples that show significant changes in the first round need to be 
ested.   
hilst detecting deletions (1:2) and duplications (3:2) is relatively straightforward, distinguishing 
atively smaller changes, e.g. in mixed or mosaic samples, requires testing each sample several 
 
  
times to determine confidence limits.  This is one of the strengths of both MAPH and MLPA, as 
multiple testing requires little extra time or expense.  It is also advantageous to be able to use data 
from more than one probe, as this strengthens the statistical analysis.  
In addition to false positives and false negatives because of variations affecting the calculations, 
incorrect conclusions can also be drawn due to inherent limitations of each technique.  For 
example, if only part of the genomic region that binds a MAPH probe is deleted then the signal 
obtained from that probe will be proportionally lower, but perhaps not enough to be significant. 
Due to the sensitivity of the MLPA reaction to mismatches at the ligation site of the two half-
probes, even a single nucleotide change may be enough to prevent successful ligation.  In such a 
case the result will be scored as a deletion, a conclusion that will not be changed by repeated 





There have been several reports on the use of MAPH and MLPA for detecting copy number 
changes.  These have focused primarily on screening either single genes for exonic deletions and 
duplications, or chromosomal regions for rearrangements.  
Given the potential to screen up to 50 loci simultaneously an obvious target was to develop 
probes for each of the subtelomeric regions of the human chromosomes (43 in total). Such a 
probe set can be used to detect trisomies and unbalanced translocations. In addition, 
rearrangements in the subtelomeric regions have been shown to be involved in mental retardation 
(MR), with rearrangements found in ~5% of cases (199). Subtelomeric screening using MAPH 
has been described in three reports.  The first used a combination of FISH and MAPH (200).  A 
total of 70 samples from MR patients had been screened with FISH, and one deletion was 
detected.  Analysis with MAPH gave the same result. The second report was of the MAPH 
screening of 37 DNA samples from patients referred for Fragile X screening (196).  In this study 
6 rearrangements were found (16%), one of the highest percentages found in subtelomeric 
screening of MR patients.  No FISH screening was performed, and the rearrangements were 
confirmed by semi-quantitative PCR.  A problem with FISH confirmation of MAPH results is 
that a negative result with FISH does not mean that the MAPH finding is not correct.  The 
difference in resolution afforded by the techniques (a minimum probe size of ~40kb vs. ~100bp) 
means that MAPH may have detected a genuine but small alteration that simply cannot be 




MAPH, MLPA, quantitative PCR or Southern blotting may be necessary. The third report (201) 
(Chapter 4) analysed 188 patients with developmental delay, and found subtelomeric 
rearrangements in 9 cases (5%). In this study a number of interstitial loci were also tested, 
resulting in a further 8 rearrangements being detected. 
In addition to the screening of the DMD gene in DMD/BMD patients (Chapter 2.1, 2.2, 2.3), we 
have also looked at genes involved in other muscular disorders, namely the sarcoglycanopathies. 
Using this approach it was possible to identify the identical single exon deletion within the SGCG 
gene in three, unrelated limb-girdle muscular dystrophy (LGMD) patients (Chapter 3). 
MAPH has also been applied to the analysis of deletions and amplifications in Chronic Myeloid 
Leukemia (192).  This clonal malignancy is characterized by the generation of a BCR-ABL1 
fusion gene after a translocation involving chromosomes 9 and 22 (the Philadelphia (Ph) 
chromosome).   The marked difference in disease progression seen in these patients was thought 
to be at least partly due to deletions at the breakpoints of the chromosome 9 derivative. Probes 
were made at the breakpoints (9q34 and 22q12), and were used to test DNA samples with known 
deletions and duplications. Using titration experiments the authors were able to show that they 
could still see deletions and amplifications when only 60% to 70% of the cells were affected. This 
is a demonstration of the ability of MAPH to detect mutations in mosaic cases.  
Another application of MAPH, testing its limits of sensitivity, was the analysis of a previously 
identified polymorphic region on 8p23.1 (202). This region is flanked by olfactory repeats, and it 
had been shown that up to 25% of the normal population carries an inversion polymorphism 
between these repeats (126). Additionally, an apparently benign duplication of the region had 
been described, with no obvious effect on the carriers. By designing several MAPH probes within 
this region, along with the use of semi-quantitative FISH, it was possible to estimate the copy 
number of this region.  It could be shown that the majority of individuals had between 2 and 7 
copies of the allele, whereas carriers of the apparent duplication had in fact 9-12 copies. 
MLPA probe sets are commercially available, and there have been several reports detailing their 
application.  To date these have been primarily focused on screening for exonic deletions and 
duplications in specific disease genes. The first genes screened were those known to be 
commonly deleted in different cancers.  These include BRCA1 (197,203) involved in breast 
cancer, and MSH2 and MLH1 involved in colon cancer (204,205).  More recently, two sets 
together covering all exons of the DMD gene have become available (Chapter 2.2). 
Subtelomeric screening has also been performed using MLPA. A total of 4 rearrangements were 
found in a group of 75 DNA samples from mentally retarded patients (198), which is similar to 




rearrangement was suspected, but further examination showed that there was a 3 bp deletion at 
the probe site.  This case illustrates the importance of confirming apparent deletions found with a 
single probe, as even a single nucleotide change may disturb the ligation of the two half-probes. 
An interesting application lies in the detection of aneuploidy directly from amniotic fluid lysates 
(206). In a study of 492 samples there were 18 aneuploidies identified, with no false positives or 
false negatives.  The probe set used contained 8 probes for each of chromosomes 13, 18 and 21, 4 
probes for chromosome X and Y and 8 probes for other chromosomes.  To determine if an 
aneuploidy was present the mean normalized ratio of all probes for a given chromosome was 
used, as it was stated that not all relevant probes showed the aneuploidy.  By combining the 
results of multiple probes the sensitivity of the assay is enhanced, and in this case the vast 
majority of samples were tested only once. 
To circumvent the time-consuming and expensive cloning required in MLPA probe preparation, 
we have looked at the possibility of using synthetic oligonucleotides for both half-probes (207) .  
Due to length limitations during the chemical synthesis the maximum size of ligated probes is 
~130 bp, considerably less than the 490 bp obtained from cloned products.  To partially 
circumvent these restrictions we combined the single base pair resolution of capillary 
electrophoresis with the ability to analyze multiple fluorescent labels simultaneously. We made 
two sets of probes, each being amplified with a defined primer pair, and each set being labeled 
with a different fluorophore.  As the primers function under the same PCR amplification 
conditions it is possible to combine all probes in the same reaction. This approach has been 
applied to the analysis of the EXT1 and EXT2 genes in patients with multiple osteochondromas 








Although MLPA and MAPH share many similarities, there are significant differences that will 
influence which of the two will be considered for a given purpose. MLPA requires ~100 ng of 
genomic DNA, considerably less than the 1µg required for MAPH analysis. While 1 µg is not an 
excessive amount, it may be a problem when dealing with older archived samples, or when 
analysing amniotic fluid.  
A genuine drawback of the MAPH technique is the necessity to immobilize the genomic DNA, 
usually performed by spotting onto a small nylon filter. This is inconvenient, and the subsequent 
washing steps are time consuming. In contrast, MLPA is essentially a one-tube assay, particularly 
important for diagnostic purposes as it minimizes the chance of sample mix-up during the assay. 
It also makes automation of the entire procedure easier. For these reasons MLPA is becoming the 
technique of choice, especially in diagnostic settings. 
As a MAPH probe is a PCR product, probe preparation requires little more than 2 primers and a 
PCR reaction.  This is in contrast to the standard manner of MLPA probe production, which 
requires a cloning step followed by single-stranded DNA isolation.  The time and expense 
required can be justified for probe sets that are commercially desirable, yet there will often be 
cases when probes will be needed for extremely rare disorders, or for determining the size of a 
rearrangement.  In these cases cloning is not an attractive option, and MLPA with synthetic oligos 
only should be considered (207).  
It is easy to foresee that new MLPA/MAPH assays will be developed that will focus not only on 
specific genes but also on high-resolution analysis of chromosomal regions associated with a 
range of diseases. Several large deletions and duplications are known to be associated with a 
specific spectrum of disorders, e.g. microdeletion syndromes and contiguous gene disorders. Such 
rearrangements can be of the order of several megabases, making them cytogenetically visible. 
Often many genes are found within these areas and the extent of the rearrangement is directly 
correlated with disease severity, i.e. the sum of the genes affected determines the overall 
phenotype. The use of MAPH/MLPA assays should make it straightforward to determine the 
extent of the deletion/duplication.  
MAPH and MLPA facilitate the versatile detection of copy number changes in a selected set of 
up to 50 target sequences. What has been lacking until recently is a technology that can be used in 
a scanning mode and genome-wide. In many cases it is not yet known where genes involved in 
specific disorders reside, e.g. mental retardation. As a first step to identify the genes responsible 




involved. These rare cases might then point to the genes involved, which could then be analyzed 
in more detail and in a much larger set of patients. Similarly, it would be desirable to have such a 
scanning tool to analyze genomic DNA of newborns presenting with initially unclear health 
problems. In a significant fraction of these newborns, de novo genomic copy number changes 
might be involved which, when detected, could provide a much earlier diagnosis and thereby 
valuable information for health care.   
To fill in this gap, array CGH (array-based Comparative Genomic Hybridization) has been 
developed. It has been successfully applied by spotting BACs/PACs (or PCR products thereof) 
onto a glass slide, and hybridizing labeled genomic DNA to these (208-210) to pick up genomic 
copy number changes.  The method could be successfully applied to detect large rearrangements, 
especially in cancer-related samples, but recently also to reveal rearrangements in patients with 
mental retardation and dysmorphisms. However, these arrays have a limited resolution. Even with 
the 30000 BAC/PAC array recently described (211) only relatively large (>50-100 kb) deletions / 
duplications will be detected. Furthermore, due to the presence of low copy repeats, some regions 
of the genome are not amenable to analysis in this way (212). 
An obvious approach to resolve the issue of resolution would be to design an array-based 
MLPA/MAPH assay. In such an assay it is no longer necessary for each probe to be of a different 
length for subsequent electrophoretic separation. This feature might help to resolve the main 
technical hurdle of this approach, namely the maximum degree of multiplicity of the assay, i.e. 
the number of loci that can be simultaneously amplified and resolved when combined in a single 
reaction. We have successfully developed an array analyzing 26 MLPA probes simultaneously, 
and preliminary results from our laboratory indicate that a 200-plex, array-based MLPA assay is 
possible (Kalf et al., unpublished). 
For high resolution, genome-wide analysis of copy number changes the most promising 
developments may be the application of whole-genome SNP-typing assays. An approach very 
similar to MLPA, also based on the ligation and quantitative amplification of oligonucleotides has 
been developed (213,214).  The primary difference lies in the analysis method. Instead of 
separating products of a different length by electrophoresis, the PCR products are captured by 
complementary sequences attached to microspheres. As up to 1500 different microspheres can be 
distinguished using a specific color-coding system, it should be possible to analyze 1500 loci in 
genomic DNA simultaneously.  In addition, the system has been set up for micro-titer plate 
analysis, up to 96 samples can be processed in parallel. This then tackles another important issue 
of these technologies, which is the number of different patient samples that can be processed in a 




The development of a 10,000 human SNP-typing microarray was initially reported (215) with a 
120,000 array recently becoming available (188). Instead of hybridizing the entire genome, a 
reduction in complexity is achieved by digesting the genomic DNA with a restriction enzyme, 
followed by attachment of a linker. This sequence allows for the subsequent amplification of the 
intervening sequences. The amplified fragments are then hybridized to short complementary 
sequences on an array. Deletions can be detected with such tools by first using the SNP itself i.e. 
inheritance of 'null alleles', or indirectly derived from the presence of exceptionally large 
homozygous regions which might point to a hidden deletion. Rearrangements should also be 
detectable using the amount of signal generated per SNP, with lower signal (and homozygosity) 
pointing to deleted regions and increased signals to duplicated regions (216).  
A very similar, linker-based approach has also been described, namely Representational 
Oligonucleotide Microarray Analysis (ROMA) (217). This used oligonucleotide microarrays 
specifically designed to detect the PCR fragments, so was not intended for SNP analysis. This 
does not allow the array to be used for LOH analysis, but does give more flexibility with regard to 
probe localization. 
Copy number analysis is not only of importance in studying disease. As this thesis was being 
finalised three reports using either Array CGH (218), ROMA (219) and MLPA (Chapter 6) (220) 
to examine copy number polymorphisms in healthy individuals were published. Whatever 
methods are used, high resolution quantitative analysis will be an important step following the 
generation of the draft human genome sequence. The information obtained will not only be 
important for the identification of new disease genes, but will also give greater insight into the 
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Comprehensive Detection of Genomic Duplications and Deletions
in the DMD Gene, by Use of Multiplex Amplifiable Probe Hybridization
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Duplications and deletions are known to cause a number of genetic disorders, yet technical difficulties and financial
considerations mean that screening for these mutations, especially duplications, is often not performed. We have
adapted multiplex amplifiable probe hybridization (MAPH) for the screening of the DMD gene, mutations in which
cause Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy. MAPH involves the quantitative
recovery of specifically designed probes following hybridization to immobilized genomic DNA. We have engineered
probes for each of the 79 exons of the DMD gene, and we analyzed them by using a 96-capillary sequencer. We
screened 24 control individuals, 102 patients, and 23 potential carriers and detected a large number of novel
rearrangements, especially small, one- and two-exon duplications. A duplication of exon 2 alone was the most
frequently occurring mutation identified. Our analysis indicates that duplications occur in 6% of patients with
DMD. The MAPH technique as modified here is simple, quick, and accurate; furthermore, it is based on existing
technology (i.e., hybridization, PCR, and electrophoresis) and should not require new equipment. Together, these
features should allow easy implementation in routine diagnostic laboratories. Furthermore, the methodology should
be applicable to any genetic disease, it should be easily expandable to cover 1200 probes, and its characteristics
should facilitate high-throughput screening.
Introduction
Most techniques currently applied to reveal disease-caus-
ing mutations are PCR based and do not readily produce
quantitative data. Consequently, although copy-number
changes (i.e., deletions and duplications) are frequently
involved, they will go undetected unless specific tech-
niques are applied (Petrij-Bosch et al. 1997; Wijnen et
al. 1998; Morgan et al. 1999). The major reason behind
this failure is economical: obtaining quantitative data is
feasible but is technically demanding, labor intensive,
and, thus, costly. When specific precautions are taken,
Southern blotting and quantitative PCR are able to de-
tect deletions and/or duplications, but they are both la-
borious and difficult to implement on a routine basis.
A technique that might fill this gap has recently been
described—namely, multiplex amplifiable probe hybrid-
ization (MAPH) (fig. 1) (Armour et al. 2000). MAPH is
based on the quantitative recovery of probes, after their
Received March 28, 2002; accepted for publication May 20, 2002;
electronically published July 8, 2002.
Address for correspondence and reprints: Dr. J. T. den Dunnen,
Human and Clinical Genetics, Leiden University Medical Center, Was-
senaarseweg 72, 2333AL Leiden, The Netherlands. E-mail: ddunnen
@lumc.nl
 2002 by The American Society of Human Genetics. All rights reserved.
0002-9297/2002/7102-0015$15.00
hybridization to immobilized DNA. Each probe is en-
gineered to allow simultaneous amplification with only
one set of primers. This overcomes one of the most dif-
ficult elements of quantitative multiplex PCR—namely,
differences, between primers, in annealing efficiency. In
the original MAPH protocol, after the hybridization step,
the PCR products were radioactively labeled during PCR
amplification and were analyzed on a polyacrylamide gel.
To facilitate a more-automated, higher-throughput ap-
plication of MAPH, we have chosen to label the products
fluorescently and to separate them on a 96-capillary se-
quencer. Each product is identifiable on the basis of
length, with the size of the resultant peak being directly
proportional to the copy number of the relevant probe.
Changes in peak heights will therefore reflect deletions
and duplications in genomic DNA.
We have applied the modified MAPH protocol to scan
for copy-number changes in patients with Duchenne
muscular dystrophy (DMD) (MIM #310200). DMD is
the most commonly inherited neuromuscular disease, af-
fecting 1 in 3,500 male individuals (Worton and Thomp-
son 1988). It is an X-linked disorder that is caused by
mutations in the DMD gene. This gene is the largest
known, covering 2.4 Mb (den Dunnen et al. 1989; Boyce
et al. 1991) and containing 79 exons that encode a 14-
kb mRNA (Koenig et al. 1987). Translation-truncating
Chapter 2.1
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Figure 1 Outline of the MAPH technique. Probes are prepared such that all can be amplified with one primer pair. After overnight
hybridization to immobilized genomic DNA, unbound probes are removed by stringent washing. Bound probes are then released and amplified
in a quantitative manner. By fluorescent labeling and capillary electrophoresis, it is possible to both discriminate and quantify each probe.
Changes in peak heights correspond to copy-number changes (i.e., deletions and duplications).
mutations in DMD lead to the lethal phenotype of DMD,
whereas mutations that retain the reading frame generally
cause the less severe phenotype of Becker muscular dys-
trophy (BMD) (Monaco et al. 1988; Koenig et al. 1989).
An accurate molecular diagnosis is therefore essential
both to confirm the clinical diagnosis and to distinguish
the two allelic forms.
In approximately two-thirds of cases, the mutation is
a deletion or duplication of one or more of the exons,
clustered in two hotspot regions (Forrest et al. 1987;
Koenig et al. 1987; Darras et al. 1988; den Dunnen et
al. 1989; Gillard et al. 1989). In affected male patients,
deletion detection is relatively simple. For multiplex PCR,
two nine-exon sets (the Chamberlain et al. [1988] and
Beggs et al. [1990] sets) have been designed around these
hotspots, which together detect 90%–95% of the dele-
tions in male patients. Alternative methods must be ap-
plied to determine the exact boundaries of the deletion,
as well as to detect duplications and carrier status in
female individuals. The size (2.4 Mb) and complexity (79
exons) of DMD, however, make this a daunting task.
Quantitative Southern blotting has been the most com-
monly used technique (den Dunnen et al. 1989; Hu et
al. 1990; Yamagishi et al. 1996). By the comparison of
band intensities between test samples and control sam-
ples, it is possible to detect copy-number changes in the
individual exons. The preparation of high-quality blots
is technically demanding, and six to eight hybridizations
are required in order to scan all the exons. In addition,
duplication detection is difficult, especially in female
carriers and when the duplications are small (i.e., cov-
ering only one or two exons). Quantitative PCR is an-
other, more recently applied technique (Ioannou et al.
1992; Mansfield et al. 1993; Yau et al. 1996), in which
a multiplex PCR is performed that has a limited number
of cycles, ensuring that quantitative products are yielded.
Again, the technique is technically demanding, and the
incomplete coverage of the exons means that mutations
outside the hotspots will be missed. Not surprisingly,
therefore, mutation-analysis reports differ considerably
in the frequency of duplications detected, ranging be-
tween 0 and 6%, depending on the techniques applied
for analysis (Koenig et al. 1987; den Dunnen et al. 1989;
Hu et al. 1990; Mendell et al. 2001).
Here we describe a MAPH-based method that scans
all 79 DMD exons for deletions and duplications. We
have been able to detect and define a large series of new
mutations—in particular, duplications—with several not
detected by Southern blotting and/or quantitative PCR.
The simplicity of this technique should allow its easy
implementation in diagnostic laboratories, and its utility
means that it can be readily adapted for the screening of
duplications and deletions in any genetic disease.
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Figure 2 Example of trace patterns obtained from an unaffected male individual. The numbers refer to DMD exon numbers: “1.x” and
“2.x” (where x is the exon number) refer to BRCA1 and BRCA2, respectively, and “NF2” denotes a probe homologous to the first exon of
the NF2 gene. Asterisks (*) indicate control peaks, and unlabeled peaks indicate noise. Probes range in size from 151 bp (DMD exon 34) to
602 bp (DMD exon 2).
Methods
Probe Generation
All probes were based on individual exons. Some DMD
probes were created using primers from the Chamberlain
et al. (1988) and Beggs et al. (1990) kits. The remainder
were based on sequences obtained from the Leiden Mus-
cular Dystrophy Pages. To facilitate analysis, we pre-
pared control probes by using genomic sequence ob-
tained from GenBank. For each product, the presence
of duplicated and/or repetitive sequences was excluded
using the BLAST program. The sequences were checked
against the nr (nonredundant) and htgs (high-through-
put genomic sequences) databases. No probe showed an
intraspecies homology 190% for a stretch of 30 nt
(expected value 1e11).
Products were amplified from genomic DNA by PCR
and were cloned into the pGEM-T easy vector (Promega).
The correct insert was confirmed by sequencing through
use of the BigDye Terminator Cycle Sequencing Ready
Reaction kit (Applied Biosystems). This was performed
at the Leiden Genome Technology Center, where reac-
tions were analyzed on the ABI 3700 Sequencer (Applied
Biosystems).
Each probe was amplified from the vector by use of
the primers MAPH-F1 (GGCCGCGGGAATTCGATT)
and MAPH-R1 (GCCGCGAATTCACTAGTG). Prod-
ucts were purified with the Qiagen PCR cleanup kit (Qia-
gen) and were then added to the appropriate probe mix-
ture, which had a final concentration of 100–500 pg/ml.
Probe sets A and B were prepared containing 40 and 39
DMD exons, respectively. Nine-probe control mixtures
were made specifically for use with each probe set.
MAPH
MAPH was performed using a protocol adapted from
the original MAPH protocol (Armour et al. 2000), as
follows (for detailed protocol, see the Leiden Muscular
Dystrophy Pages). At least 1 mg genomic DNA was de-
natured in 1 ml 1N NaOH and spotted on a small nylon
filter, followed by UV cross-linking. Up to 16 filters were
hybridized together in one tube; the filters were prehy-
bridized in 1 ml prehybridization solution (0.5 M so-
dium phosphate [pH 7.2], 1 mM EDTA, 7% SDS, and
100 ng/ml Herring Sperm DNA [Gibco BRL]) for ∼2 h
at 60C; this solution was replaced with 200 ml prehy-
bridization solution that contained 2 mg denatured Cot1
DNA (Gibco BRL) and was incubated at 60C for 30
min. Probe mixture (1 ml combined probes, 1 ml Cot1
DNA [1 mg/ml], 1 ml Herring Sperm DNA [10 mg/ml;
Gibco BRL], 1 ml blocking mixture [blocking primers
that each had a final concentration of 20 mM], and 3 ml
H2O) was denatured by the addition of 2 ml 1N NaOH
and incubated at 37C for 1 min. After cooling on ice,
3 ml 1M NaH2PO4 was added, and the mixture was
added to the tube that contained the filters. Hybridi-
zation was performed overnight at 60C. Washing was
performed the next day with five times in 25 ml salt-
sodium citrate (SSC) and 1% SDS, followed by five
washes in 25 ml 0.1 # SSC and 0.1% SDS, all at 60C.
Each filter was transferred to a PCR tube, and a five-
cycle PCR amplification was performed under the fol-
lowing conditions: 94C for 5 min; five cycles of 94C
for 45 s, 57C for 1 min, and 68C for 1 min; and 68C
for 10 min.
Two and one-half microliters of this mixture was trans-









D1 (M) 1,3 Del 5-7 Del 5-7
D2 (F) Dup 52-55
D3 (M) 3 Del 50 Del 50
D4 (F) Dup 50-55
D5 (M) 1,3 nm Dup 50-55
D6 (M) 3 Del 8-44 Del 8-44
D7 (M) 1,3 nm nm
D8 (M) 1,3 Dup 43 Dup 43
D9 (F) Dup 58-63
D10 (M) 1,3 ?c Dup 58-63
D11 (M) 3 Del 49-52 Del 49-52
D12 (M) 3 Del 48-50 Del 48-50
D13 (F) Del 45
D14 (M) 3 Del 1m Del 1m
D15 (M) 3 nm Del 53
D16 (M) 1,3 nm nm
D17 (M) 3 Del (3)-(10) Del 4-12
D18 (M) 3 Del 14-60 Del 14-60
D19 (M) 1,3 Del 69 Del 64-67
D20 (F) 3 Del (45)-(50) Del 49-54
D21 (M) 3 Del 2-(33) Del 2-30
D22 (M) 3 nm nm
D23 (M) 3 Dup 12 Dup 12
D24 (F) Dup 2
D25 (M) 2,3 nm Dup 2
D26 (M) 1,3 nm nm
D27 (F) Dup 12-13
D28 (F) Dup 44
D29 (M) 3 Dup 2-9 Dup 2-9
D30 (F) nm
D31 (M) 3 Del 1-79 Del 1-79
D32 (F) 3 Dup 44-57 Dup 44-57
D33 (F) Dup 2-7
D34 (M) 1,3 Dup 2-7 Dup 2-7
D35 (M) 1,3 Dup 2-7 Dup 2-7
D36 (F) 3 Del 10-(?) Del 10-46
D37 (M) 3 Del 3-(?) Del 3-19
D38 (F) 3 Del (50) Del 48-50
D39 (M) nm
D40 (M) 1,3 Del 46-51 Del 46-51
D41 (M) 3 Del XJ10d Del 4-13
D42 (M) 2,3 Del 3-16 Del 3-16
D43 (M) 1,3 nm nm
D44 (F) 2,3 Dup 2e Dup 2
D45 (M) Dup 2
D46 (F) 3 nm nm
D47 (M) 1,3 nm nm
D48 (M) 1,3 nm nm
D49 (M) 3 Del 8-(16) Del 8-39
D50 (M) 1,3 nm nm
D51 (F) 2,3 nm nm
D52 (M) 1,2,3 Dup 51 Dup 51
D53 (M) 1,3 nm nm
D54 (M) 1,3 nm nm
D55 (M) 1,3 nm nm
D56 (M) 1,3 nm nm
D57 (M) Dup 6
D58 (M) 1,3 nm nm
D59 (M) 1,2,3 nm nm
D60 (M) 1,3 nm nm
D61 (M) 1,3 Del 2-7 Del 3-6
D62 (M) 1,2,3 Del 20-29 Del 20-29
D63 (F) Dup 2-(7) Dup 3-7
D64 (M) Dup 17 Dup 17
D65 (M) 1,2,3 nm nm
D66 (F) nm
D67 (M) 1,2,3 Del 19-43 Del 21-43







D69 (M) 1,3 nm nm
D70 (F) Dup 3-7 Dup 3-7
D71 (M) Dup 3 Dup 3
D72 (F) Dup 3
D73 (M) 1,2,3 nm nm
D74 (M) Dup 51-55 Dup 51-55
D75 (F) 2,3 Dup 51-55 Dup 51-55
G1 (M) 1,4 nm Del 21
G2 (M) 1,4 nm Dup 10-11
G3 (M) 1,4 nm Dup 18-23
G4 (M) 1,4 nm nm
G5 (M) 1,4 nm Del 48
G6 (M) 1,4 nm Dup 6-7
G7 (M) 1,4 nm Del 66
G8 (M) 1,4 nm nm
G9 (M) 1,4 nm nm
G10 (F) 1,4 nm Del 48-50
G11 (M) 1,4 nm nm
H1 (M) 1 nm nm
H2 (M) 1 nm nm
H3 (M) 1 nm nm
H4 (F) 1 nm nm
H5 (M) 1 nm Del 45-50
H6 (M) 1 nm Dup 44
H7 (M) 1 nm nm
H8 (M) 1 nm nm
H9 (M) 1 nm nm
H10 (M) 1 nm Dup 3-4
L1 (M) 1,4 nm Dup 8-13
L2 (M) 1,4 nm Del 18
L3 (M) 1,4 nm nm
L4 (M) 1,4 nm nm
L5 (M) 1,4 nm Dup 5-6
L6 (M) 1,4 nm Dup 54
L7 (M) 1,4 nm Dup 8-9
L8 (M) 1,4 nm nm
L9 (M) 1,4 nm Dup 45-52
L10 (M) 1,4 nm Dup 2
L11 (M) 1,4 nm Dup 8-13
L12 (M) 1,4 nm Dup 53-55
L13 (M) 1,4 nm Dup 61-64
L14 (M) 1,4 nm nm
L15 (M) 1,4 nm Dup 51-57
L16 (M) 1,4 nm Dup 8-9
L17 (M) 1,4 nm Dup 2
L18 (M) 1,4 nm Dup 3-30
L19 (M) 1,4 nm Dup 20
L20 (M) 1,4 nm Dup 14-21
L21 (M) 1,4 nm nm
L22 (M) 1,4 nm Dup 2
L23 (M) 1,4 nm Dup 8-9
L24 (M) 1,4 nm Dup 42-43
L25 (M) 1,4 nm Dup 6-7
L26 (M) 1,4 nm Del 56
L27 (M) 1,4 nm nm
M1 (M) 1,4 nm Dup 18-32
M2 (M) 1,4 nm Dup 20-27
a 1 p PCR by use of the Chamberlain et al. (1988) and Beggs et al. (1990)
sets; 2 p quantitative Southern blotting; 3 p quantitative multiplex PCR; 4 p
point-mutation detection.
b Del p deletion; Dup p duplication; nm p no mutation found. Numbers
denote exons; those in parentheses indicate an uncertain breakpoint.
c Duplication of 30–50 kb around exon 60 detected using pulsed-field gel
electrophoresis.
d Probe located in intron 7.
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Figure 3 Patterns obtained from analysis of patients by use of probe set A. A, Male patient’s duplicated exon 2, male patient’s duplicated
exons 14–21, and male control individual. B, Female carrier’s duplicated exons 52–54 and female control individual.
same conditions as the first reaction except that one of
the primers was fluorescently labeled and the reaction was
for 23 cycles. Two microliters of this product was added
to 10 ml (Hi Di) Formamide (Applied Biosystems) and
0.15 ml ROX-500 size standard (Applied Biosystems) in
a 96-well plate. This was heated at 95C for 5 min,
followed by immediate cooling on ice. The samples were
analyzed on an ABI 3700 capillary sequencer (Applied
Biosystems).
Data Analysis
Data were analyzed using the programs Gene Scan
(Applied Biosystems) and Excel (Microsoft). Peaks
were considered unreliable if they were outside pre-
defined thresholds (upper and lower limits of 12,000
and 150 units, respectively).
Male samples were initially visually assessed, to detect
any deletions. Presence of a peak that corresponds to a
Y chromosome–specific probe confirmed the sex of the
sample. Absence of one or more DMD peaks was taken
to be a deletion, and no calculations were performed.
Samples were analyzed using a combination of methods
described for analysis of MAPH (Armour et al. 2000;
Sismani et al. 2001) and array-based comparative ge-
nomic hybridization (Hodgson et al. 2001) experiments.
In the original MAPH publication (Armour et al. 2000),
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Figure 4 Analysis of different patient samples. A, Male patient
L1’s duplicated exons 8–13, with SD 0.05. B, Female carrier D36’s
deleted exons 10–46, with SD 0.05 C, Female carrier D70’s duplicated
exons 3–7, with SD 0.06.
each peak was compared with the two nearest peaks, for
normalization. Since each DMD exon could potentially
be altered in copy number, we also added probes from
exons of autosomal genes unrelated to DMD. For each
dystrophin exon, the peak height was divided by the sum
of the peak heights of the two nearest unlinked probes,
to give a ratio. Within one hybridization, the median of
the ratio for each exon was calculated and was used as
a reference value against which all exons were compared.
Each exon was divided by this number, thereby normal-
izing all unaffected exons to 1.0. For each sample, initial
estimates for deletions or duplications were performed
visually, by setting arbitrary thresholds on the basis of
expected ratios (Hodgson et al. 2001). Wild-type exons
were expected to fall in the ranges of for male1.0  0.5
patients and for female carriers. The median1.0  0.25
and SD of the exons that fell within this range were cal-
culated, and each exon was divided by the median to
correct for variations between samples. Any exon that
was outside 3 SDs of the “normal” exons was assumed
to be altered in copy number. Samples that showed an
SD 115% over the unaffected exons or that appeared
to show noncontiguous deletions or duplications were
deemed to be unreliable.
Results
Probes were initially tested by hybridization to control
DNA from 24 healthy individuals, as well as to DNA
from a patient with a deletion encompassing the entire
DMD gene. From the control samples, all the probes
could be recovered (fig. 2), whereas only control probes
from outside DMD were recovered from the patient
sample (data not shown). Thus, none of the probes
hybridize to other regions in the genome, which would
lead to false-positive signals.
A total of 125 samples were screened in a semiblind
manner (table 1 and figs. 3 and 4). These were a mixture
of fully and partially characterized cases, as well as sam-
ples from cases in which no mutation had been found.
In several cases, the DNA was from a potential carrier
in whom the mutation sought was already known. With
a threshold of 3 SDs and the assumption that the unaf-
fected ratios are normally distributed, a false-positive re-
sult should only occur ∼0.3% of the time, which is the
equivalent of one exon per four DMD genes tested. This
is approximately the ratio of false-positive results seen
among samples that were not excluded for other reasons
(e.g., peak height being outside the boundaries or SD
being 115%). Therefore, all samples that showed a sin-
gle-exon rearrangement were tested at least twice. Fol-
lowing these criteria, we found no sample that showed
evidence of more than one mutational event.
False-negative results are more difficult to assess. An
estimate can be made by looking at patient samples in
which more than two exons are deleted or duplicated.
A result would be considered to be false negative when
one or more exons within a mutated series was found
to be normal. In no patient sample was this seen. Al-
though this does not exclude the possibility that false-
negative calls will occur, it does suggest that they will
happen very rarely.
The exon 75 probe was the probe that showed the
highest variation among the 79 DMD probes used. This
appeared to be due to slight variations in PCR/washing
conditions, rather than variations in a polymorphic se-
quence, since no sample consistently showed a dupli-
cation of exon 75. For any hybridization in which exon
75 showed such variation, the results for that exon were
ignored, and the exon was retested in a subsequent ex-
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Figure 5 Independent mutations detected during the present study. Vertical bars represent the 18 exons tested using the Chamberlain et
al. (1988) and Beggs et al. (1990) kits. A, Mutations detected in samples in which point mutations and deletions had been excluded, mainly
by multiplex PCR. B, All other mutations detected.
periment. In no cases could an exon 75 duplication be
confirmed.
Initially, some probes could not be recovered. Close
examination of the sequences revealed that all had a
relatively low GC content (!40%). In some cases—for
example, exon 2—it was not possible to raise this per-
centage, since the entire region was extremely AT rich.
To solve this problem, we made the probes longer. In
this manner, we were able to use a 602-bp exon 2 probe
with a GC content as low as 30%.
Discussion
Of the 24 mutations previously characterized in our lab-
oratory, all were detected using the MAPH technique
(table 1). In one case, the breakpoints did not match
exactly. This was in a male patient (D61) that, with
MAPH, was seen as having a deletion of exons 3–6 but
had previously been diagnosed as having a deletion of
exons 3–7. Southern blot analysis showed a junction
fragment for exon 7, suggesting that the breakpoint may
be within the exon. In a hybridization-based technique,
a breakpoint may be misdiagnosed if the deletion occurs
within the sequence to which it is bound by the probe
and if there is enough of the exon remaining for the
probe to hybridize; this is likely to occur rarely however,
since it has been calculated that, in ∼99% of cases of
DMD and/or BMD, the breakpoints are outside the cod-
ing exon (den Dunnen et al. 1989). By contrast, PCR
from genomic DNA may lead to false-negative results if
there is a polymorphism within the priming site (Abbs
et al. 1991).
Of the 72 male samples in which no mutation had
previously been found, 37 (51%) had mutations that
were detectable by use of MAPH (table 1). When only
those samples that had been checked for deletions and
point mutations were included, the frequency was 74%
(29/39). These were composed of five deletions (all of
one exon) and, strikingly, but not unexpectedly, 24 du-
plications. To present an unbiased view of duplication
distribution, we have depicted those mutations detected
in samples that were also screened for point mutations
and deletions (fig. 5A) separately from an overview of
all the mutations detected (fig. 5B).
Samples LA1–LA27 (table 1) were from a point-mu-
tation screening by use of the DOVAM-S (detection of
virtually all mutations–SSCP) technique (Mendell et al.
2001). A total of 141 samples were tested, and 108 point
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mutations were found. We analyzed 27 of the remaining
33 samples, finding two deletions and 20 duplications.
Samples M1 and M2 (table 1) remained from a study,
using denaturing high-performance liquid chromatog-
raphy, that screened eight patients with DMD for point
mutations (Bennett et al. 2001) but found no obvious
pathological mutations in two of these samples. By use
of MAPH, both samples showed a duplication, thereby
completing the mutation study.
A total of 23 female potential or proven carriers were
tested. Of the 15 samples in which no mutation had
previously been found, two deletions and eight dupli-
cations were found. Analysis of potential carriers was
facilitated when it was known what mutation to expect.
Newly found mutations could often be confirmed us-
ing other methods. Small duplications, such as that in
sample D52 (with an exon 51 duplication), could be
confirmed by retrospective examination of Southern
blots that had been previously prepared and analyzed
in our laboratory. The DNA in sample D45 showed an
exon 2 duplication by use of MAPH, as did DNA from
the mother (sample D44). The result from sample D44
was confirmed by quantitative PCR, yet was not evident
on a Southern blot.
The exon 2 (samples D25 and D120.7) and exons
58–63 (samples D10 and DL33.2) duplications, which
have been described elsewhere (den Dunnen et al. 1989),
are interesting cases. Pulsed-field gel electrophoresis anal-
ysis indicated that there were rearrangements of ∼150
kb, at the 5′ end of the gene, and 30–50 kb, around exon
60. Despite a focused analysis of both regions, no du-
plications could be detected using Southern blotting.
Duplication of exon 2 alone is extremely difficult to
detect by Southern blotting, since the band is very weak.
This may be due to the very low GC content (∼30%) of
exon 2 and its surrounding region, leading, under strin-
gent conditions, to weak hybridization. Given the ex-
tremely large size (190 and 170 kb) of the introns flanking
exon 2, it is not surprising that a deletion or duplication
of exon 2 by itself is a mutation that has been found
more than once. In fact, it was the single most common
duplication found, occurring five times. Interestingly,
however, no deletion of exon 2 alone has so far been
reported (Leiden Muscular Dystrophy Pages).
Our results show that, even when the DMD gene is
screened for deletions, duplications, and point muta-
tions (DOVAM-S or denaturing gradient gel electro-
phoresis), a small number of samples remain in which
no disease-causing mutation can be detected. There are
several possible explanations why no mutation was
found in these samples. When RNA has not yet been
analyzed in a patient, mutations that affect splicing are
the most plausible candidates. Indeed, RNA-based tech-
niques, such as the protein-truncation test, detect mu-
tations that would be missed using DNA-based tech-
niques (Roest et al. 1996; Whittock et al. 1997). It is
also possible that the disease was misdiagnosed and that
the mutation lies in a gene responsible for other mus-
cular disorders. Germline mosaicism has been reported
elsewhere (Bakker et al. 1987; Wood and McGillivray
1988) and would not necessarily be detectable by use
of the methods described herein. Another, less likely
reason is mutations in a gene that is involved in the
regulation of dystrophin expression.
Although mutation detection obviously is critical for
diagnosis, it may also be important for future therapeutic
purposes. Recent reports have showed the potential use
of read-through protein synthesis (Gentamycin) (Barton-
Davis et al. 1999) and exon skipping (with antisense
oligoribonucleotides) (van Deutekom et al. 2001) in the
restoration of the reading frame of the dystrophin tran-
script. In particular, single-exon duplications, as detected
in 12 cases in this study, would make an ideal target for
exon skipping. The presence of two targets not only
would double the efficiency but also should produce a
normal transcript, leading to a wild-type protein.
The MAPH approach’s primary advantages over
Southern blotting and quantitative PCR are the relative
simplicity, speed, and completeness of coverage of all 79
exons. Although 90%–95% of the deletions can be de-
tected using multiplex PCR, the breakpoints are often
not determined, and rare mutations outside the hotspots
will be missed. In previously published reports on MAPH
(Armour et al. 2000; Sismani et al. 2001), recovered
probes were radioactively labeled and were separated on
a polyacrylamide gel. For speed and convenience, we
chose to use a combination of fluorescent labeling and
capillary electrophoresis. Capillary electrophoresis is be-
coming more widely used in mutation detection, since it
provides greater sensitivity and has high-throughput
capabilities (Bosserhoff et al. 2000). We used the ABI
3700 (Applied Biosystems), which allows the simul-
taneous analysis of 96 samples. One run of 96 samples
takes ∼4 h, with the data analyzed by software pro-
vided with the machine.
There are several ways in which the current system
can be further enhanced. In the present study, only two
(blue [FAM sample] and red [ROX size standard]) of
the four available colors were used. By use of up to
three sets of primers, each labeled with a different fluo-
rophore, it should be possible to expand the potential
number of probes by threefold. Hybridizing the PCR
products to a microarray composed of each individual
probe could further increase the number of probes
tested, with the additional advantage that they would
no longer need to be differentiated in length.
In contrast to many other methods, this technique
should be easy to implement in a standard diagnostic
laboratory, since no new technology needs to be in-
troduced. The critical techniques are hybridization and
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PCR, and the products can be analyzed on any ap-
paratus that is used for sequence analysis. Further-
more, it can easily be applied to any disease gene of
interest, and the resolution provided and the potential
of array implementation may even allow future ge-
nomewide screening.
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Duplications in the DMD gene are non-randomly distributed and can be complex 
rearrangements 
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Abstract 
Using Multiplex Amplifiable Probe Hybridization (MAPH) and Multiplex Ligation-dependent Probe 
Amplification (MLPA) we have screened different cohorts of Duchenne/Becker Muscular Dystrophy 
(DMD/BMD) patients for duplications. In an unselected series the duplication frequency was 8%; in a 
group of patients already screened for deletions and point mutations we found a duplication in 64% of 
cases. The majority were simple, contiguous duplications, however we detected 4 non-contiguous 
duplications, with two also including a triplication. In two instances the 3’ end of the gene was affected, a 
region not usually screened by multiplex PCR. These mutations would therefore go undetected, whilst 
potentially disturbing the reading frame of the mRNA.  This emphasizes the importance of screening the 
entire gene for rearrangements. 
More than 50% of the duplications found were at the 5` end of the gene, whereas most deletions are found 
in the middle of the gene. A more detailed comparison of the regions affected showed that a duplication of 
exon 2 only was the single most common duplication found. Analysis of the breakpoints of 11 such cases 
revealed two recombination hotspots within intron 2, whereas the breakpoints within intron 1 were 
scattered. We propose that unequal crossing over between sister chromatids is not responsible for exon 2 
duplications. Instead, a mechanism such as synthesis-dependent non-homologous end joining may be 
responsible. Assuming this also applies to other duplications within the gene, this may explain the 





The Duchenne Muscular Dystrophy (DMD) gene is the largest known, spanning ~2.4 Mb of genomic 
sequence on Xp21 (Den Dunnen et al., 1992; Mandel, 1989). Mutations in the gene cause DMD, the most 
commonly inherited neuromuscular disorder, and Becker Muscular Dystrophy (BMD), the milder allelic 
form of the disease. The mutation spectrum within the gene is unusual in that deletions of one or more 
exons are found in ~65% of cases (Den Dunnen et al., 1989). These deletions are known to cluster in hot 
spot regions (Oudet et al., 1992; Forrest et al., 1987), and can easily be detected in males using simple 
PCR reactions. Two multiplex PCR kits of 9 exons each were developed (Beggs et al., 1990; Chamberlain 
et al., 1988), and together detect ~98% of all deletions. Duplication analysis and the determination of 
carrier status, however, require a quantitative method of analysis. Until recently the most commonly 
applied have been Southern blotting (Forrest et al., 1987) and quantitative multiplex PCR (Ioannou et al., 
1992; Abbs and Bobrow, 1992). Southern blotting can cover all exons of the gene, but requires 6-8 blots 
to do this. This makes it time consuming, and it can be difficult to get blots of the necessary quality. 
Quantitative multiplex PCR has proven difficult to apply, and will miss mutations outside the hotspot 
regions. In addition, it implicitly assumes that the majority of duplications will be found within the 
deletion hotspots. 
We recently reported the use of Multiplex Amplifiable Probe Hybridization (MAPH) for screening all 79 
exons of the DMD gene for deletions and duplications in 2 reactions. Using this approach we were able to 
identify several small deletions and duplications not detected with other techniques, and showed that a 
duplication of exon 2, previously undescribed, was the single most common duplication found (White et 
al., 2002). 
A similar technique, Multiplex Ligation-dependent Probe Amplification (MLPA) (Schouten et al., 2002), 
has become widely used for the detection of deletions and duplications in a variety of diseases (Taylor et 
al., 2003; Rooms et al., 2004; Slater et al., 2003). In comparison to MAPH, removal of any unbound 
probes is unnecessary, making the approach easier to perform.  
In this report we have used both MAPH and MLPA to screen for duplications in different series of 
DMD/BMD patients.  
 
Materials and Methods 
 
Patients 
All patients were diagnosed with either DMD or BMD by a medical specialist. DNA samples were 




All samples were screened for deletions and duplications with either MLPA or MAPH. The MLPA 
reaction was performed with the P034 and P035 kits from MRC-Holland (Amsterdam, the Netherlands). 
These sets contain probes for all 79 exons of the DMD gene as well as the cortical promoter (Dp427c). 
The reaction was performed following the protocol described in Schouten et al 2002. After the PCR 
amplification (33-35 cycles) 2 µl of product was mixed with 10 µl Hi Di formamide and 0.1 µl ROX 500 
size standard, and separated on the ABI 3700 capillary sequencer (Applied Biosystems). MAPH was 
performed as described in White et al 2002. Peak data was derived with GeneScan and exported into 
Excel for analysis. Both MAPH and MLPA analysis was performed as described for MAPH in White et al 
2002. 
 
Determination of exon 2 duplication breakpoints.  
MLPA probes were designed in intron 1 and intron 2, based on criteria outlined in White et al 2004. 
Probes within intron 1 ended with sequences allowing amplification with the MAPH primers; the intron 2 
probes used the MLPA amplification sequences. All probes were combined in a single mix, with the 
reaction and analysis being performed as described previously (White et al., 2004).  
Based on the estimated duplication borders primers for PCR amplification were designed using the Primer 
3 program, with the forward primers in intron 2 and the reverse primers in intron 1.  Long range PCR was 
performed using the Expand Long Template PCR system (Roche), and the resulting PCR products were 
separated on a 0.8% agarose gel by electrophoresis. Bands of interest were excised and purified using the 
QIAquick PCR purification kit (Qiagen), and sequenced by the Leiden Genome Technology Center 
(www.LGTC.nl). 
 
MyoD infection, RNA isolation and RT-PCR analysis 
Amniocytes from sample LM7 were forced into myogenesis by infection with a MyoD-containing 
adenovector as described previously (Havenga et al., 2002; Aartsma-Rus et al., 2003) . RNA isolation and 
RT-PCR analysis were performed as described (Aartsma-Rus et al., 2002). The full list of primers used is 





Different patient cohorts were screened for deletions and duplications in the DMD gene using either 
MLPA or MAPH. In the first series 120 patients had been screened for deletions within the hot spot 
regions using modified multiplex PCR kits. Rescreening these revealed 9 duplications, as well as several 
smaller deletions falling outside the hot spots (Lalic et al, manuscript in preparation). One of the 
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Figure 1. Graphical results based on MLPA analysis of a non-contiguous duplication/triplication. 
 
The second series consisted of 50 patients that had been screened for point mutations and deletions. In this 
cohort we found 32 (64%) duplications. Non-contiguous rearrangements were seen in 3 samples, and a 
duplication of exon 2 was the single most common duplication seen, in this study making up 28% of all 
duplications found. The distribution of the remainder of the mutations was relatively even throughout the 
gene, but overall the mutations tended to cluster more in the 5' end of the gene. The duplications found in 
both study populations are listed in table 1. 
To see if the large number of exon 2 duplications was due to specific rearrangement hotspots we 
attempted to define the breakpoints in 11 samples, 10 from these studies and one identified previously 
(White et al., 2002). MLPA analysis with probes initially spaced ~20 kb apart throughout introns 1 and 2 
showed that the breakpoints in intron 1 were scattered, whereas 10 of the 11 breakpoints in intron 2 were 
found in the first 40 kb. The largest duplication was maximally 220 kb, whereas the smallest duplication 




D1 dup 02 
D2 dup 02 
D3 dup 02 
D4 dup 02 
D5 dup 02 
D6 dup 02 
D7 dup 02 
D8 dup 02 
D9 dup 02 
D10 dup 02 
D11 dup 02-11 
D12 dup 03-04 
D13 dup 03-11 
D14 dup 03-44 
D15 dup 03-06 
D16 dup 5-18; trip 19-41; dup 42; trip 43-44 
D17 dup 5-19; dup 38-41 
D18 dup 06-07 
D19 dup 08-13 
D20 dup 08-13 
D21 dup 08-29 
D22 dup 08-44 
D23 dup 12-30 
D24 dup 17-18 
D25 dup 22-25 
D26 dup 29-43 
D27 dup 37-43 
D28 dup 43 
D29 dup 45-55; 65-79 
D30 dup 45-65 
D31 dup 46-47 
D32 dup 46-60 
D33 dup 49-60 
D34 dup 50-59 
D35 dup 51 
D36 dup 52-55; dup 63-67; trip 68-79 
D37 dup 56-63 
D38 dup 61 
D39 dup 61-62 
D40 dup 61-63 
D41 dup 61-63 
LM7 dup 52-62 
 
Table 1. The duplications found in this study. The numbers refer to exons of the DMD gene; non-contiguous rearrangements are 




Given the apparent clustering of breakpoints within intron 2, more MLPA probes were designed within 
the first 40 kb of this intron. Retesting the 10 samples with apparently clustered intron 2 breakpoints 
showed that five of the samples had the intron 2 breakpoint within a 7 kb area, with the other five 






























72Pm                                                                  ex 2                                                           ex e 2. The minimum extent of the different exon 2 duplications, as determined by MLPA and long range PCR.  The vertical 
ndicate the approximate position of the MLPA probes; the shaded columns indicate the hotspots. 
g long range PCR (see materials and methods) it was possible to precisely define the sequence at the 
kpoint in 4 of the samples, indicating that these rearrangements were in tandem. All of the breakpoints 
an insertion or deletion of one or more nucleotides at the breakpoint junction.  
solated sample tested was derived from amniocytes, and showed a deletion of exon 63 at the mRNA 
l. Exon 63 was present in the genomic DNA, and sequence analysis did not reveal any mutation that 
t affect splicing. Analysis with MLPA showed that the mutation at DNA level was in fact a 
ication of exons 52-62.  In order to gain a greater insight as to how such a rearrangement could lead to 
kipping of an exon we performed further RT-PCR analysis. By amplifying different fragments it was 
ible to show that the rearrangement juxtaposed the duplicated exon 62 onto the original exon 64 
ure 3). 
ussion 
have screened DMD/BMD patients for duplications using the MAPH and MLPA techniques. The 
nts could be divided into different cohorts, the first unselected and the second where deletions and 
 
point mutations had already been excluded. Duplications were found in 8% of the first group, an overall 
duplication frequency comparable with what other studies have found (White et al., 2002; Den Dunnen et 
al., 1989).  In patients that had already been screened for deletions and point mutations we detected 
duplications in 64% of cases. As these samples have not been tested at the RNA level, it is likely that the 
majority of the remaining patients have mutations affecting splicing. Studies have shown that mutations 
deep in intronic sequences can activate cryptic splice sites (Beroud et al., 2004), changes that can only be 
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– An example of how a duplication at DNA level can lead to an apparent deletion at RNA level. A. RT-PCR analysis of 
 a healthy control (HC) encompassing the duplication breakpoints of LM7 in full-length dystrophin (Dp427m) and Dp71 
s. Using primers flanking exon 63 a shorter fragment lacking exon 63 was detected for LM7 when compared to the 
oth in the Dp427m and Dp71 transcripts (upper two panels). Using a reversed primer in exon 53 in combination with 
rimers in exon 62 (third panel) or in the first exon of Dp71 (fourth panel) a clear band containing exon 62 and 63, or the 
t exon spliced to exon 52 could be produced for LM7, whereas only aspecific bands were observed for the control. Using 
 cDNA and reversed primer, a fragment could be amplified for both LM7 and the control with forward primers in exon 
 panel).  M is 100 bp size marker, -RT is negative control.  
der of the exons in the duplicated region, with the arrows indicating the different primers that were used in determining 
rs of the rearrangement.  
 
Combining the data in this report with all other duplications previously described, and comparing these 
with the most common deletions, shows a marked difference in distribution of the two types of 
rearrangements (table 2). More than 50% of duplications are located in the 5’ end of the gene, whereas the 
most common deletions cluster almost exclusively between exons 45-52. The reason for this difference is 
not clear, but the disparity, coupled with the far greater incidence of deletions, suggests that there are 
fundamental differences in the origins of the two types of rearrangements in the DMD gene.  
It has been previously described for several genes on the X chromosome, including the DMD gene, that 
deletions are predominantly maternally inherited, whereas duplications mostly originate in the male 
germline (Hu et al., 1990; Grimm et al., 1994). It has also been shown that the distribution of mutations in 
the DMD gene when comparing mosaic and nonmosaic cases is significantly different (Passos-Bueno et 
al., 1992). It is likely that different chromosomal regions show varying levels of susceptibility to 
rearrangement, depending on the type or stage of cell division. This has been described for rearrangements 
in the NF1 gene, where the extent of the deletion is dependent on whether the rearrangement occurs 
during mitosis or meiosis (Kehrer-Sawatzki et al., 2004). The specific mechanism responsible for the 
rearrangement may also be dependent on factors such as cell type and position in the cell cycle. 
 
ranking deleted exon(s) % ranking duplicated exon(s) % 
1 45-47 7.0 1 2* 8.5 
2 45 5.3 2= 3-7 3.5 
3 48-50 5.1 2= 8-9 3.5 
4 45-48 4.3 4= 2-7 3.0 
5 45-50 4.0 4= 51 3.0 
6 51 3.9 6= 3-11 2.0 
7 44 3.5 6= 8-13 2.0 
8 49-50 2.8 8= 3-4 1.5 
9= 3-7 2.3 8= 9-14* 1.5 
9= 45-52 2.3 8= 17 1.5 
11 46-47 2.3 8= 22-25* 1.5 
12 50 2.2 8= 43 1.5 
13 45-49 2.0 8= 44 1.5 
 
Table 2. The most frequently occurring deletions and duplications. It is clear that the region most commonly deleted is between 
exons 45-52; in contrast the duplications occur more frequently in the 5' end of the gene. A * indicates a duplication that has not 
been described as a deletion. Data from The Leiden Muscular Dystrophy pages (LMDp), based on the DMD_deldup database at 
2004/10/26 (Data kindly provided by Ivo Fokkema). 
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Several different mechanisms are known to cause rearrangments (Shaffer and Lupski, 2000; Helleday, 
2003; Hu et al., 1991). For example, intrachromatid looping can occur through the interaction of 
palindromic sequences, with the intervening sequence being deleted. This mechanism is not expected to 
produce a duplication. In contrast, unequal crossing over is expected to produce deletions and duplications 
at an equal frequency. This mechanism has been demonstrated to be responsible for many genomic 
disorders, via nonallelic homologous recombination between low copy repeats (Emanuel and Shaikh, 
2001; Ji et al., 2000; Stankiewicz and Lupski, 2002). Unequal crossing over between Alu repeats has also 
been described within several genes, including DMD (Prior et al., 1997; Deininger and Batzer, 1999; Hu 
et al., 1991). The 3 duplication breakpoints in the DMD gene that had previously been described showed 
that all were tandem duplications. In one case homologous recombination between Alu elements was seen, 
the other 2 cases appeared to be due to non-homologous end joining (NHEJ), possibly mediated by 
topoisomerases. It was suggested that the rearrangements were the result of unequal crossing over between 
sister chromatids (Hu et al., 1991; Hu et al., 1990; Hu et al., 1989) .  
The most frequently occurring duplication described to date in the DMD gene is of exon 2. Our initial 
analysis of the size and location of 11 unrelated exon 2 duplication cases showed that they differed in size. 
Sequencing of four of the breakpoints of the exon 2 duplications showed the removal or addition of one or 
more nucleotides at the junction, consistent with NHEJ. Scattered breakpoints is another characteristic 
feature of NHEJ, yet two distinct hotspots of ~4 kb and ~7 kb were seen, each containing five of the intron 
2 breakpoints. This suggests that the event initiating the duplication occurred in intron 2. 
It is interesting to note that a deletion of only exon 2 has never been reported. There are several possible 
reasons for this. It could be that such deletions do occur, but do not result in a severe DMD phenotype. It 
is also possible that such a mutation is somehow embryonic lethal. These explanations seem unlikely, as 
there is no obvious reason why an out of frame deletion should not lead to a DMD-like phenotype, when 
other deletions in the same region do. Likewise, larger deletions encompassing exon 2 have been 
described in DMD patients, making it unlikely that an individual with a smaller deletion in the same 
region would be non-viable before birth. A more feasible explanation is that the mechanism responsible 
for the duplication does not involve unequal crossing over.  An example of such a mechanism is synthesis 
dependent NHEJ (Helleday, 2003). This will result in a tandem duplication at the site of a double stranded 
break, without unequal crossing over taking place. If the repair can procede in either direction, then one 
would also expect a similar number of duplications starting in intron 2, i.e. extending from exon 3. As can 
be seen in table 2, this is in fact the case, where duplications starting at exon 3 occur at a similar 
frequently to exon 2 duplications. Alternative mechanisms for duplication and deletion formation may 
therefore underly the differences seen in distribution and parent-of-origin of the two mutation types. 
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We found 4 cases involving non-contiguous duplications and/or triplications, suggesting multiple 
mutational events. The chance of 2 independent duplications is low, and it is more likely that the initial 
duplication was larger, covering the full extent of the different rearrangments. It is known that 
duplications can be unstable, with reversion to the normal situation (Helleday et al., 1998; Monnat et al., 
1992; Hu et al., 1990). It is possible that this reversion will not always be absolute, leading to unusual, 
non-contiguous rearrangements. Notably in two of these cases a duplication would have been detected in 
both samples using probes located in the hotspot regions, yet the complete extent of the rearrangements 
would not have been identified. Indeed, in the case of sample D29, the duplication of exons 45-55 is 
expected to be an in-frame mutation, which is presumed to lead to a BMD-type phenotype. This patient in 
fact has a DMD phenotype, presumably as the more 3' duplication disrupts the reading frame. Despite 
non-contiguous rearrangements being rare events, the fact that they have been shown to occur reinforces 
the importance of screening the entire gene, in particular when the reading frame rule is going to be used 
prognistically. 
The application of the reading frame rule to duplications assumes that the duplication is in tandem.  
Although this has been the case in all the DMD gene duplication breakpoints described to date (Hu et al., 
1991), the consequence of a duplication on the RNA molecule may not always be as simple. An example 
of this was a duplication of exon 52-62 seen in sample LM7. The actual effect of this mutation at RNA 
level was an apparent skip of exon 63. This is of importance not only in the predictive diagnosis of disease 
progression, but also for targetted gene therapy (van Deutekom et al., 2001; Lu et al., 2003). In addition, it 
is theoretically possible that the apparent duplication is in fact a transposition, which, if outside the DMD 
gene, would have no effect on the reading frame. 
In conclusion, we show here that duplications within the DMD gene are distributed differently compared 
to deletions, and can be complex rearrangements. In addition, we provide evidence that the mechanism 
involved in generating the exon 2 duplications, and by extension other duplications as well, does not 
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A
range of genetic disorders has been revealed to be
caused by deletions and duplications within the
genome.1–3 In addition, computational analysis of the
recently completed human genome sequence4 suggests that
many more rearrangements might exist. Such rearrange-
ments are either directly involved in genetic disease or may
play an important, but yet to be determined, role in human
variation and multifactorial diseases. Efficient methods are
thus required to screen for and detect such rearrangements.
While changes of several megabases are usually cyto-
genetically visible, smaller changes require other methods of
analysis. Many techniques have been applied, including
dinucleotide repeat polymorphism analysis,5 array compara-
tive genomic hybridisation,6 fluorescent in situ hybridisation
(FISH),7 8 quantitative multiplex PCR,9 10 and Southern
blotting.11 12 The last three mentioned are the most commonly
applied techniques,13 with FISH analysis preferred as the
method of choice in many clinical centres. FISH has the
advantage that the analysis is visual, with the number of
fluorescent signals determining the copy number of the
region examined. However, the method is rather laborious,
with cell culturing and preparation of metaphase spreads
being necessary, but difficult and time consuming steps.
FISH is thus expensive and not suitable for high throughput
analysis. In addition, as FISH probes are usually artificial
chromosomes or cosmids, it precludes the analysis of small
rearrangements, and duplications can be difficult to detect.
Quantitative multiplex PCR seems an attractive alternative.
It can co-amplify up to 15 products per sample, with the
amount of each product corresponding to the copy number of
the locus. However, achieving consistent results has proven
to be technically challenging, and the method requires
fluorescent labels and sophisticated equipment.
Southern blotting is more flexible and does not require
sophisticated equipment. Its disadvantages are that it is
laborious, requiring several blots if multiple loci are to be
examined, and its accuracy critically depends on the quality
of the blot, with duplications being particularly difficult to
detect.
We have applied an alternative method, based on multiplex
amplifiable probe hybridisation (MAPH).14 MAPH facilitates
the quantitative recovery of probes hybridised to immobilised
genomic DNA, and thus the detection of deletions and
duplications. Previous studies have separated the resultant
PCR products on acrylamide gels or with a capillary
sequencer, using a radioactively14 or fluorescently15 labelled
primer respectively. To speed up the analysis, we used a chip
based gel electrophoresis system (Lab-on-a-chip; Agilent,
Palo Alto, CA, USA) to analyse and quantify the reaction
products. This system analyses 12 unlabelled samples in
,30 min, with quantitative data being generated automati-
cally by the accompanying software.
We have tested the efficacy and reliability of this
methodology by performing carrier detection in Duchenne
muscular dystrophy (DMD). This lethal disease is caused by a
deletion or duplication of one or more of the 79 exons of the
DMD gene in ,70% of cases.11 16 As the DMD gene is located
on the X chromosome, deletion screening in male DMD
patients is relatively simple.17 18 Detecting duplications or
carrier status in females, however, requires a quantitative
method of analysis. By selecting probes for exons within and
outside the rearranged regions, it is possible to compare the
relative ratios for the two groups. As multiple probes in
parallel hybridisations are used, a high level of redundancy,
and thus reliability, can be obtained.
In this paper, we show the validity of this approach by
analysing 17 potential carriers for deletion/duplication
mutations.
METHODS
Probe preparation and the MAPH protocol used have been
described previously.15 Based on the mutation to be tested, a
specific set of probes were selected. Where possible, at least
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: FISH, fluorescent in situ hybridisation; MAPH, multiplex
amplifiable probe hybridisation; MLPA, multiplex ligation dependant
probe amplification
Key points
N When a deletion or duplication mutation has been
detected in an index case, relatives may wish to be
analysed for carrier status. Methods currently applied
are either technically demanding, time consuming or
not always applicable.
N We have previously described multiplex amplifiable
probe hybridisation (MAPH) as a versatile method for
the detection of deletions and duplications, applied to
the analysis of Duchenne muscular dystrophy patients.
N Here we show that MAPH is a reliable, quick, and
inexpensive alternative for fluorescent in situ hybridisa-
tion as a method for carrier detection of deletion/
duplication mutations. Following MAPH-based hybri-
disation and PCR, the amplification products are
separated using ‘‘Lab-on-a-chip’’ electrophoresis,
which quantitatively processes 12 samples in 30
minutes.
N The method is very rapid, taking less than 24 h.
Moreover, as several independent probes and dupli-
cates can be run in parallel, it is also very reliable. This
approach is an attractive alternative for current FISH-
based screens, and should especially facilitate genetic






two probes within the rearrangement were included, with a
minimum of 1 exon from an unaffected region of the gene. In
addition, at least two control probes were chosen from a set
of autosomal probes. A minimum of two hybridisations were
performed on each sample; if the mutation was of a single
exon, then three separate hybridisations with the specific
probe were carried out.
Following hybridisation and washing, the PCR reaction
was performed as previously described,15 with both primers
being unlabelled. Bioanalyzer 2100 (Agilent) analysis was
carried out according to the manufacturer’s instructions
(http://www.chem.agilent.com). Briefly, the DNA500 chip
was preloaded with a gel matrix containing a DNA dye. From
each PCR sample, 1 ml (,10 ng) of product was added, with
a maximum of 12 samples loaded per chip. The samples were
then separated, with the data being subsequently exported to
Excel (Microsoft Corp.).
Exon specific peaks were normalised within each sample to
unlinked probes, with each exon subsequently being normal-
ised to 1.0 based on those samples known to be unaffected at
the respective loci.
Ratios derived from probes outside the rearranged regions
were compared with those from probes within the rearranged
regions with an independent samples Student’s t test. An
individual was considered to be a carrier of the mutation if
the difference between the two groups was statistically
significant (p,0.01). Confidence intervals of 99% were
calculated, giving a predicted error rate of 1%. Statistical
analysis was performed using SPSS 10.0.7 (SPSS Inc., Palo
Alto, CA, USA).
RESULTS
Analysis started with the selection of the probes to be tested.
After hybridisation and subsequent amplification, the PCR
products were separated on the Lab-on-a-chip. In the
resulting trace pattern, each peak corresponded to a specific
probe. As shown in fig 1, changes in peak height and area
correspond to a deletion or duplication at that specific locus.
Although most mutations could be detected visually,
quantitative analysis was always performed. The area under-
neath each peak was calculated by the Bioanalyzer software
and subsequently tabulated in Excel. A typical example is
shown in table 1. In this analysis, six samples were tested:
two deletion and four duplication carriers. Based on the
exons known to be affected, four DMD exon probes were
chosen, ensuring that for each sample at least one exon gave
a normalised ratio of ,1.0. This probe represents the control
for hybridisation quality. As can be seen in this example,
deletions and duplications could be detected as ratios of
around 0.5 and 1.5 respectively. All samples were screened at
least twice, with the data from each sample being collated.
In total, 17 potential DMD carriers were analysed, with the
results summarised in table 2. The extent of the mutations
varied, ranging from a deletion or duplication of a single exon
to a deletion of 37 exons. Of the 17 samples tested, 13 were
shown to be mutation carriers. This agreed completely with
the results found with other methods, namely FISH,
Southern blotting or by MAPH analysed by capillary
electrophoresis.
Although duplications are known to be more difficult to
detect than deletions, the results were unequivocal in all
cases. All carriers had a p value of ,0.001, whereas the four
non-carriers had p values >0.10.
DISCUSSION
We describe a novel method for the clinical diagnosis of
deletion/duplication mutations, which we consider an attract-
ive alternative for FISH analysis. Based on prior knowledge
as to where a mutation might be (index patient), a set of
probes is selected, of which some are located inside the
rearranged region, some directly flanking and some from
other, unrelated regions in the genome. Rapid, quantitative
analysis of the reaction products is possible using the Lab-
on-a-chip from Agilent. This chip allows the electrophoretic
separation of 12 samples in ,30 min, providing a detailed
analysis of each peak.
Unless the suspected mutation was of a single exon, at
least two probes within the region of interest were chosen,
Figure 1 An example of the trace patterns obtained from the Bio-
analyzer software. Changes in the peak height and area correspond to
changes in copy number of the specific probe. The numbers refer to
DMD exons, with autosomal control probes indicated with C. M indicates
the two marker alignment peaks, at 15 and 600 bp. These are used by
the software for lane to lane alignment. Four different cases are shown
here: A, no mutation; B, duplication exon 4; C, duplication exon 12; D,
deletion exon 45. In each case, the affected exon is indicated with an
asterisk.
Table 1 Lab-on-a-chip analysis
Sample number
Mean1 2 3 4 5 6
A
Exon 52 5.31 6.86 8.08 14.81 7.27 6.40 —
Exon 62 12.66 8.14 13.68 12.16 5.71 5.08 —
C1 16.77 12.11 14.50 18.43 8.84 7.06 —
C2 16.12 8.86 11.54 13.42 7.03 5.69 —
C3 17.74 12.14 13.73 18.08 8.61 6.82 —
Exon 54 6.68 8.71 10.93 18.75 9.51 6.76 —
Exon 49 7.32 4.34 10.18 12.46 6.60 4.88 —
B
Exon 52 0.10 0.21 0.20 0.30 0.30 0.33 0.21
Exon 62 0.25 0.25 0.34 0.24 0.23 0.26 0.25
Exon 54 0.13 0.26 0.27 0.38 0.39 0.35 0.27
Exon 49 0.14 0.13 0.26 0.25 0.27 0.25 0.25
C
Exon 52 0.48 1.00 0.95 1.43 1.43 1.57 —
Exon 62 1.00 1.00 1.40 0.96 0.92 1.04 —
Exon 54 0.48 0.96 1.00 1.41 1.44 1.30 —
Exon 49 0.56 0.52 1.04 1.00 1.08 1.00 —
Following electrophoresis, the peak data areas from six samples (1–6)
were imported into Excel from the Bioanalyzer software (Section A).
By dividing the area under each exon (specific peak is divided by the sum
of the area of the control peaks), a ratio for each exon was obtained
(Section B).
These ratios are were then normalised to 1.0 based on the mean ratio of
samples known to be unaffected at that specific locus (Section C).
The normalised ratios of the exons that are duplicated are shown in bold,
those of the deleted exons are in italics.




and all samples were tested in at least two hybridisations
(three hybridisations for single exon mutations). Due to the
simplicity of the technique, it is little extra effort to perform
these hybridisations in parallel, and no time is lost. Data
derived from the different hybridisations for each sample
were collated, and the ratios were separated into two groups
based on whether the probes were localised within or outside
the potential breakpoints. By combining the data, the
potential influence of any false positives and negatives was
minimised. Previous studies have used different methods of
assessing a positive result, ranging from setting arbitrary
boundaries of 0.75 and 1.25,19 to bivariate analysis for each
affected probe.20 We have taken advantage of the fact that the
potential mutation was already known, by comparing the
ratios derived from probes within and outside the rearranged
region. If the difference was not statistically significant
(p.0.01) then it was assumed that the individual was not a
carrier. Conversely, a significant difference was taken to
indicate the presence of the suspected mutation. This was
confirmed by the results obtained. As can be seen by the 99%
confidence intervals, the actual error rate will be considerably
lower than the 1% predicted.
In some cases, the mother may be a mosaic, meaning that
the mutation will not be present in all cells. This makes the
analysis more difficult. Whether such cases would be
detected by the described method depends on several factors,
including the standard deviation of the probes, the number of
different probes that can be used, and the degree of
mosaicism. Due to the influence of the unaffected cells, a p
value between 0.01 and 0.1 may occur, prompting further
analysis.
There are several advantages to using MAPH in combina-
tion with the Lab-on-a-chip. It can be broadly applied, as a
variety of probes can be chosen and all can be used under
identical PCR conditions. The resolution is limited only by the
size of the probes, which can be as short as 100 base pairs.
Analysis is rapid, simple and can be readily automated, as
data can be exported to Excel. The DNA chip can measure
DNA fragments at less than 1 ng, meaning that unlabelled
samples can be directly loaded on the chip without any prior
concentration.
The advantages described here for MAPH based analysis
also apply to a similar technique, multiplex ligation
dependant probe amplification (MLPA).21 MLPA is based on
the specific hybridisation and subsequent ligation of two
oligonucleotides, with only ligated end products generating a
target for PCR amplification. MLPA has the advantage of
being a ‘‘single tube’’ assay, and requiring less input DNA.
However, compared to MAPH, probe preparation for MLPA is
more time consuming. The method of choice would be based
on the exact goal and probe availability.
Many probes for MAPH/MLPA have already been devel-
oped15 19–22 and as more probes become available, the
possibility of screening other regions of the genome increases
(Kriek et al, manuscript in preparation). The combination of
these techniques with a rapid and simple method of analysis
should allow diagnostic laboratories to implement this as a
broadly applicable, robust, and readily automated method for
high resolution copy number determination.
ACKNOWLEDGEMENTS
We would like to thank Professor Bert Bakker (LUMC) for providing
the DNA samples. This work was financially supported by Zon MW
(Grant 2100.0026).
Authors’ affiliations
. . . . . . . . . . . . . . . . . . . . .
S J White, E Sterrenburg, G-J B van Ommen, J T den Dunnen,
M H Breuning, Human and Clinical Genetics, Leiden University Medical
Center, Wassenarrseweg 72, Leiden, the Netherlands
Correspondence to: Dr Johan T den Dunnen , Human and Clinical
Genetics Leiden University Medical Center Wassenarrseweg 72 Leiden,
the Netherlands; ddunnen@lumc.nl
REFERENCES
1 Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M,
Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H,
Klijn JG, Vasen HF, Cornelisse CJ, van ’t Veer LJ, Bakker E, van Ommen GJ,
Devilee P. BRCA1 genomic deletions are major founder mutations in Dutch
breast cancer patients. Nat Genet 1997;17:341–5.
2 Patel PI, Garcia C, Montes de Oca-Luna R, Malamut RI, Franco B,
Slaugenhaupt S, Chakravarti A, Lupski JR. DNA duplication associated with
Charcot-Marie-Tooth disease type 1a. Cell 1991;66:219–32.
3 Kurotaki N, Imaizumi K, Harada N, Masuno M, Kondoh T, Nagai T,
Ohashi H, Naritomi K, Tsukahara M, Makita Y, Sugimoto T, Sonoda T,
Hasegawa T, Chinen Y, Tomita Ha HA, Kinoshita A, Mizuguchi T, Yoshiura
Ki K, Ohta T, Kishino T, Fukushima Y, Niikawa N, Matsumoto N.
Haploinsufficiency of NSD1 causes Sotos syndrome. Nat Genet
2002;30:365–6.









99% CI of the
difference p Value Carrier?
1 dup 58-63 1.44 (3) 1.01 (11) –0.58 to –0.28 ,0.001 Yes
2 del 10-46 0.47 (10) 0.97 (13) 0.30 to 0.70 ,0.001 Yes
3 dup 44-57 1.51 (13) 1.07 (24) –0.58 to –0.31 ,0.001 Yes
4 dup 50-55 1.39 (6) 0.98 (19) –0.51 to –0.30 ,0.001 Yes
5 dup 52-55 1.48 (6) 1.03 (13) –0.61 to –0.29 ,0.001 Yes
6 dup 51-55 1.60 (7) 0.99 (18) –0.94 to –0.26 ,0.001 Yes
7 del 45 0.39 (3) 1.02 (15) 0.46 to 0.80 ,0.001 Yes
8 del 49-54 0.51 (10) 1.00 (19) 0.39 to 0.59 ,0.001 Yes
9 del 48-50 0.53 (5) 1.01 (12) 0.41 to 0.55 ,0.001 Yes
10 dup 2-9 1.01 (4) 0.98 (11) –0.16 to 0.11 0.63 No
11 dup 3-7 1.43 (6) 0.94 (20) –0.65 to –0.32 ,0.001 Yes
12 dup 12-13 1.47 (4) 1.03 (17) –0.64 to –0.23 ,0.001 Yes
13 dup 2-6 1.28 (4) 1.01 (17) –0.42 to –0.11 ,0.001 Yes
14 dup 2-7 1.07 (4) 0.94 (8) –0.35 to 0.12 0.13 No
15 del 52 0.55 (3) 0.96 (12) 0.10 to 0.63 ,0.001 Yes
16 del 8-43 1.00 (4) 0.96 (6) –0.24 to 0.15 0.47 No
17 dup 12 1.10 (3) 1.00 (12) –0.28 to 0.07 0.10 No
Listed are the ratios derived from probes within and outside the rearrangements.
The mean ratio for each sample is given (duplicated in bold, deleted in italics), with the figure in brackets being the
number of probes tested.
The p values were determined with Student’s t test, and the associated 99% confidence intervals (CI) of the
differences are also shown.




4 Bailey JA, Gu Z, Clark RA, Reinert K, Samonte RV, Schwartz S, Adams MD,
Myers EW, Li PW, Eichler EE. Recent segmental duplications in the human
genome. Science 2002;297:1003–7.
5 Clemens PR, Fenwick RG, Chamberlain JS, Gibbs RA, de Andrade M,
Chakraborty R, Caskey CT. Carrier detection and prenatal diagnosis in
Duchenne and Becker muscular dystrophy families, using dinucleotide repeat
polymorphisms. Am J Hum Genet 1991;49:951–60.
6 Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL,
Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG. High
resolution analysis of DNA copy number variation using comparative genomic
hybridization to microarrays. Nat Genet 1998;20:207–11.
7 Rosenberg C, Navajas L, Vagenas DF, Bakker E, Vainzof M, Passos-
Bueno MR, Takata RI, Van Ommen GJ, Zatz M, Den Dunnen JT. Clinical
diagnosis of heterozygous dystrophin gene deletions by fluorescence in situ
hybridization. Neuromusc Disord 1998;8:447–52.
8 Petrij F, Dauwerse HG, Blough RI, Giles RH, van der Smagt JJ, Wallerstein R,
Maaswinkel-Mooy PD, van Karnebeek CD, van Ommen GJ, van Haeringen A,
Rubinstein JH, Saal HM, Hennekam RC, Peters DJ, Breuning MH. Diagnostic
analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for
microdeletion detection and low number of protein truncating mutations. J Med
Genet 2000;37:168–76.
9 Duponchel C, Di Rocco C, Cicardi M, Tosi M. Rapid detection by fluorescent
multiplex PCR of exon deletions and duplications in the C1 inhibitor gene of
hereditary angioedema patients. Hum Mutat 2001;17:61–70.
10 Yau SC, Bobrow M, Mathew CG, Abbs SJ. Accurate diagnosis of carriers of
deletions and duplications in Duchenne/Becker muscular dystrophy by
fluorescent dosage analysis. J Med Genet 1996;33:550–8.
11 Den Dunnen JT, Grootscholten PM, Bakker E, Blonden LA, Ginjaar HB,
Wapenaar MC, van Paassen HM, van Broeckhoven C, Pearson PL, van
Ommen GJ. Topography of the DMD gene: FIGE and cDNA analysis of 194
cases reveals 115 deletions and 13 duplications. Am J Hum Genet
1989;45:835–47.
12 van Overveld PG, Lemmers RJ, Deidda G, Sandkuijl L, Padberg GW,
Frants RR, van der Maarel SM. Interchromosomal repeat array interactions
between chromosomes 4 and 10: a model for subtelomeric plasticity. Hum
Mol Genet 2000;9:2879–84.
13 Armour JA, Barton DE, Cockburn DJ, Taylor GR. The detection of large
deletions or duplications in genomic DNA. Hum Mutat 2002;20:325–37.
14 Armour JA, Sismani C, Patsalis PC, Cross G. Measurement of locus copy
number by hybridisation with amplifiable probes. Nucl Acids Res
2000;28:605–9.
15 White S, Kalf M, Liu Q, Villerius M, Engelsma D, Kriek M, Vollebregt E,
Bakker B, van Ommen GJ, Breuning MH, den Dunnen JT. Comprehensive
detection of genomic duplications and deletions in the DMD gene, by use of
multiplex amplifiable probe hybridization. Am J Hum Genet
2002;71:365–74.
16 Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM.
Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and
preliminary genomic organization of the DMD gene in normal and affected
individuals. Cell 1987;50:509–17.
17 Chamberlain JS, Gibbs RA, Ranier JE, Nguyen PN, Caskey CT. Deletion
screening of the Duchenne muscular dystrophy locus via multiplex DNA
amplification. Nucl Acids Res 1988;23:11141–56.
18 Beggs AH, Koenig M, Boyce FM, Kunkel LM. Detection of 98-percent DMD/
BMD gene deletions by polymerase chain reaction. Hum Genet
1990;86:45–8.
19 Sismani C, Armour JA, Flint J, Girgalli C, Regan R, Patsalis PC. Screening for
subtelomeric chromosome abnormalities in children with idiopathic mental
retardation using multiprobe telomeric FISH and the new MAPH telomeric
assay. Eur J Hum Genet 2001;9:527–32.
20 Hollox EJ, Atia T, Cross G, Parkin T, Armour JA. High throughput screening of
human subtelomeric DNA for copy number changes using multiplex
amplifiable probe hybridisation (MAPH). J Med Genet 2002;39:790–5.
21 Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G.
Relative quantification of 40 nucleic acid sequences by multiplex ligation-
dependent probe amplification. Nucleic Acids Res 2002;30:e57.
22 Akrami SM, Winter RM, Brook JD, Armour JA. Detection of a large TBX5
deletion in a family with Holt-Oram syndrome. J Med Genet 2001;38:E44.












White S.J., Uitte de Willige S., Verbove D., Politano L., Ginjaar H.B., 
Breuning M.H., den Dunnen J.T. Sarcoglycanopathies and the risk of 







Sarcoglycanopathies and the risk of undetected deletion alleles in diagnosis 
 
Stefan J. White, Shirley Uitte de Willige, Dennis Verbove, Luisa Politano*, Ieke Ginjaar, 
Martijn H. Breuning and Johan T. den Dunnen. 
 
Human and Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands;  





We have designed Multiplex Amplifiable Probe Hybridization (MAPH) probes for each exon of 
the sarcoglycan genes SGCA, SGCB, SGCG and SGCD (33 in total). The set was used to screen 
DNA from limb-girdle muscular dystrophy (LGMD) patients for the presence of pathogenic 
deletion or duplication mutations. An unexpected heterozygous deletion of SGCG exon 7 was 
detected in a patient from a consanguineous family segregating a known c.525delT mutation. The 
exon 7 deletion was inherited from the father, who was part of the consanguineous c.525delT 
branch of the family but who screened negative for the c.525delT mutation. The deletion 
breakpoint was mapped, isolated and sequenced. Identical breakpoints were detected in 2 
unrelated LGMD patients from Southern Italy. Haplotype analysis showed identical alleles 
segregating with the mutation in all three patients, suggesting a common ancestor. Exonic 
deletions in sarcoglycanopathies appear to be rare events. However, we recommend screening for 
exonic deletions / duplications in patients where a mutation has not been identified in both alleles, 
as well as in seemingly homozygous cases where segregation of the mutations can not be 
confirmed in the parents. 
87
Introduction
The Limb-Girdle Muscular Dystrophies (LGMD) are a heterogeneous group of neuromuscular 
disorders, characterized by progressive wasting of the limb-girdle musculature. The proteins 
involved show a wide range of functions and cellular localization (1). A subset of these are α, β, γ 
and δ sarcoglycan, which are transmembrane glycoproteins that form part of the dystrophin-
associated glycoprotein complex (DAG)(2,3). The absence of any one of these subunits leads to 
the reduction or loss of the other sarcoglycans, which in turn disrupt the DAG complex.  
The sarcoglycanopathies are recessive disorders, however there are often cases where a mutation 
can be identified in only one allele. In addition, it is not always possible to confirm homozygous 
mutations through analysis of the parents. As the majority of sarcoglycan mutations described 
have been point mutations, screening at the DNA level has been almost exclusively performed by 
direct sequencing. This method however is not quantitative, meaning that deletions or 
duplications will not be detected.  
Although several different methods have been described for detecting copy number changes (4), 
these have not yet been been applied for the sarcoglycanopathies in a routine setting.  The most 
commonly used methods include quantitative Southern blotting (5), quantitative multiplex PCR 
(6) and  fluorescent in situ hybridization (FISH) (7), but these are either time consuming, 
technically challenging or of insufficient resolution to find small rearrangements. We have used 
Multiplex Amplifiable Probe Hybridization (MAPH) (8) to look for copy number changes in the 
sarcoglycan α, β, γ and δ genes in 5 sarcoglycanopathy patients diagnosed as being homozygous 





All patients were diagnosed by a neurologist as having a neuromuscular disorder, based on their 
clinical features. Immunohistochemical analysis was performed as previously described (9), and 
had shown in each case the presence of dystrophin and abnormal levels of  the sarcoglycan 
proteins. Based on these results, sequence analysis of the gene(s) showing the lowest levels of 
expression was performed as previously described (9). This revealed an apparent homozygous 
point mutation in one of the sarcoglycan genes in 5 cases (LG 1-5), whereas a mutation was 






Mutations detected by sequencing  exon(s) of gene 
L1 SGCG [c.525delT]+ [c.525delT] 6 
L2 SGCG [c.525delT]+ [c.525delT] 6 
L3 SGCG [c.525delT]+ [c.525delT] 6 
L4 SGCA [c.229C>T]+ [c.229C>T] 3 




6 and 7 
Table 1. The patients tested in this study. The mutations are described based on the following reference sequences; 
SGCA:NM_000023.1, SGCB:NM_000232.3, SGCG:NM_000231.1. In each case +1 is taken to be the A of the ATG 
initiation codon. 
 
This was a 5-year-old boy, born of non-consanguineous North African parents. He showed tip-toe 
walking and progressive lower limb weakness from the age of 2 years. Motor skills such as stair 
climbing and cycling were progressively lost. Clinical examination at the age of 5 years showed 
muscular weakness of the upper and lower limb girdle and Gower's sign, with no overt cognitive 
impairment. The patient has three healthy siblings. Further investigation showed a family history 
of neuromuscular disorders (Figure 1). The brother of the patient's paternal grandfather has three 
grandchildren (one boy and two girls) with a DMD-like phenotype: these grandchildren born 
from consanguineous Moroccan parents were diagnosed as LGMD2C patients, and one has been 
described in a previous paper (9). The siblings were homozygous for a 1 bp deletion (525delT) in 




To allow screening for whole exon rearrangements MAPH probes for the exons of the α, β, γ and 
δ sarcoglycan genes were developed (33 in total).  Probe preparation and the MAPH protocol 
have been described (10).  Briefly, a DNA sequence covering or in close proximity to each exon 
was PCR amplified and cloned into the pGEM-T easy vector (Promega). This sequence was 
reamplified with vector-specific primers.  In this way all probes could be co-amplified with only 
one pair of primers.  The probes were combined and hybridized to immobilized genomic DNA.   
Following stringent washing the remaining probes were recovered from the filter and amplified 
by PCR. Using a fluorescent primer and capillary electrophoresis the peaks corresponding to each 
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MAPH analysis was initially performed on genomic DNA from 12 healthy control samples to 
determine probe variation. In total 28 of the 33 probes gave consistent ratios, and were included 
in subsequent screening tests.  The five probes excluded (SGCA exons 5 and 7, SGCG exon 3 and 
SGCD exons 2 and 4), did not cover any of the homozygous point mutations to be analyzed. 
Following MAPH analysis no copy number mutations were detected in any of the 5 patients 
diagnosed as having a homozygous point mutation. Analysis of DNA from patient LG 6 showed 
that exon 7 of the SGCG gene was heterozygously deleted, i.e.  the height of the corresponding 
peak was ~50% of that in normal controls, whereas the other 27 probes were within normal 
limits.  Testing DNA from the parents showed that the father (LG 6.1) was a carrier for the 
deletion, whereas the mother (LG 6.2) did not have the deletion.  As there were several relatives 
of the father who also had been diagnosed with γ-sarcoglycanopathy, genomic DNA from these 
patients was also tested for an exon 7 deletion. No deletion was detected (data not shown). 
Long Range PCR 
To confirm the deletion and determine the breakpoints, long range PCR was initially performed 
on genomic DNA from both LG 6 and LG 6.1. As exon 8 of the SGCG gene was known to be 
present, the reverse primer was located within this sequence. Using the DNA sequence from the 
Human Genome Working Draft  (April 2003) several forward primers were designed in intron 6. 
These primers were spaced at  ~5kb intervals,  extending  from the 5' end of exon 6, until exon 7.  
With one particular pair of primers (forward – TGGATGTGGTATATATGCGATCGTG; reverse 
- GCTTGGGTAAGCACACAGTTTCAG) a 9kb fragment was expected, but a product of ~2.5 
kb was amplified from both the patient and his father.  Sequence analysis showed that the PCR 
product spanned the deletion breakpoint, and that the entire exon was deleted.  It was not a simple 
rearrangement, with an insertion of 6 bp between the breakpoints (Figure 2). 
Two unrelated patients (N66 and N950) from Italy, previously reported as being homozygous for 
a deletion of exon 7 of the SGCG gene (12), were also tested with the same primer pair. Both 
DNA samples gave a similar size PCR junction fragment, and sequence analysis revealed the 
identical deletion breakpoint as seen in LG 6. Analysis of the parents of N950 showed that both 
were heterozygous carriers of the deletion. As the identical mutation suggested either a recurrent 
mutation or a common ancestor, haplotype analysis was performed on the 3 patients and 25 
CEPH control samples. The haplotype D13S115 (165 bp), D13S232 (112 bp) and D13S292 (205 
bp) was found in 5/6 chromosomes in the affected individuals, and in a maximum of 4/50 
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chromosomes in the control samples. Analysis with Fisher's exact test showed this difference to 
be significant (p<0.001), strengthening the argument for a common ancestor. 
 
 
22788031 CCAACTGGTGACCTCAGCAGAGAAGGATTTTAATAATCAAGTG 22788073 
         |||||||||||||||||-------------------------- 
         CCAACTGGTGACCTCAGACACTAGCTCCGATGTCCTTCACAGA 
         -----------------------||||||||||||||||||||    
22794597 GTGTTGCAAGGGATGGGCCAGGCGCTCCGATGTCCTTCACAGA 22794639 
 
Figure 2. The sequence across the deletion breakpoint (middle row). The six nucleotides underlined indicate the 
insertion. The numbers indicate the nucleotide position based on the sequence of chromosome 13 from the Human 




We report here the identical single exon deletion in three unrelated individuals diagnosed with γ-
sarcoglycanopathy. The extended family of patient LG 6 has been described (9).  Several 
individuals had been diagnosed with γ-sarcoglycanopathy, but were all concluded to be 
homozygous for the single nucleotide deletion c.525delT. Unexpectedly, these were all on the 
paternal side, and the index patient inherited the point mutation c.525delT from his mother. We 
found that the father has an exon 7 deletion in one allele, with no other affected relatives tested 
having the same deletion. 
Exonic deletions in the SGCG gene have been rarely described (table 2). There was a single 
report in the literature of a deletion of exon 7 of SGCG, which had been found homozygously in 
two unrelated individuals in a village in Southern Italy (12).  
Comparison of the deletion junction in our patient (of North African heritage) and those of Italian 
origin showed that they were identical. Analysis of the deletion breakpoint showed an insertion of 
6 bp, suggesting that the mechanism involved was non-homologous end-joining. Such 
rearrangements are associated with scattered breakpoints and insertions at the junction site 
(13,14), making it less likely that the deletions had occurred independently of each other. Indeed, 
haplotype analysis showed that the mutation segregated with the same haplotype in all 3 patients, 
supporting the hypothesis of a common ancestor.  
There have been founder mutations described for several LGMD genes, although these have all 
been small mutations that were detected by sequencing. The c.525delT mutation in SGCG, seen 
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heterozygously in LG 6 and homozygously in LG 1, 2 and 3, is common within the North African 
population, segregating with the rare 122 bp allele of marker D13S232 (15). The mutation has 
also been found in Brazilians of African heritage, again segregating with the same allele (16). 
Another change within the SGCG gene, c.87insT was found in patients in Northern Italy (17). 
This mutation has not been described in other populations, and it was proposed that the 
mountainous surroundings in that region of Italy contributed to the relative genetic isolation. In 
contrast, it is likely that villages in Southern Italy had more contact with other regions via sea 
travel. It is therefore not surprising that a mutation in this region spreads across the 
Mediterranean.  
 
SGCG deletion Times Reported References 
-124-?_1500+?del 
(entire gene) 2 (20,21) 
c.506-?_578(702)+?del 
(exon 6*) 1 (22) 
c.579-4730_702+1721delinsACACTA 
(exon 7) 2 (12), this report 
Table 2. Deletions of one or more exons described for the SGCG gene. The mutations are described based on reference 
sequence NM_000231.1, with +1 taken to be the A of the ATG initiation codon. * In this case it was not determined 
whether exon 7 was also deleted. 
 
Partial gene deletions or duplications as founder effects have been described, although  less 
commonly than mutations that can be detected by sequencing. Within the Dutch population 
deletions of one or more exons of the BRCA1 gene occur in ~30% of breast cancer cases (18). 
There was a report of a partial gene duplication within the SCL3A gene, found in several 
individuals of German descent (19). Although no haplotype analysis was performed, it was a 
complex rearrangement with identical breakpoints.  
The relatively low number of partial gene rearrangements detected as a founder mutation is 
probably due, at least partly, to the use of sequencing as the predominant method for mutation 
detection, and it is likely that the number of such cases will increase as more genes are screened 
with quantitative methods. 
It has already been the suggested that exonic deletions may be present in γ-sarcoglycanopathy 
(20), particularly since many cases were reported to be homozygous.  If parental DNA is not 
available it is difficult to distinguish with certainty whether the mutation is truly homozygous or 
93
is a compound heterozygote, with the loss of the second allele masking the true situation. In 
addition, when parental DNA is unavailable, the fact that one of either parent does not carry the 
mutation may be erroneously explained as either non-paternity or a de novo occurrence of the 
mutation. An associated danger in the latter situation is that the de novo change suggested is 
taken as proof that this change has pathogenic consequences. 
As exonic deletions have been shown to occur in at least some sarcoglycanopathy patients it 
suggests that screening for such mutations should be routinely implemented in a diagnostic 
setting. Our report shows that such analysis is highly recommended in cases where a mutation can 
be found in one allele only, or when segregation from the parents can not be confirmed. An 
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Introduction: It has been estimated that cytogenetically visible rearrangements are present in ,1% of
newborns. These chromosomal changes can cause a wide range of deleterious developmental effects,
including mental retardation (MR). It is assumed that many other cases exist where the cause is a
submicroscopic deletion or duplication. To facilitate the detection of such cases, different techniques have
been developed, which have differing efficiency as to the number of loci and patients that can be tested.
Methods: We implemented multiplex amplifiable probe hybridisation (MAPH) to test areas known to be
rearranged in MR patients (for example, subtelomeric/pericentromeric regions and those affected in
microdeletion syndromes) and to look for new regions that might be related to MR.
Results: In this study, over 30 000 screens for duplications and deletions were carried out; 162 different
loci tested in each of 188 developmentally delayed patients. The analysis resulted in the detection of 19
rearrangements, of which ,65% would not have been detected by conventional cytogenetic analysis. A
significant fraction (46%) of the rearrangements found were interstitial, despite the fact that only a limited
number of these loci have so far been tested.
Discussion: Our results strengthen the arguments for whole genome screening within this population, as it
can be assumed that many more interstitial rearrangements would be detected. The strengths of MAPH for
this analysis are the simplicity, the high throughput potential, and the high resolution of analysis. This
combination should help in the future identification of the specific genes that are responsible for MR.
T
he evolution of the human genome has resulted in a
mixture of large and small interspersed and tandem
segmental duplications throughout the genome. Such
duplications provide substrates for homologous recombina-
tion, and consequently, the intervening regions show a
considerable rate of rearrangement.1–3 Many of these re-
arrangements occur in regions where a change in gene dosage
does not affect human health. However, after the description by
Lejeune of trisomy 21 in Down’s syndrome,4 and the many
subsequent publications on different aneuploidies, it became
clear that the genome contains many loci for which the
correct copy number is critical for normal development.
Change in genetic dosage of one or more genes is one of the
most common causes of mental retardation (MR). Examples
of known important loci include the subtelomeric regions
and the areas involved in microdeletion syndromes.
The subtelomeric regions, localised proximal to the
telomeres, have been found to be especially susceptible to
copy number changes, owing to repeat rich sequences that
show a high frequency of recombination.1 It has been
hypothesised that about 6% of the patients with idiopathic
MR will have a subtelomeric rearrangement,5 a figure
confirmed in several studies that have reported a frequency
of 2–9% of cryptic rearrangements in MR patients.6 7
The cause for MR is only established in approximately 50%
of cases, limiting the efficiency of genetic counselling,
detection of carriers, and prenatal diagnosis in these families.
This rather low percentage of diagnosis may have several
explanations. A routine cytogenetic analysis gives a mini-
mum resolution of only 4–10 Mb. Fluorescent in situ
hybridisation (FISH) largely overcomes this limitation of
resolution; however, it can only be applied to simultaneously
test a limited number of chromosome regions. FISH is
therefore mostly used to confirm well recognised microdele-
tion syndromes in patients who present a suggestive
phenotype. Another potential explanation is that the genome
contains undiscovered loci that are involved in the aetiology
of MR. New technologies, such as multiplex amplifiable
probe hybridisation (MAPH),8 multiplex ligation dependent
probe amplification (MLPA),9 and array based comparative
genomic hybridisation (array CGH),10 have recently been
developed to search for such undiscovered regions. We chose
to implement a high resolution, high throughput, rapid, and
simple method, MAPH,8 which allows the simultaneous
screening at the exon level for copy number changes of 40–50
different chromosomal loci in up to 96 patients in one assay.
Hollox et al11 previously described subtelomeric screening
using MAPH of patients with a developmental delay. In our
study, we screened loci known to be involved in MR
(subtelomeric/pericentromeric regions and genes involved in
microdeletion syndromes) as well as interstitial genes
randomly spaced throughout the genome. A total of 30 000
gene dosage screens were performed from 188 cases with
unexplained developmental delay that were each scanned for
copy number changes at 162 loci. We were able to detect
subtelomeric, pericentromeric, and interstitial rearrange-
ments in a group of patients with MR and dysmorphic
features and/or multiple congenital abnormalities, as well as
in patients selected solely on the basis of developmental
delay.
SUBJECTS AND METHODS
Probe design and MAPH
The probe design has been previously described,12 using
unique sequences only. The primers of the chosen sequences
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: BAC, bacterial artificial chromosome; CGH,
comparative genomic hybridisation; FISH, fluorescent in situ
hybridisation; MAPH, multiplex amplifiable probe hybridisation; MCA,
multiple congenital abnormalities; MLPA, multiplex ligation dependent






were designed using Prophet (http://www.basic.nwu.edu/
biotools/prophet.html), and supplied by Invitrogen Life
Technologies. Products were amplified from genomic DNA
by PCR and cloned into the pGEM-T easy vector (Promega).
The correct insert was confirmed by sequencing with the
BigDye Terminator Cycle Sequencing Ready Reaction kit
(Applied Biosystems) at the Leiden Genome Technology
Center, using an ABI 3700 Sequencer (Applied Biosystems).
MAPH was performed as described by White et al12 (see also
Leiden Muscular Dystrophy Pages (http://www.dmd.nl/
DMD_MAPH.html)).
Study population
The DNA of 188 patients (110 males and 78 females) from
the Center for Human and Clinical Genetics Leiden (a DNA
diagnostic laboratory) was analysed. The patients had
been seen by a clinical geneticist or a paediatrician and
diagnosed with developmental delay. The study population
was divided into two groups. The first group contained 123
coded patients who had been referred for fragile X screening.
Before testing, information about the results of additional
tests, such as karyotyping, was not known to the investiga-
tors. The second study group (n = 65) was known to have a
normal karyotype and had tested negative for fragile X
screening. All patients had (multiple) congenital malforma-
tions or dysmorphic features in addition to psychological
developmental delay.
Data analysis
The data were analysed with GeneScan Analysis and
Genotyper Software (Applied Biosystems). These programs
provide information about the length, peak height, and
peak area of the DNA fragments. Peaks were not used for
analysis if they were outside predefined thresholds (upper
and lower limits of 12 000 and 150 units, respectively). To
obtain a ratio, the height of a given peak was divided by
the sum of the heights of the four nearest peaks. As it is
not likely that all four probes from diverse regions of the
genome are altered in one patient, adding unrelated
standards was not necessary in most of the probe sets. For
the chromosome 22 probe set, however, unrelated probes,
containing sequences from other chromosomes, were used as
references.
The median ratio for each probe within a single hybridisa-
tion (minimum number of samples 8; maximum number 12)
was determined and used to calculate a normalised ratio
for each patient. Within each patient, initial ‘‘normal’’
thresholds were set as 0.75 and 1.25. The standard deviation
from the ratios within these limits was calculated, and three
times this standard deviation was used as the threshold for
any given patient. Any probe that was outside these limits
was retested, and samples that showed an apparent copy
number change in duplicate were examined further using
other techniques. Samples that showed a standard deviation
of .10% over probes within the normal thresholds were
retested.
Verifying the MAPH results
Copy number changes detected by MAPH were verified using
another technique, primarily FISH with a bacterial artificial
chromosome (BAC) or cosmid probe covering the appropriate
genomic region. The BACs used were designed by Flint,13 or
supplied by Vysis Abbott Laboratories (TV, Telvysion, LSI,
locus specific identifiers) or selected from the RPCI human
BAC library. The FISH experiments were performed following
standard operating procedures as described in Dauwerse
et al.14 Some MAPH results were verified using MLPA.9
RESULTS
Genotyping
We designed several probe sets covering both the subtelo-
meric/pericentromeric and interstitial regions, including
genes involved in microdeletion syndromes, genes on
chromosome 22, and genes spread across all chromosomes
(table A, supplemental). The subtelomeric probe set is
composed of probes corresponding to the 41 subtelomeric
regions, preferably an exon of a gene within 1 Mb from the
telomere, five genes near the centromere on the q arm of the
acrocentric chromosomes, a sequence in the pseudoautoso-
mal region of chromosome Xq and Yq, and an exon of a Yp
specific gene. The microdeletion probe set was made up of 27
probes from 21 different genes involved in microdeletion
syndromes (Williams, Prader Willi, Angelman, Smith-
Magenis, Sotos, 22q11, Alagille, and Wolf-Hirschhorn syn-
dromes). The chromosome 22 probe set included 19 probes
from genes on chromosome 22 with approximately 1 Mb
spacing. Finally, we used two probe sets containing a total of
68 interstitial genes spread throughout the genome.
We applied these probe sets following two methods of
validation. Firstly, a probe was considered to be reliable when
the standard deviation over 12 unaffected samples (one
hybridisation) was ,15%. Secondly, where possible, we
verified the unique and correct localisation of the probes
using DNA from patients with known aberrations (42% of the
subtelomeric probes, 70% of the microdeletion probes).
Overall, 188 patients were screened for deletions and
duplications at 162 loci, resulting in the detection of 19 copy
number changes. Of these, four aberrations turned out to be
cytogenetically visible, namely an isochromosome 18p
(karyotype 47, XY, +i(18p)), a marker chromosome (karyo-
type 47, XY, +mar.ish der(22)t(8;22)(q24.1;q11.2)), a triple X
female (karyotype 47, XXX) and a Turner syndrome
(karyotype 45, X), because the outcome of additional
investigations had not been made known to the investigators
before testing. These patients and their corresponding
aberrations were not included in the calculation of the
percentage of rearrangements found by MAPH; however,
they emphasise the usefulness of MAPH for detecting copy
number changes.
In total, eight subtelomeric/pericentromeric rearrange-
ments were found (table 1; upper part). Five of these
mutations were detected in the group of MR patients with
additional dysmorphic features or additional congenital
malformations (5/65 = 7.7%) and the remaining three sub-
telomeric aneusomies were diagnosed in the group selected
on the basis of developmental delay only (3/123 = 2.4%).
The smallest mutation found was a deletion of 110 kb
maximum present in chromosome band 7p22.3 (table 1, F;
and data not shown). Seven rearrangements were inter-
stitial mutations. These are summarised in the lower part
of table 1. Where possible, the DNA of both parents of
these patients was tested; 75% (9/12) were shown to be de
novo. The duplication of 14q11.2 (table 1, O) and the 7ptel
deletion (table 1, F) were also found in the parental DNA,
and one of the parents of patient E was a balanced
translocation carrier.
As the number of cytogenetically detectable aberrations is
highly dependent on the banding resolution, the karyograms
of all 15 patients with a MAPH detected rearrangement were
re-examined. At a resolution of 500–550 bands per haploid
set, the karyograms showed that two subtelomeric copy
number changes should have been detected cytogenetically
(table 1; A, C). The detection of a 1ptel deletion (table 1, H)
was doubtful; however, the duplication of 1ptel (table 1, H)
was picked up. This implies that although the presence of the
copy number change was known, 63% (12/19) of these
genomic changes found in this study were cytogenetically








This 15 year old girl was diagnosed with total anomalous
pulmonary venous return, hearing loss in combination with
a narrow external auditory meatus, and MR. Physical
examination at the age of 14 years showed a short stature
(23 SD) and some facial dysmorphic features (small
palpebrae, broad mouth, thin upper lip). Karyotyping at a
resolution of 400 bands and FISH studies of the 22q11 region
did not detect any rearrangements. MAPH study showed a de
novo deletion of the subtelomeric region of 18q, which was
confirmed by FISH using probe TV18q. The clinical features
of this patient are consistent with those of the 18q syndrome
phenotype.15
Case 2
A male patient, who had previously tested negative for
Williams syndrome, was diagnosed with a de novo deletion
of 16ptel by MAPH. FISH analysis confirmed this finding and
limited the proximal breakpoint to chromosome band
16p13.3, distal to the PKD1–TSC2 (LocusLink 5310–7249)
gene cluster16 using probe COS15A. As expected, owing to the
location of the alphaglobin gene (HBA1; LocusLink 3039) in
this region (16p13.3),17 further investigation showed that this
patient had mild anaemia (alpha thalassaemia heterozygos-
ity) in addition to his moderate mental handicap and
dysmorphic features.
Table 1 An overview of all 15 patients (A–O) with MAPH detected subtelomeric/pericentromeric and interstitial aneusomies.
After the verification of these imbalances by FISH or MLPA, the karyograms of the patients were re-examined at a resolution of
500–550 bands. The results obtained are shown in the column ‘cytogenically visible’. The clinical features known to be related
to the rearrangement found by MAPH are highlighted. The presence or absence of a genotype–phenotype correlation is
summarised under ‘‘Pathogenic’’.
Case Aneusomy Group Gender Confirmed by
Cytogenetically
visible Clinical features Pathogenic References
Subtelomeric/Pericentromeric




MR, small stature, hearing loss,




B 2 Deletion 16p13.3 DD only1 Male FISH clone
ID;COS15A
No Moderate MR, mild facial
dysmorphism, mild alpha
thalassemia
Yes Many: latest is17










of chr. 22, duplication
of 22q11.2
MR++ Male FISH clone ID:
RP11_3018K1
No Mild MR, hearing loss, palatoschisis,
cataract, microcephaly, double set of
teeth
? Kriek et al
E Deletion 6qtel,
duplication 20qtel




No MR, hypotonicity, microcephaly,
brain anomalies, mild facial
dysmorphism.
*
F Deletion 7ptel DD only Male MLPA No Mild developmental delay in early
childhood, mild facial dysmorphism
No/? 36






double sided ptosis, parasis of VI
cranial nerve, strabismus
? 37











I Duplication 17p11.2 MR++ Female FISH clone ID:
LSI-SMS




J 3 Deletion 17p11.2 DD only Male FISH clone ID:
LSI-SMS, MLPA
No Psychomotor developmental delay
(speech delay), infantile hypotonicity,
tent shaped mouth
Yes Many: latest is40
K 4 Deletion 4q34.1 DD only Male FISH clone ID:
RP11-475B2
No Mild learning disability, short
stature, severe delay of bone
maturation, aberrant hand shape
Yes 19
L 5 Duplication 20p12.2 DD only Male MLPA No Mild MR, psychiatric disorder ? 21
M 6 Duplication 22q11.2 MR++ Female FISH clone ID:
LSI TUPLE1
No Severe psychomotor retardation,




N Deletion 22q11.2 MR++ Female FISH clone ID
LSI TUPLE1
No Developmental delay, tetralogy of
Fallot, absent pulmonary valve,
respiratory complications
Yes Many: latest is43
O Duplication 14q11.2 DD only Male MLPA No MR, mild facial dysmorphism, short
hands and feet, shawl scrotum
No/?
*The rearrangement is probably causative, as a sibling with a similar phenotype has the same aberration.
Manuscript in preparation.
Group of patients `with mental retardation and additional features, 1selected solely on the basis of developmental delay.
Fluorescent in situ hybridisation, **multiplex ligation dependent probe amplification, total anomalous pulmonary venous return.
No/?: one of the parents also has the aberration; however, imprinting, variable expression and low penetrance have not been excluded; TAPVR, total anomalous
pulmonary venous return.
Cases 1–6 are described in more detail in the text.





This boy was seen by a clinical specialist at the age of
2.5 years for his psychomotor retardation and joint hyper-
flexibility. Physical examination showed few dysmorphic
features (a tent shaped mouth), hypotonia, and hypermobi-
lity. MAPH analysis revealed a de novo deletion within
chromosome band 17p11.2 corresponding to the Smith-
Magenis syndrome (SMS) region, using a probe for the DRG2
gene (LocusLink: 1819). The more distally located COPS3 gene
(LocusLink: 8533) showed two copies (fig 1a). Additional
MLPA testing showed that the RAI1 gene (LocusLink: 10743)
was also deleted in this patient (fig 1b), and FISH analysis
(probe LSI-SMS) verified the deletion of part of chromosome
band 17p11.2 (fig 1c). Recently, three dominant frameshift
mutations in RAI1 have been identified in three patients with
phenotypic characteristics of SMS but no cytogenetically
detectable deletion of chromosome band 17p11.2.18 The
authors argue that mutations in RAI1 are responsible for
most of the characteristic features of SMS and that further
variation is caused by hemizygosity of the other genes in the
chromosome region.
Case 4
This male patient showed at the age of 12 years a mild
learning disability, a low voice, a disproportionally short
stature (height 22 SD, span 23 SD for height, sitting height
20.5 SD, head circumference 22 SD), limited elbow
extension, a permanently extended, inflexible fifth digit of
both hands with a ram’s horn shaped nail and hypotrophy of
the hypothenar muscles (fig 2), and a short broad great toe
on both feet. The hand x ray revealed short metacarpals I and
V, short distal phalange V, and a delay of bone maturation. In
this patient, a de novo deletion of 4q34.1 was detected and
confirmed by FISH (probe RP11-475B2). Analysis with a
more distally located MAPH probe at chromosome band
4q35.1 showed that this latter region was still present,
indicating an interstitial rearrangement. Additional FISH
experiments using different BAC probes limited the deletion
to a maximum of 3 Mb (data not shown).
Patients with an interstitial 4q deletion have been
described with a range of features, depending on the
proximal and distal breakpoints of the deletion.19 As it is
known that fifth finger anomalies and short stature are
found in patients with an interstitial deletion of 4q including
4q34,20 as well as in patients with a terminal deletion of 4q, it
is possible that the genes responsible for these features are
located within this region.
Figure 1 The plots correspond to the MAPH results showing (A) a
deletion of the DRG2 gene, two normal copies of COPS3A (RAI1 not
present), and the MLPA results; and (B) a deletion of RAI1, a deletion of
DRG2, and a normal ratio of COPS3A. (C) The additional FISH analysis
using the LSI-SMS probe specific for the Smith Magenis chromosomal
region shows a normal signal on the short arm of only one copy of
chromosome 17.
Figure 2 The right hand of case 4 showing a short, inflexible fifth digit
with a ram’s horn shaped nail and hypotrophy of the hypothenar
muscles.





This mildly retarded man, with a de novo duplication within
chromosome band 20p12.2, containing the Jagged1 gene
(JAG1; LocusLin: 182), died at the age of 60 years from
multiple myeloma. He had been institutionalised for over
40 years in a psychiatric hospital because of aggressive
behaviour, and was diagnosed as schizophrenic. To the best
of our knowledge there has been only one previous report21 of
a duplication of 20p11.21–p11.23, in four members of a
family with clinical signs of Alagille syndrome. As our patient
is not available for further investigation, it remains unclear
whether he had such features.
Case 6
After 41 weeks of gestation, this child was born with a birth
weight of 1995 g ((2.5 SD) and a head circumference of
28.5 cm ((2.5 SD). At the age of 25 months, her psycho-
motor development was severely delayed and she suffered
from epilepsy. Physical examination showed growth retarda-
tion (length (2 SD; weight 26 SD), microcephaly (head
circumference 26 SD), hypertonicity, dystonic movements,
facial dysmorphisms (ptosis of the left eye, flat philtrum, thin
upper lip; fig 3) ear pits, café au lait spots, and absence of the
labia minora. Further investigation revealed corpus callosum
hypoplasia and deformed gyri, the presence of only one
kidney and mildly increased urinary glutaric acid.
Using the microdeletion probe set, a duplication of 22q11.2
was detected by MAPH, and FISH analysis in interphase
nuclei confirmed this finding (LSI TUPLE1). The patient’s
mother did not carry the duplication, and the father was
unavailable for testing. We plan to use polymorphic markers
to determine the parental origin of the aberrant chromosome
22.
DISCUSSION
Using MAPH analysis, we performed a high resolu-
tion duplication/deletion screening of 188 patients with a
developmental delay; 162 loci per patient were tested,
amounting to over 30 000 typings. The MAPH probes
designed for this study can be broadly divided into two
groups: (a) subtelomeric and pericentromeric probes (n = 48)
and (b) interstitial probes (n = 114), containing sequences
located in regions previously found to be rearranged in
mentally retarded individuals, and genes randomly spaced
through out the genome.
We detected 4.3% (8/184) subtelomeric/pericentromeric
rearrangements (six deletions, one duplication, and one
subtelomeric deletion/duplication in one patient), using 48
MAPH probes. A subdivision of subtelomeric aberrations over
our two study populations agrees with the findings of Knight
et al22 and Yasseen et al.23 The percentage of subtelomeric
mutations detected was higher in a group of MR patients
with additional malformations (7.7%) than in a group
selected on the basis of developmental delay only (2.5%). This
supports the suggestion of De Vries et al that pre-selection
of patients for subtelomeric screening is worthwhile.
However, pre-selection of these patients for subtelomeric
rearrangements is difficult, as only two clinical features
(perinatal onset growth retardation and a positive family
history) differed significantly between patients with sub-
telomeric aneusomies and patients with idiopathic MR.24
Our overall percentage is similar to that reported in a recent
paper that summarised all previous subtelomeric publica-
tions.7 A total of 131 subtelomeric imbalances were found
using several different methods among 2582 MR patients,
resulting in an overall frequency of 5.1%. A review of the
corresponding clinical aspects of these subtelomeric rearran-
gements has been published recently.25 After re-examining
the karyogram of our patients at a banding resolution of 500–
550 bands, it showed that five MAPH detected subtelomeric
imbalances were not cytogenetically visible, despite the
knowledge of a copy number change present. This means
that the percentage of ‘‘true’’ submicroscopic subtelomeric/
pericentromeric findings is ,3% (5/184) in this study.
Previous reports by Sismani et al26 and Hollox et al11 had
already shown the ability of MAPH to detect subtelomeric
copy number changes. Hollox et al found a copy number
change in 5 of 37 male patients (13.5%) who had been
referred for fragile X screening. The higher percentage of
mutations found by this group may be due to differences in
selection criteria for fragile X screening.
We also screened the subtelomeric/pericentromeric regions
in eight newborns suffering multiple congenital abnormal-
ities (MCA). Among these patients, one deletion of the
subtelomeric region of chromosome 15 was detected and
subsequently confirmed by FISH (data not shown).27 To
determine whether it is worthwhile to test this group for
submicroscopic mutations, more newborns with MCA should
be examined. The ease and relatively low cost of the MAPH
technique means that such analysis is feasible. Moreover,
new techniques such as MAPH/MLPA and array CGH provide
the possibility of genetic diagnosis at a younger age. As the
suggestive phenotype for some microdeletion syndromes
emerge only later in life, this diagnosis would be very
important for providing appropriate healthcare.
In addition to the reports published by Sismani et al25 and
Hollox et al,11 we also examined interstitially localised genes,
including genes involved in several microdeletion syndromes,
genes on chromosome 22 (as this was the first chromosome
to be completely sequenced), and genes that are spread
throughout the genome and might be involved in cognitive
development. Recently, Bailey et al3 argued that regions
between highly similar duplications (low copy repeats) are
prone to recombination and consequently, copy number
changes occur at a higher frequency in these regions
compared with other loci in the genome. Several of the areas
Figure 3 Facial dysmorphism of case 6. Note the microcephaly, ptosis
of the left eye, flat philtrum, and thin upper lip.




described were also tested in this study, mostly correspond-
ing to chromosomal regions involved in microdeletion
syndromes. In total, seven interstitial deletions and duplica-
tions were detected, of which five were diagnosed in three
different regions known to be involved in the microdeletion
syndromes and flanked by segmental duplications. Three of
these interstitial rearrangements detected include duplica-
tions of regions that are usually deleted (the chromosome
regions of Smith Magenis (17p11.2), DiGeorge (22q11.2),
and Alagille syndromes (20p12.2)). This observation supports
the theory that the regions between low copy repeats can
both be deleted and duplicated, and implies that the number
of patients suffering from a microduplication syndrome is
currently probably underestimated. The phenotype (if any) of
a microduplication syndrome might, however, be less severe,
and under standard diagnostic conditions, the detection of
duplications is more problematical. It should be noted that in
the second study group, the cases with a distinctive pheno-
type for a specific microdeletion syndrome were not included.
As has been the case during the development of every new
technique, the genomic variations detected can be divided
into the following subclasses: (a) genetic changes that are
clearly pathogenic, (b) rearrangements that may or may not
be causal to the patient’s problem, and (c) polymorphic
changes. In some cases, extensive clinical studies will be
needed to determine to which category a newly detected
aberration belongs. In two of our cases, we could detect the
rearrangement in one of the parents (the duplication of
chromosome band 14q11.2 and the deletion of 7ptel on
chromosome band 7p22.3). One explanation is that these
imbalances are polymorphic, and that the phenotype of the
patient is not related to the copy number change. However,
other explanations are possible: (a) the affected region is
imprinted, and the parental origin of this region is critical in
causing the deleterious phenotype;28 (b) allelic variation in
the expression of the genes may influence the phenotype;29
and (c) low penetrance of the rearrangement—that is, a
genetic defect does not always lead to a phenotypic effect.
The detection of such rearrangements will increase as high
resolution techniques are applied, and this will pose new
problems for genetic counselling. Therefore, it is important to
map these familial imbalances in further detail to allow a
genotype–phenotype correlation in larger populations of
individuals with the same copy number change. In this
way, the understanding of any clinical consequence of such a
rearrangement should be improved.
Based on previous publications, seven rearrangements
found in this study were considered to be pathogenic
(table 1). In the remaining cases, the data available in
literature were insufficient to support a conclusion that the
aneusomy detected is related to the phenotype of the patient.
It should be noted that the fact that a rearrangement is de
novo is not in itself proof that it is causally related to the
deleterious phenotype.
Several different methologies have been described to
identify changes using MAPH and MLPA. These include
visual comparison of traces from controls and patients,30 the
setting of arbitrary thresholds,26 and bivariate analysis.11 We
observed that the standard deviations for each probe varied
slightly between hybridisations, and could be normalised
only within a single hybridisation. The standard deviation of
‘‘normal’’ probes within each patient was calculated, with
3 times this figure defining the threshold for a potential
rearrangement, thus minimising the effect of any genuine
copy number changes on the analysis. As false negative
results are, by definition, mutations that were not detected,
it is difficult to determine the percentage. To gain an
estimate as to the actual false negative rate, we looked at a
number of samples where a mutation was previously
known. We tested 30 samples that had aberrations at loci
corresponding to 39 of the probes used. The appropriate
copy number changes were detected in all cases. Using the
LaPlace formula p = (x+1)/(n+2) to provide a false negative
rate from our data yields an expected value of ,2.5%. This
figure suggests that the true false negative rate would be, at
least for the 39 probes examined, comparable to the 2%
theoretically predicted by Hollox et al.11 Of course, it would be
desirable to test all the probes on known mutations in the
future.
The number of interstitial aneusomies found in this report
strengthens the arguments for genomewide screening for
copy number changes in developmentally delayed patients. In
most clinical laboratories, deletions and duplications are
detected by FISH. This usually focuses on only one region per
hybridisation, and is therefore relatively slow and expensive.
Several new technologies have emerged that facilitate large
scale and genomewide screening of deletion and duplication
mutations. For genomewide screening, array CGH currently
seems to be the most attractive, with recent publications
describing screening with approximately 2000 BAC-PAC
clones at an average resolution of 1.5 Mb.31 32 This is
impressive, but inherently means that 90% of the genome
is not screened. In addition, probes in array CGH are 100–
200 kb BAC clones, often covering more than one gene and
thus able to pick up large multi-gene deletions/duplications
only—that is, those .100 kb, while it is probable that a
significant proportion of deletion/duplication mutations are
smaller than this. In contrast, it is possible to detect
rearrangements of only 100 bp using MAPH and MLPA
technology. By applying a high resolution method, however,
the percentage of the genome that can be screened using the
same number of probes will be much less compared with
array CGH. Using MAPH/MLPA, it is not possible to screen
the whole genome for copy number changes at this moment,
unless a very large number of probes are included. For this
reason, a different approach is required. We consider array
CGH to be an excellent tool for finding large regions in the
genome where genes involved in particular diseases reside.
As soon as these areas have been identified, targeted and much
cheaper assays can be designed, zooming in on these regions
only. For these reasons, we believe that gene specific screening
is ultimately more attractive. With that in mind, MAPH/
MLPA have an important role in such analyses, as they are
able to pick up both large and small deletions/duplications.
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Genomic deletions and duplications play an important role in the etiology of human disease. Versatile tests are
required to detect these rearrangements, both in research and diagnostic settings. Multiplex ligation-dependent
probe amplification (MLPA) is such a technique, allowing the rapid and precise quantification of up to 40
sequences within a nucleic acid sample using a one-tube assay. Current MLPA probe design, however, involves
time-consuming and costly steps for probe generation. To bypass these limitations we set out to use chemically
synthesized oligonucleotide probes only. The inherent limitations of this approach are related to oligonucleotide
length, and thus the number of probes that can be combined in one assay is also limited. This problem was
tackled by designing a two-color assay, combining two sets of probes, each amplified by primers labeled with a
different fluorophore. In this way we successfully combined 28 probes in a single reaction. The assay designed
was used to screen for the presence of deletions and duplications in patients with hereditary multiple exostoses
(HME). Screening 18 patients without detectable point mutations in the EXT1 and EXT2 genes revealed five
cases with deletions of one or more exons: four in EXT1 and one in EXT2. Our results show that a two-color
MLPA assay using only synthetic oligonucleotides provides an attractive alternative for probe design. The
approach is especially suited for cases in which the number of patients to be tested is limited, making it
financially unattractive to invest in cloning. Hum Mutat 24:86–92, 2004. r 2004 Wiley-Liss, Inc.
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DATABASES:
EXT1 – OMIM: 608177; GenBank: NM_000127.1
EXT2 – OMIM: 608210; GenBank: NM_000401.1
INTRODUCTION
Intragenic rearrangements are a common cause of
human disease. As mutation screening is usually based on
sequence analysis of PCR-amplified fragments, deletions
and duplications of complete exons will be missed unless
quantitative methods are applied. Many alternatives have
been described [reviewed in Armour et al., 2002].
Southern blotting [Den Dunnen et al., 1989], quantitative
multiplex PCR [Yau et al., 1996], and fluorescent in situ
hybridization (FISH) [Petrij et al., 2000] have been most
commonly used, but all have limitations that hinder routine
implementation in a flexible and high-throughput manner.
A quick and simple technique for quantitative analysis
has recently been described, termed multiplex ligation-
dependent probe amplification (MLPA) [Schouten et al.,
2002]. This method is based around the hybridization and
ligation of two adjacently-annealing probes. Only if these
half-probes are ligated can they serve as a template for
PCR amplification. The different probes in a set are
designed to have common ends, meaning all can be
simultaneously amplified with one primer pair. By using a
fluorescently-labeled primer, the resulting products can be
separated according to size and quantified. This method,
which can be performed in a one-tube format, has been
successfully applied to several genes in which deletions
and duplications are known to frequently occur [Gille
et al., 2002; Hogervorst et al., 2003; Taylor et al., 2003].
A significant drawback of the method is the time-
consuming nature of probe production. Following the
original protocol [Schouten et al., 2002], the generation
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of single-stranded DNA fragments of several hundred
nucleotides requires cloning into, and subsequent
isolation from, a specifically modified M13 vector.
Theoretically, it is possible to use chemically-synthe-
sized oligonucleotides for both of the half-probes, but
length limitations mean that relatively fewer probes can
be used within the size range available (2  B40–60
nt). This can be partially circumvented by making use of
the increased resolution of capillary electrophoresis, as
well as the ability to use multiple colors for detection. By
designing the probes such that two different fluorophores
can be used simultaneously, it is possible to combine
twice as many probes within a single reaction.
To test the efficacy of this approach we designed probe
sets to screen for deletions and duplications in the EXT1
(MIM# 608177) and EXT2 (MIM# 608210) genes, in
which mutations cause hereditary multiple exostoses
(HME). This is a genetically heterogeneous disorder,
characterized by multiple bony outgrowths (osteochon-
dromas) on the ends of the long bones, having an
incidence of B1 out of 50,000. EXT1 is found on
chromosome 8q24 [Ahn et al., 1995], and is an 11-exon
gene, spanning 250 kb. EXT2 is a smaller gene,
composed of 14 exons and covering 110 kb on 11p11.2
[Stickens et al., 1996]. Both genes code for glycosyl-
transferases, which are involved in heparan sulfate
synthesis.
The disease shows a dominant pattern of inheritance,
and mutations are found in either EXT1 or EXT2 in 70
to 80% of all cases [Wuyts et al., 1998; Wuyts and Van
Hul, 2000]. The mutations found to date have been
mostly truncating mutations or missense mutations, most
probably leading to loss of EXT function. Linkage
analysis has implicated a third region (on chromosome
19p) in this disease [Le Merrer et al., 1994], but no gene
has been identified to date.
Several cases remain, however, where no mutations
could be found. As mutation screening was performed
almost exclusively at the sequence level, quantitative
(deletions, duplications), and positional (inversions,
translocations) changes will not have been detected.
Entire gene deletions have been seen involving EXT1 (in
Langer Gideon syndrome [Ludecke et al., 1995]) and
EXT2 (in P11pDS [Bartsch et al., 1996; Wuyts et al.,
2001]) as part of contiguous gene syndromes, but to date
there has only been one suggestion of a partial gene
deletion, in EXT2 [Stickens et al., 1996]. Using the two-
color MLPA assay, we detected single- and multi-exon
deletions in 5 out of 18 HME cases, with exon 1 of EXT1
being deleted in three unrelated cases.
MATERIALSANDMETHODS
Patients
The DNA of 18 unrelated HME patients was studied to identify
mutations in the EXT1 or EXT2 genes. The entire coding
sequence of the EXT1 and EXT2 genes had been previously
analyzed with direct sequence analysis, with no mutations being
detected. All patients showed multiple osteochondromas, and 11
were known to have no family history of HME.
ProbeDesign
Probes were designed for each coding exon of EXT1 and EXT2
(Table 1). To allow simultaneous probe amplification, each set of
probes were designed to allow amplification with one pair of
primers. For each EXT1 probe, the common ends corresponded to
the MLPA primers described in Schouten et al. [2002], and the
EXT2 probes used the multiplex amplifiable probe hybridization
(MAPH) amplification primers described in White et al. [2002].
To ensure specific hybridization, the presence of repetitive
sequences was excluded using the BLAT program from the
University of California Santa Cruz (UCSC) website (http://
genome.ucsc.edu) [Kent, 2002]. Probes within each set were
designed to produce PCR products with a minimum separation of
2 bp, with the products ranging in size from 80 to 125 bp. The
hybridizing regions of the probes had a Tm of at least 651C
(defined using the RAW program (MRC-Holland, Amsterdam,
The Netherlands), with a GC% between 35 and 60%.
Oligonucleotides were ordered from either Sigma Genosys (UK,
www.sigma-genosys.com) or Illumina, Inc. (San Diego, CA). The
oligonucleotides from Sigma Genosys were desalted without
further purification, whereas the oligonucleotides from Illumina
were synthesized in a salt-free environment and were unpurified.
All oligonucleotides were synthesized at a starting scale of 50
nmol. The downstream oligonucleotide of each pair was 50
phosphorylated to allow ligation to occur.
Probe mixes were prepared by combining each oligonucleotide
so that all were present at a final concentration of 4 fmol/ml. The
EXT MLPA mixes are available on request (www.LGTC.nl).
MLPA Reaction
All reagents for the MLPA reaction and subsequent PCR
amplification were purchased from MRC-Holland (Amsterdam,
The Netherlands), with the exception of the MAPH-F and
MAPH-R primers (Sigma Genosys). The MLPA reactions were
performed essentially as described in Schouten et al. [2002].
Briefly, 50–200 ng of genomic DNA (concentration determined
using a UV spectrophotometer) in a final volume of 5 ml was
heated at 981C for 5 minutes. After cooling to room temperature,
1.5 ml probe mix and 1.5 ml SALSA hybridization buffer were
added to each sample, heat denatured at 951C for 2 minutes,
followed by hybridization for 16 hr at 601C.
Ligation was performed at 541C by adding 32 ml ligation mix.
After 10–15 minutes, the reaction was stopped by heat inactiva-
tion at 951C for 5 minutes.
PCR amplification was carried out for 30–33 cycles in a final
volume of either 25 ml or 50 ml. In addition to the reagents
described [Schouten et al., 2002], MAPH-F and MAPH-R were
added to each PCR reaction to a final concentration of 100–200
nM, with MAPH-F being fluorescently labeled with either HEX or
ROX. The MLPA primers were labeled with FAM. From each PCR
reaction, 1–2 ml of product was mixed with 10 ml (Hi Di)
formamide in a 96 well plate. For reactions performed with HEX
labeled MAPH-F, 0.1 ml ROX 500 size standard (Applied
Biosystems, www.appliedbiosystems.com) was also added to each
well. Product separation was performed using capillary electro-
phoresis on the ABI 3700 (Applied Biosystems).
Data Analysis
For quantitative analysis, trace data were retrieved using the
accompanying software (GeneScan; Applied Biosystems). These
data were then exported to Excel (Microsoft; www.microsoft.com)
for further calculations. Within each probe set, two probes for
unlinked loci were included as a reference, and all calculations
were performed within one probe set. The height of each exon-
specific peak was divided by the sum of the heights of the two
reference peaks, to give a ratio. The median ratio for each probe
across all samples was calculated, and this value was used for






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































normalizing each probe to 1.0 (corresponding to a copy number of
two). Thresholds for deletions and duplications were set at 0.75
and 1.25, respectively, meaning that the adjusted ratios within
each sample needed to be normalized to 1.0. The normalizing
factor was calculated by determining the mean value of the
unaffected probes within a sample (defined as falling between 0.8
and 1.2), and dividing all values within that sample by this value.
All samples were tested at least twice.
Con¢rmation of Single-Exon Mutations
Because sequence changes at the ligation site of the two half-
probes can also appear as deletions, all single-exon changes were
confirmed using another technique. Two of the EXT1 exon 1
deletions were confirmed using MAPH. The sequences for
amplification of the probe were forward; AGATGCAGG-
GATTTGTGAGG, reverse; CATCTTTGGGTTGCACAATG.
Further probe preparation and MAPH was carried out as
previously described [White et al., 2002].
The third EXT1 exon 1 deletion was confirmed by FISH
analysis. This was performed using standard protocols, with the
following probes: D822 (orange), 90D8 (red), and 46F10 (green).
D822 is the reference probe for chromosome 8, 90D8 matches
exon 1 and the 50 upstream region of EXT1, and 46F10 covers
exons 6–11 of EXT1 [Bernard et al., 2001].
The exon 2 deletion in EXT2 was confirmed by long-range PCR
and sequencing across the breakpoints. The PCR reaction was
performed using the Expand Long Template PCR System (Roche,
www.roche-applied-science.com), with the primers used being
forward; CATGATGGGTGCTCAATAATGGTTT, reverse;
GCTGTGTTATAATCTGGGGGACCTC. The sequencing reac-
tion used the nested primer, ATTATGTAAGTGCTACGAG-
GAGGTG, and was analyzed by the Leiden Genome Technology
Center on an ABI 3730 capillary sequencer.
RESULTS
To maximize the number of loci that can be analyzed
in a single MLPA assay, we chose to test whether
different primer sets can be efficiently coamplified under
the same PCR conditions. Testing showed that the
primer sequences we used for MAPH analysis [White
et al., 2002] were also effective under the MLPA
conditions. The probes for EXT1 were designed with
the MLPA primer sequences attached, and the probes for
EXT2 used MAPH primer sequences. To circumvent the
laborious cloning step, we decided to use synthetic
oligonucleotides, ranging in size from 39–64 nt, including
amplification sequence. The probes were tested on 12
control samples to assess their reliability and consistency,
as well as to determine the influence of the two primer
pairs on the amplification. The signal strength between
the two colors was not always equal, which complicated
analysis. Titration experiments showed that adding the
MAPH primers at half the concentration of the MLPA
primers resolved this issue, usually yielding similar peak
heights for both probe sets. The accuracy of analysis,
however, was not affected when equimolar amounts of
MLPA and MAPH primers were added, even though up
to a 10-fold difference in peak height between the two
probe sets was occasionally observed.
Of the 24 exonic probes tested, two (EXT2 exon 7 and
EXT2 exon 13) gave a standard deviation of greater than
10% (Table 1). These probes were considered to be
unreliable, and were not included in further calculations.
Of note, the smallest standard deviations were obtained
when comparisons were only performed between samples
from the same source.
To see if any deletion or duplication mutations could be
detected in patients suffering from HME, a total of 18
samples were examined, in which previous sequence
analysis was unable to identify any mutations. We
identified five rearrangements (Table 2; Figs. 1 and
2)—four in EXT1 and one in EXT2. These mutations
were seen irrespective of whether the two probe sets were
used separately or combined. The most common deletion
was exon 1 of EXT1, which was seen in three unrelated
individuals. The deletion was confirmed in one of the
samples using FISH (Fig. 3). A probe covering exon 1 and
the 50 upstream region was deleted on one copy of
chromosome 8. A probe covering exon 6–11 was present
on both copies. In addition, heterozygosity for a single
nucleotide polymorphism (SNP) in exon 3 confirmed that
the deletion did not extend past exon 2 (data not shown).
Additional analysis of the sample with the deletion of
exon 2 of EXT2 showed that the deletion did not include
exon 1 (data not shown). Long-range PCR and
sequencing defined the deletion to be 422 bp, with one
of the breakpoints being in exon 2. The last five
nucleotides before the upstream breakpoint (ctccc) are
also the last five nucleotides of the deleted sequence, but
no further sequence homology was seen.
DISCUSSION
We describe here a further development of MLPA,
using synthetic oligonucleotides and two colors. In the
original description, one of the two half-probes was
generated by cloning into an M13 vector. This approach
allows the generation of single-stranded DNA molecules
several hundred nucleotides long. The cloning and
subsequent restriction digestion, however, is time-con-
suming and expensive. Using chemically synthesized
TABLE 2. A Summary of theMutations Foundn
Sample Gene Mutation at DNA-level Description of mutation Con¢rmed by
1 EXT1 c.-772-?_962+?del EX1del MAPH
2 EXT1 c.-772-?_962+?del EX1del MAPH
3 EXT1 c.-772-?_962+?del EX1del FISH
4 EXT1 c.963-?_3287+?del EX2_EX11del Multiple exons
5 EXT2 c.-30-10_441del EX2del Long rangePCR and sequencing
nThe cDNA reference sequences used are NM_000127.1 for EXT1andNM_000401.1 for EXT2. Nucleotide numbering uses theA of theATG-translation
initiation codon as nucleotide +1.
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oligonucleotides allows rapid and cheap probe develop-
ment. Furthermore, as each test is performed with only 6
fmol of each oligonucleotide, a synthesis yield of 6 nmol
would be sufficient for 1 million reactions.
A size range of 80–125 bp was used for the different
probes, with up to 15 probes being combined within a
single probe mix. The use of synthetic oligonucleotides
limits the length of the probes that can be used. We
partially compensated for this by combining two probe
sets, each labeled with a different fluorophore. Using two
colors effectively doubles the number of probes that can
be used in this size range, and in this report 28 probes
were used. The size range available is dependent on the
maximum length of oligonucleotide synthesis that can be
achieved. Our observations with other probe sets are that
individual oligonucleotides of up to 75 nt in length can
be effectively used, meaning that products of up to 150
bp can be generated. Work is in progress regarding the
possibility of using a third primer pair, labeled with a
different fluorophore. Together, these factors could allow
up to 75 probes to be combined in a single reaction.
We observed that, as previously reported [Schouten
et al., 2002], the reliability and reproducibility of the
technique is primarily dependent on the quality of the
FIGURE 1. Traces showing the peaks from the two probe sets for EXT1exons (blue) and EXT2 exons (green). Each set contains two
control probes for normalization purposes (markedwith n). A: A normal trace. B: An B50% reduction in the height of the peak cor-
responding to exon1of EXT1 (indicated by arrow).The redpeaks are size standard peaks (from left to right;75 bp and100 bp).C: An
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FIGURE 2. Graphs showing two of the mutations found. A: EXT1
exon1deletion. B: EXT1exons 2^11deletion.
FIGURE 3. FISH analysis showing a deletion of EXT1exon1.The
following probes have been hybridized: D822 (orange), 90D8
(red), and 46F10 (green). D822 is the reference probe for chro-
mosome 8, 90D8 matches exon1and the 50 upstream region of
EXT1, and 46F10 covers exons 6^11 of EXT1 [Bernard et al.,
2001]. The two copies of chromosome 8 are circled, and the
EXT1 region is indicated with an arrow.There is no red signal on





genomic DNA. We noticed that comparisons made
between DNA samples from different sources lead to
larger standard deviations than when the same data were
normalized only within samples from one source. This
was presumably due to different methods of DNA
isolation. This observation may have implications when
analyzing a series of samples from different laboratories.
The ability to multiplex allows much greater flexibility
with regard to future applications. We previously
described the use of MAPH as an alternative to FISH
with regards to confirming the presence or absence of a
rearrangement [White et al., 2003]. Although this
multicolor approach should be equally applicable to
MAPH, MLPA is perhaps more attractive. The ligation
step means that it is not necessary to immobilize the
genomic DNA on a filter, and consequently the washing
steps can be omitted.
We detected exonic deletions in 5 out of 18 HME
samples (28%), four in EXT1 and one in EXT2. The
mutations found in EXT1 all have one of the breakpoints
within intron 1 of the gene. Notably, this intron makes
upB85% of the total size of the gene. There has recently
been a report of a familial translocation, also within
intron 1 [Pramparo et al., 2003]. Further work needs to
be performed on these samples to characterize the
breakpoints and to see if there is a common mechanism
involved. Additionally, haplotype analysis could be
performed on the patients with the EXT1 exon 1
deletion to see if a common ancestor might be involved.
This, however, is unlikely, as the three DNA samples are
from three different countries (Spain, the Netherlands,
and the United States). In addition, the patient from the
Netherlands has no previous family history of HME.
As point mutations are found in EXT1 and EXT2 in
70 to 80% of HME patients, our findings suggest that
deletions of one or more exons occur in 5 to 8% of all
cases. There are several possible reasons mutations were
not found in the remaining samples. The methods
applied so far will not detect positional changes (i.e.,
translocations, inversions, insertions, or transpositions)
that affect the structure of the gene without changing
the sequence or dosage of any of the exons. This kind of
rearrangement will not usually be detected by either
MLPA or sequencing. To detect such mutations, analysis
at the RNA level may be appropriate [Gardner et al.,
1995; Beroud et al., 2004]. Another possibility is that the
causative mutation lies not in EXT1 or EXT2, but in
another gene. The existence of a third gene (EXT3) on
19p has been postulated [Le Merrer et al., 1994], but to
date no specific gene has been identified. Both EXT1 and
EXT2 belong to the EXT gene family [Duncan et al.,
2001], whose other members also show glycosyltransfer-
ase activity. No mutations, however, have been reported
in any of the genes (EXTL1, EXTL2, or EXTL3) in HME
individuals [Wuyts and Van Hul, 2000]. These genes are
potential targets for future copy number analysis.
In summary, we show that MLPA is compatible with
the use of synthetic oligonucleotides and a two-color
analysis. This combination should facilitate quick and
inexpensive probe set development, allowing any gene or
region of interest to be rapidly scanned for changes in
copy number. In total, design, testing, and application
should be feasible within two weeks, with most of the
time taken up by oligonucleotide ordering and delivery.
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CREB Binding Protein and p300 function as transcriptional coactivators in the regulation 
of gene expression through various signal transduction pathways. Both are potent Histone 
Acetyl Transferases. The level of CREB Binding Protein is essential for normal 
development, as inactivation of one allele causes Rubinstein-Taybi syndrome. There is a 
direct link between loss of acetyl transferase activity and Rubinstein-Taybi syndrome, 
which indicates that the disorder is caused by aberrant chromatin regulation. We screened 
the entire CBP gene for mutations in Rubinstein-Taybi syndrome patients using methods to 
find point mutations and larger rearrangements. In 92 patients we were able to identify a 
total of 36 mutations in the CBP gene. Using Multiple Ligation-dependent Probe 
Amplification we not only found several deletions but also the first duplication in a 
Rubinstein-Taybi syndrome patient. We extended the search for mutations to the EP300 
gene and showed that mutations in EP300 also cause this disorder. These are the first 




Rubinstein-Taybi syndrome (RSTS) is a congenital disorder characterized by mental and growth 
retardation and a wide range of typical dysmorphic features. Facial dysmorphology includes 
down slanted palpebral fissures, broad nasal bridge, a beaked nose and micrognathia. Particularly 
noticeable are the broad thumbs and broad big toes. In addition, RSTS patients have an increased 
risk for tumor formation. Although various types of tumors have been described, there is an 
excess of tumors arising from developmental defects and tumors of brain or neural crest cell 
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derived tissue (Miller and Rubinstein 1995). Mutations in the gene coding for the CREB binding 
protein (CREBBP, also known as CBP), located on chromosome 16p13.3, were found to be 
responsible for causing the disorder (Petrij et al. 1995). 
CBP serves as a transcriptional coactivator (Kwok et al. 1994). It has a transactivation domain but 
does not specifically bind to DNA. The name of the protein is based on the interaction with the 
CRE binding protein (CREB); however, CBP interacts with a large number of transcription 
factors. It is thought that CBP acts as an integrator of the signals from various pathways 
(Goodman and Smolik 2000). Transcription factors downstream from these pathways need to 
compete with each other for the limited amount of CBP available in the nucleus. The protein 
forms a physical bridge between the DNA binding transcription factors and the RNA polymerase 
II complex. In addition, CBP has intrinsic histone acetyl transferase (HAT) activity (Bannister 
and Kouzarides 1996). By acetylating histones it opens the chromatin structure at the locus that 
needs to be expressed, a process essential for gene expression. CBP is also capable of acetylating 
a large number of other proteins, for example the transcription factor p53 (Gu and Roeder 1997). 
RSTS is considered to be an autosomal dominant disorder, however patients very rarely have 
children. Almost all mutations, therefore, occur de novo. The mutations found in patients range 
from relatively large microdeletions, removing the gene entirely, to point mutations. In addition, 
five translocations and two inversions disrupting the gene have been reported (Petrij et al. 2000). 
The microdeletions that remove the entire gene indicate that haploinsufficiency is the ultimate 
cause of the syndrome. Presumably, at critical moments during development the amount of CBP 
drops below a certain threshold because of the loss of one allele. How this loss of one allele 
actually causes the particular symptoms of RSTS, however, is unclear. Nevertheless, we know 
from patients with missense mutations and splice site mutations affecting only the HAT domain 
of CBP, that loss of HAT activity is sufficient to cause the syndrome (Murata et al. 2001; 
Kalkhoven et al. 2003).  
In order to elucidate the complete spectrum of mutations we screened 92 RSTS patients for point 
mutations, small deletions or insertions and for larger deletions and duplications. Because we 
could not find mutations in the CBP gene in the majority of our patients we assumed that the 
remaining patients have mutations in other genes.  
CBP shares homology with another protein, p300, encoded by the EP300 gene on chromosome 
22q13.2 (Lundblad et al. 1995). Both proteins are particularly homologous at their binding sites 
for transcription factors and p300 also has a HAT domain. Like CBP it serves as a transcriptional 
coactivator. A likely candidate to screen, therefore, is EP300 and, indeed, we found three 
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mutations. These are the first mutations described in EP300 in a congenital disorder and they also 
prove that RSTS is a genetically heterogeneous disorder. 
 
Material and Methods 
 
The majority of the DNA samples described in this study were sent to us by clinicians in the 
Netherlands and many other countries as soluble genomic DNA from patients with a clinical 
diagnosis of RSTS. DNA from the rest of the patients was isolated from peripheral blood in our 
laboratory using standard protocols. 
DGGE  
DGGE was performed with a GC-clamp on either the forward or the reverse primer. Primers were 
selected to anneal to the flanking intron sequences in order to screen the splice sites and the 
branch sites, and were chosen using either WINMELT (Biorad) or MELT-INGENY (Ingeny 
B.V.) software. All oligonucleotides were synthesized by Sigma-Aldrich. Amplified fragments 
were analyzed on 9% polyacrylamide gels (37.5:1) with various linear denaturing gradients, 
optimized for each fragment, on the DCode system from Biorad. Gels were run at 90V at a 
constant temperature of 60ºC. An acrylamide mixture with 40% formamide and 7M urea was 
defined as 100% denaturant and acrylamide without these denaturing agents was defined as 0% 
denaturant. 
SSCP 
Electrophoresis was performed at room temperature using two types of gels. The first type was a 
polyacrylamide gel (49:1) with 1*TBE without glycerol and the second type was 0.5*MDE 
(National Diagnostics, Atlanta, Georgia) with 0.6*TBE and 10% glycerol. During amplification 
the fragments for SSCP analysis were radioactively labeled either by incorporation of  α32P-dCTP 
or by using primers that were kinated using γ32P-dATP (Amersham). Visualization of the 
fragments was done using the PhosphorImager (Molecular Dynamics). 
MLPA 
Probes were designed for 20 exons of the CBP and EP300 genes. MLPA was performed as 
described in (White et al. 2004). All samples were tested at least twice. 
Sequencing and restriction digestions. 
Sequencing was performed on the ABI 3700 from Applied Biosystems using the manufacturers 
standard protocol and reagents. Restriction digestions were performed according to the 
instructions of  the manufacturer. Digestions or second sequencing reactions to confirm the first 
result were done on PCR fragments generated in an independent reaction. The deletion of 8 
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nucleotides in patient 256-1 was confirmed by PCR with an allele-specific primer, 
tcctccatctactagtagtg, that skips the deleted part and anneals with 2 nucleotides after the deletion. 




Point mutations and small deletions or insertions in the CBP gene 
We screened the entire CBP gene for point mutations and small deletions or insertions using 
primarily DGGE, with target sequences that were not suited for DGGE being screened by SSCP 
analysis. The complete coding sequence and splice sites of the CBP gene required a total of 49 
fragments of which 40 were screened using DGGE, approximately 83% of the coding sequence. 
Direct sequencing was used to identify the mutation after aberrant bands were found on DGGE or 
SSCP gels. All mutations were confirmed either by digestion with restriction enzymes when a 
restriction enzyme site was altered or by a second sequence analysis. 
In 92 patients we found a total of 27 mutations (see table 1). The majority is predicted to lead to a 
premature translation stop but we also detected 5 putative missense mutations. Base substitutions 
leading to a premature stop codon or deletions and insertions leading to frame shifts can be 
clearly identified as disease causing mutations. A change of amino acids is much less clear, 
however, RSTS patients as a rule have de novo mutations. Since we were able to confirm the 
mutation as de novo for three of the mutations we consider them most likely to be disease 
causing. We do not have parental DNA of patients 228-1 and 260-1. All putative missense 
mutations are at the highly conserved HAT domain of CBP and the amino acids that are changed 
have residues that are conserved in both the mouse and the fruit fly (see fig.1).  
Unless we have an RNA sample from a patient we cannot check whether a splice site mutation 
actually leads to aberrant splicing. These mutations however, should also comply with the rule 
that mutations in RSTS patients occurred de novo. Except for the mutation in patient 39-1 for 
which parental DNA was not available, we could confirm the mutations that way. The mutation, a 
G to A, in the splice donor site flanking exon 24 in patient 39-1, however, is at the first position, 
which should in all splice donor sites, without exception, be a guanine. The splice site mutation of 
patient 211-1 could be analyzed on RNA isolated from a cell line. Subsequent sequence analysis 
proved that the mutation in the splice acceptor site flanking exon 22 leads to a deletion of exon 22 




Mutations in the CBP gene 
Individual Exon Mutation  
  Nonsense mutations  
7-1 Exon 2 c.304 C>T Q102X 
177-1 Exon 5 c.1237 C>T R413X 
212-1 * Exon 28 c.4669 C>T Q1558X 
27-1 Exon 29 c.4879 A>T K1627X 
2-1 Exon 31 c.6010 C>T R2004X 
16-1 Exon 31 c.6133 C>T Q2045X 
178-3 Exon 31 c.6283 C>T Q2095X 
  Missense  mutations  
209-1 * Exon 21 c.3823 G>A E1278K 
201-1 Exon 26 c.4340 C>T T1447I 
260-1 Exon 26 c.4348 T>C Y1450H 
228-1 Exon 27 c.4409 A>G H1470R 
2644 * Exon 30 c.4991 G>A R1664H 
  Deletions & Insertions  
153-1 Exon 2 c.235 del G G79fsX86 
199-3 Exon 3 c.904_905 del AG S302fsX348 
205-1 Exon 6 c.1381_1388 del 8  G461fsX469 
239-1 Exon 6 c.1481 dup A N494fsX527 
203-1 Exon 8 c.1735 dup A A581fsX586 
57-3 Exon 18 c.3396_3400 del 6  P1132fsX1166 
10-1 Exon 18 c.3432_3433 del AG T1144fsX1168 
232-1 Exon 21 c.3824 dup T F1275fsX1282 
231-1 * Exon 25 c.4256_4258 del CT S1419fsX1419 
34-3 Exon 27 c.4399 del G V1467fsX1467 
213-1 * Exon 29 c.4837 del G V1613fsX1634 
  Splice site mutations  
198-3 * Exon 20 c.3779 +5 G > C  
211-1 * Exon 22 c.3837 -2 A > T  
47-3 Exon 23 c.3915 -1 G > A  
39-1 * Exon 24 c.4133 +1 G > A  
            Rearrangements found by MLPA  
267-1 Del Exon 1 c.-198-?_85+? del 
36-3 Del Exon 1_2 c.-198-?_798+? del 
74-1 Del Exon 1_19 c.-198-?_3698+? del 
15-1 Del Exon 1_31 c.-198-?_+1150+? del 
41-3 Del Exon 1_31 c.-198-?_+1150+? del 
127-2  * Del Exon 2 c.86-?_798+? del 
252-1 Del Exon 12 c.2159-?_2283+? del 
253-1 Del Exon 31 c.5173-?_+1150+? del 
162-1 Dup Exon 1 c.-198-?_85+? dup 
 
Mutations in the EP300 gene 
Individual Exon Mutation  
254-1 Exon 10 c.1942 C>T R648X 
256-1 Exon 15 c.2877_2884 del 8 S959fsX966 
149-1 Del Exon 1 c.-1200-?_94+? del  
 
Table 1: List of all mutations found in the CBP gene, described in relation to GenBank file NM_004380, and EP300, 
GenBank file NM_001429.1, counting the A of the ATG start codon as nucleotide +1. The mutations are denoted 
according to the nomenclature as published by (den Dunnen and Antonarakis 2001). Del and dup means deletion and 
duplication; question marks indicate the breakpoints are unknown. The changes on DNA level have been confirmed by 
restriction digests or by second sequencing reactions. The changes on protein level listed here are predictions. All 
patients marked with an asterisk have mutations that have been published before in Kalkhoven et al. (2003) except for 
127-2, which has been described as a deletion in mRNA  by Petrij et al.(2000). 
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Large deletions and duplications at the CBP gene 
Previous research suggests that approximately 10% of the mutations of RSTS patients are 
microdeletions affecting the CBP gene (Blough et al. 2000; Petrij et al. 2000). We performed 
Fluorescent in situ Hybridization (FISH) using five cosmids spanning the entire gene to detect 
such deletions when metaphase chromosome spreads of patients are available (Petrij et al., 2000). 
The recently developed technique of Multiple Ligation-dependent Probe Amplification (MLPA) 
can also be used to detect microdeletions on soluble genomic DNA (Schouten et al. 2002). 
Because that is the type of material available to us for the majority of our patients we set up 
MLPA on the CBP gene. 
 
 E1278K  T1447I 
Hs: KKKNDTLDPEPFVDCKECG Hs: HFFRPRCLRTAVYHEILIG 
Mm: KKKNDTLDPEPFVDCKECG Mm: HFFRPRCLRTAVYHEILIG 
Dm: EKKNDHLELEPFVNCQECG Dm: HFFRPRQYRTAVYHEILLG 
209-1: KKKNDTLDPKPFVDCKECG 201-1: HFFRPRCLRIAVYHEILIG 
    
 Y1450H  H1470R 
Hs RPRCLRTAVYHEILIGIFH Hs VKKLGYVTGHIWACPPSEG 
Mm: RPRCLRTAVYHEILIGIFH Mm: VKKLGYVTGHIWACPPSEG 
Dm: RPRQYRTAVYHEILLGYMD Dm: VKQLGYTMAHIWACPPSEG 
260-1: RPRCLRTAVHHEILIGIFH 228-1: VKKLGYVTGRIWACPPSEG 
    
 R1664H   
Hs LLSCDLMDGRDAFLTLARD   
Mm: LLSCDLMDGRDAFLTLARD   
Dm: LLSCDLMDGRDAFLTLARD   
2644: LLSCDLMDGHDAFLTLARD   
 
Figure 1: Conservation of amino acids predicted to change by missense mutations. All five mutations that are predicted 
to change the amino acid residue that we have found are situated in the highly conserved HAT domain. The changed 
residues are conserved  in man (Homo sapiens), mouse (Mus musculus) and the fruit fly (Drosophila melanogaster). 
 
The resolution of MLPA is related to the number of probes one uses. We made a set of 20 MLPA 
probe pairs covering most of the CBP gene. This allows us to screen for deletions that cannot be 
detected by FISH. Southern blotting could have been an alternative but is in our case impractical, 
if not impossible, because it requires too much DNA. 
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 The quality of DNA is slightly more critical in MLPA than in a normal PCR, therefore, we could 
not screen all patients with MLPA that have been screened with DGGE and SSCP. In total we 
screened 53 patients and as controls we used material from 3 patients with known microdeletions 
already detected using FISH, including one with a deletion of the entire gene. Our MLPA analysis 
detected those positive controls flawlessly and we found a number of previously undetected 
mutations. In total we found 9 new deletions, ranging from single exon deletions to the entire 
gene. One deletion, of exon 2, has been described previously on RNA level (Petrij et al. 2000). At 
the time Southern blots did not reveal a deletion in the genomic DNA, therefore, it was not clear 
whether this was a genomic deletion or a splicing aberration. This mutation has been found in 
family 127, which consists of an affected mother and child, one of the very few cases of inherited 
RSTS. 
Next to the nine deletions we have detected we also found a duplication in one individual. Patient 
162-1 has a duplication of the first exon of the CBP gene. How this leads to the inactivation of 
this allele is not clear but a disease causing duplication of first exon has been described before in 
Opitz syndrome (Winter et al. 2003). 
The exon 1 deletions and duplication were confirmed using extra probe pairs, one at the promoter 
region and three probe pairs in intron 1. 
 
Mutations in the EP300 gene 
Point mutation screening and MLPA analysis of CBP yielded a total of 36 mutations in 92 
patients, suggesting that other genes could be involved in RSTS as well. The most likely 
candidate is the EP300 gene, coding for p300, on chromosome 22q13.1. That gene was screened 
as well, using the same approach. We used 37 DGGE fragments, covering approximately 79% of 
the coding sequence of EP300, with the remaining part was covered by 10 SSCP fragments. 
MLPA was performed with a set of 20 exon specific probe pairs.  
Indeed, 3 inactivating mutations were detected in the EP300 gene (see fig.2). Two mutations were 
found using DGGE: one mutation, in exon 10, is a transition (c.1942 C>T) that converts the 
triplet coding for the arginine at position 648 into a stop codon. The other mutation, in exon 15, is 
a deletion of 8 nucleotides that predicts a frameshift from codon 959 with a stop codon after 7 
amino acids. The exact location of the 8 bp deletion (c.2877_2884) was confirmed with an allele 
specific PCR. We analyzed DNA from the healthy parents of both patients with DGGE and 
sequencing and confirmed that the mutations occurred de novo. The biological parentage was 
confirmed by genotyping with 17 independent markers (data not shown). Both mutations lead to 
predicted proteins less than half their normal size, that do not contain the HAT domain. The third 
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mutation, a deletion of the first exon, was found using MLPA. Four probes revealed this deletion, 
two probes upstream of exon 1, one in exon 1 and the fourth in intron 1, close to the first exon. 
They all showed decreased signal whereas a probe in exon 2 showed a normal dosage (see fig.2c). 





DGGE        DGGE        Allele-specific 
PCR 
 
Figure 2: Mutations in EP300 in RSTS patients. (a) Patient 254-1. DGGE of patient 254-1 and the healthy parents 
shows that only the affected child has the mutation. Subsequent sequence analysis revealed a transition c.1942 C>T that 
predicts p.Arg648X in this patient. (b) Patient 256-1. DGGE of family 256 with patient 256-1 shows a de novo 
mutation. The allele specific PCR confirms the exact location of the deletion seen by sequence analysis. The patient has 
an 8 bp deletion (c.2877_2884 del) in the following sequence: gcctcctccatctactagtagCACAGAAGtgaat. The deleted 
region is indicated with capitals. The allele specific forward primer, consisting of the underscored nucleotides, skips the 
deleted part and anneals with 2 nucleotides after the deletion. Only  the PCR on DNA from the patient shows a band of 
168 bp, in the lanes with the PCR on DNA from the healthy parents only the prominently visible primer dimers can be 
seen. (c) Bar diagram of MLPA results for patient 149-1. MLPA reveals a deletion at the first exon of the EP300 gene. 
The bars indicate the dosage of the various probes used. The probes upstream of the first exon are at positions 787 to 
716 and 54 to 5 bp before the transcription start site. In the figure they are indicated as –787 and –54 respectively. Ex 
refers to exon and Int to intron. The Y-axis represents the dosage of DNA: a dosage of 1 indicates the presence of the 
normal amount of DNA, that is, both alleles are present, whereas bars reaching approximately 0.5 typically indicate a 
deletion of one allele. In the figure it can be clearly seen that the deletion runs from the upstream region of exon 1 into 





We undertook a rigorous screening for point mutations, small deletions or insertions as well as 
larger deletions and duplications in the coding region of the CBP gene on genomic DNA of a 
large set of RSTS patients. There is no predominant type of mutation, nor is there a clear 
indication for clustering of mutations within the CBP gene. If we take a look, however, at 
missense mutations we see that they are all situated in the HAT domain of CBP. We have 
published some of these mutations previously and have shown that they affect the HAT activity 
of CBP. In addition, two papers each reported a de novo missense mutation that is within the 
HAT domain, clearly underpinning the importance of this domain in relation to the disorder 
(Murata et al. 2001; Bartsch et al. 2002). A study by Coupry et al. reported 4 putative missense 
mutations, of which only one was located in the HAT domain (Coupry et al. 2002). The sequence 
variations were not found in the other patients, and the affected residues were conserved in 
mouse.  
We have found mutations in less than half of the patients, approximately 40%, which is 
comparable with the outcome of the study by Coupry et al. DGGE and SSCP analysis are, 
together with detection of nucleotide substitutions, only capable of identifying relatively small 
deletions and insertions. To detect larger deletions we chose to set up MLPA for the CBP gene 
and for EP300 as well. We have shown that MLPA is capable of detecting deletions in the CBP 
gene that were previously identified by FISH. Because we have probe pairs corresponding to the 
majority of exons in both CBP and EP300 our MLPA screening also negates the need for 
Southern blotting. The use of MLPA has increased the detection power for mutations, allowing us 
to find smaller deletions than could be detected with FISH.  
The combined analysis of our samples with both MLPA and DGGE or SSCP nevertheless 
resulted in mutations being found in less than half of the patients. Although some of the patients 
we screened could possibly have a different syndrome that resembles RSTS we think the majority 
should be considered as true RSTS patients. Diagnosis of the syndrome has been performed by 
many clinicians but we do not see that some have a significantly better record in number of 
mutations found than others. Either the CBP gene is mutated at parts where we did not screen, 
such as the promoter or other regulatory elements, or the mutations are in other genes. The 
unscreened parts of the CBP gene may harbor some mutations but it is highly unlikely they will 
contain the majority of the missing 60%. Indeed, RSTS is genetically heterogeneous since we 
identified mutations in the EP300 gene. 
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A striking finding in our study is that the number of RSTS patients with EP300 mutations, now 3, 
is small compared to the number of RSTS patients, 36, with CBP mutations. Possibly, this ratio of 
1 to 12 represents the different chances of mutations occurring in these two genes. Alternatively, 
the EP300 gene could have an equal mutation rate as the CBP gene but the carriers may not be 
diagnosed with RSTS. In view of this latter explanation it is interesting that we found many more 
polymorphisms in the EP300 gene including some that lead to amino acid changes (data not 
shown). Nevertheless, the majority of point mutations found in the CBP gene are likely to lead to 
truncated proteins and two mutations in the EP300 gene are also predicted to truncate the protein 
so it is difficult to explain the skewed ratio with a different genotype/phenotype relationship. We 
therefore think that there is a different mutation rate between the two loci. 
The CBP gene contains an unstable region around exon 2. This region was designated as unstable 
because all translocation and inversion breakpoints in RSTS patients, except for one, could be 
found there, as well as all leukemia breakpoints where CBP functions as a fusion partner. In 
addition, this same genomic piece of DNA proved very difficult to clone when the positional 
cloning of the RSTS syndrome gene took place (Giles et al. 1997). The deletion of exon 2 and the 
deletions and duplication of exon 1 may be caused by this unstable region. The instability in this 
region, however, cannot explain the majority of deletions found at the CBP locus as most of these 
deletions have their breakpoints elsewhere (Petrij et al. 2000). 
Although CBP and p300 are probably redundant to a large extent, there are subtle but clear 
differences between the two proteins. During embryogenesis the two genes have similar but not 
completely overlapping expression patterns (Partanen et al. 1999). In addition, experiments with 
F9 teratocarcinoma cell lines showed that retinoic acid signaling is p300 dependent and does not 
require CBP, whereas cAMP signaling depends on CBP and not p300 (Kawasaki et al. 1998; 
Ugai et al. 1999). Recent work with transgenic mice indicated the importance of the acetyl 
transferase function of p300 in myogenesis, but the acetyl transferase function of Cbp does not 
seem to be necessary for this process (Roth et al. 2003). The skeletal abnormalities found in 
heterozygous Cbp knockout mice have not been reported for heterozygous Ep300 knockout mice 
(Tanaka et al. 1997). We, however, do not see clear phenotypical differences in RSTS patients 
with mutations in the EP300 gene instead of the CBP gene. Patient 256-1 has a very short 
metatarsal bone (figure 3), not often seen in RSTS patients, however, similar dysmorphology has 
been found in a patient with a deleted CBP gene (Petrij et al. 1995). Double heterozygous 
knockout mice for the Cbp and Ep300 genes resemble the homozygous knockout mice for either 




Figure 3: Patient 256-1 overall has the typical appearance of an RSTS patient with the exception of the feet. These feet 
have an abnormally short metatarsal I bone, as can clearly be seen in the X-ray photograph. Although it is not a typical 
feature, it does appear in some other RSTS patients as well with mutations in the CBP gene. The photograph of the foot 
was taken when the patient was 6 years old whereas the X-ray was taken when the patient was 9 years old. Photographs 
courtesy of the patient’s parents. 
 
CBP and p300 are critical during development (Yao et al. 1998). Our finding supports this 
hypothesis and reveals that even a relatively small decrease of either protein has significant 
developmental consequences. It is, however, unclear how a decrease of either protein leads to the 
specific features of RSTS. Perhaps the partial loss of p300 is compensated for by recruitment of 
CBP and subsequent depletion of CBP than leads to RSTS. Alternatively, both proteins could be 
involved in a common function and, therefore, the total dosage is required to prevent a syndrome 
like RSTS. If so, then this common function has a relationship with the HAT activity of the 
proteins because loss of only the HAT activity of CBP causes RSTS.  
Interestingly, there is a direct link between HAT activity and long-term memory. Heterozygous 
Cbp knockout mice have diminished mental capabilities. Experiments on these knockout mice 
revealed that inhibiting histone deacetyltransferase could ameliorate the problems the mice have 
with their long-term memory (Alarcon et al. 2004). Transgenic mice with a dominant negative 
CBP gene, where only the HAT activity was ablated, also showed the long-term memory 
problems. Again, this could be reversed by a histone deacetylase inhibitor (Korzus et al. 2004). In 
view of these data it could be possible that other proteins with HAT activity, or with a function 
coupled to HAT activity, may also be involved in RSTS. After all, the three mutations we have 
found in the EP300 gene together with the CBP gene mutations still leaves us with more than half 
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L E T T E R S
There is uncertainty about the true nature of predicted single-
nucleotide polymorphisms (SNPs) in segmental duplications
(duplicons) and whether these markers genuinely exist at
increased density as indicated in public databases. We explored
these issues by genotyping 157 predicted SNPs in duplicons and
control regions in normal diploid genomes and fully homozygous
complete hydatidiform moles. Our data identified many true
SNPs in duplicon regions and few paralogous sequence variants.
Twenty-eight percent of the polymorphic duplicon sequences we
tested involved multisite variation, a new type of polymorphism
representing the sum of the signals from many individual
duplicon copies that vary in sequence content due to duplication,
deletion or gene conversion. Multisite variations can masquerade
as normal SNPs when genotyped. Given that duplicons comprise
at least 5% of the genome and many are yet to be annotated in
the genome draft, effective strategies to identify multisite
variation must be established and deployed.
Duplicons defined as being >1 kb with >90% similarity between
copies comprise at least 5% of the human genome1,2. Their minimal
extent has been defined3, but the public human genome draft portrays
duplicons neither accurately nor completely4–6. SNP databases report
that SNPs are over-represented by a factor of ∼ 2 in duplicon
regions3,7,8. This is a minimum value, as SNP discovery efforts discard
predicted variants from regions where densities are high or a duplicon
is suspected9,10. Many or most duplicon SNPs may be nothing more
than paralogous sequence variants (PSVs)3,7,8. Alternatively, gene con-
version in duplicons may generate allelic diversity and SNP con-
tent11,12. Additionally, reduced selective pressure in duplicons may
allow new mutations to increase in frequency more easily 13.
Initially, we undertook an in silico study of SNPs in duplicons to
search for informative features. We noted an increased gene density in
duplicons and observed that validated SNPs (65.2% of the dbSNP ver-
sion used) were under-represented in duplicons compared with non-
validated SNPs. Specifically, 3.7% (5.6% by two hit–two allele, 3.4% by
cluster, 1.9% by frequency) of valid SNPs versus 13.1% of nonvali-
dated SNPs reside in the 4.5% of the genome comprised of duplicons.
This could imply that duplicon SNPs are mostly PSVs, or it could
reflect the difficulty of doing experiments with nonunique sequences.
We therefore devised an experiment to resolve PSVs from real SNPs.
We used dynamic allele-specific hybridization (DASH)14, which gen-
erates a DNA melting curve by heating an oligonucleotide probe
duplexed with a PCR amplicon. Negative derivatives of these curves
allow for direct comparisons of allele ratios in heterozygotes. Sample
DNAs were from 16 normal Swedish females and 8 pathologically con-
firmed monospermic complete hydatidiform moles (CHMs)15. CHMs
are fully homozygous genomes that allow distinction between true
SNP alleles at a single genome locus (genotypes will always show single
alleles) and PSV signals originating from multiple sites (genotypes will
be ‘heterozygote-like’, including both alleles). The tested samples gave
98% power to detect alleles of 10% frequency16. We targeted 17 dupli-
cons (Table 1) that fell into four broad classes according to their repre-
sentation in the public genome assembly, their degree of sequence
similarity and whether they seemed to be multicopy by analysis of
whole-genome shotgun sequencing data (WSSD)3. We also included
two genome regions known to be unique. For each tested region, we
genotyped eight predicted SNPs that were outside known repeats as
detected by RepeatMasker17, as well as five other previously validated
true SNPs of random location.
We knew that DASH would convert 90–95% of all true SNPs to use-
able assays14, and we assumed that most copies of the duplicon targets
would be amplified in the PCR (given the high sequence similarities of
the tested duplicons). The derived results comprised various melting-
curve patterns (Fig. 1b) that correspond to specific genetic structures
(Fig. 1a). Overall, 107 markers were polymorphic and useable for our
investigation, including 13 control markers that gave genotypes con-
sistent with single-copy true SNPs (Fig. 2a). The 15 markers in dupli-
cons that lacked WSSD support likewise produced signals consistent
with true SNPs (Fig. 2a). This indicates that these unique genome
regions were inappropriately assembled, leaving them as apparent
duplicons in the public draft. It is estimated that >50% of duplicons
represented in the genome draft are not real3. As illustrated by our
data, SNP genotyping can provide an efficient means to identify these
for targeted resolution.
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L E T T E R S
Behavior of markers in WSSD-positive regions was substantially dif-
ferent from that of those in control regions (Fig. 2a,b). A full 91% (72
of 79) of duplicon assays gave apparent heterozygote signals in at least
one CHM. To interpret the various genotype patterns, we established a
classification schema (Table 2). Many duplicon markers behaved as
real SNPs, residing either in unique sequence (7 of 79, 8.9%) or in one
copy of a duplicon (32 of 79, 41%). This total (50%) equates to a SNP
density that is equivalent to the genome average, as duplicons are
enriched for predicted SNPs by a factor of 2 in public databases3,7,8. In
addition, and contrary to previous evidence3,7,8, only 23% (18 of 79)
of duplicon markers behaved as PSVs. The remaining 28% (22 of 79)
of predicted SNPs in duplicons were neither PSVs nor SNPs but gave
complex genotyping patterns that have not been described before. We
called this new form of polymorphism multisite variation (MSV).
When we assessed MSVs in CHMs, they generated either homozy-
gous genotypes, indicative of SNPs, or apparently heterozygous sig-
nals, indicative of PSVs, (Fig. 1b). Two such signals are combined in
diploid DNAs, and so MSVs gave genotypes in normal samples that
862 VOLUME 36 | NUMBER 8 | AUGUST 2004 NATURE GENETICS
Table 1  Target regions
Region WSSD NCBI Chrom ChromStart (bp) ChromEnd (bp) Size (bp) Name Dispersal
A Dup Unique 1 85,402,915 85,427,399 24,485 – Unknown
B Dup Unique 2 89,796,158 89,812,623 16,466 – Unknown
C Dup Unique 16 18,167,513 18,191,332 23,820 – Unknown
D Dup Unique 16 69,832,810 69,854,823 22,013 – Unknown
E Dup Dup <98% 7 75,865,780 75,891,118 25,339 – Intra
F Dup Dup <98% 9 85,988,721 86,012,093 23,373 – Inter
G Dup Dup <98% 10 46,657,428 46,672,624 15,197 – Intra
H Dup Dup <98% 11 88,972,901 88,996,892 23,992 – Intra
I Dup Dup <98% 16 32,022,851 32,039,556 16,706 – Inter
J Dup Dup >98% 8 7,161,589 7,293,710 132,121 8p23 Intra
K Dup Dup >98% 15 20,852,650 20,890,966 38,316 HERC2 Intra
L Dup Dup >98% 15 30,161,462 30,293,362 131,900 CHRNA7 Intra
M Dup Dup >98% 16 16,603,367 16,682,029 78,662 LCR16a Intra
N Dup Dup >98% 17 44,072,366 44,126,506 54,140 MS Intra
O Unique Dup >98% 1 57,845,958 57,856,075 10,117 – Intra
P Unique Dup >98% 11 133,555,034 133,578,684 23,650 – Intra
Q Unique Dup >98% 12 51,307,117 51,382,529 75,412 – Intra
R Unique Unique 16 21,560,883 21,636,826 75,943 – Unique
S Unique Unique 22 20,825,861 20,875,861 50,000 – Unique
T Unique Unique Various Random validated SNPs – Unique
Coordinates are from the July 2003 NCBI assembly. These comprise 17 duplicons and additional controls, covering a total of 1 Mb, taken from 12 different chromosomes. The
target regions were grouped into four broad classes: A–D, domains that are present uniquely in the NCBI assembly but that are indicated to be duplicons by WSSD; E–I, duplicated
domains in the NCBI assembly having 90–98% sequence similarity and WSSD support; J–N, duplicated domains in the assembly with >98% similarity and WSSD support; O–Q,
duplicated domains in the assembly with >98% similarity but no WSSD support. Regions R–T are unique control sequences.
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Figure 1 Genotyping patterns identifying evolutionary sequence states. (a) Evolutionary sequence changes from a monomorphic base to a
polymorphic MSV. Arrows depict processes such as mutation, fixation, duplication, deletion and gene conversion. Most events are reversible. (b)
Representative DASH genotyping patterns observed in normal and CHM samples for the corresponding structures in a. Each line shows the negative
derivative of the melting curve of a probe-target duplex for one DNA sample. The temperature on the x axis ranges from 45 to 75 °C. Peaks marked
by arrowheads indicate the presence of each particular allele as marked, with peak heights indicating the relative amount of each allele present in







































L E T T E R S
masqueraded as typical SNPs, but with variable allele ratios across
individuals. These patterns may be explained as the sum of individual
genotyping signals from various similar-sequence duplicon copies,
with those duplicons themselves varying in the population. This varia-
tion may be due to (i) duplicon copy-number differences that lead to
an increase, decrease or elimination of signals from different alleles
that reside on the inserted or deleted duplicon copies (Fig. 1a ; MSV1
pattern) or (ii) gene conversion events that lead to dispersion, mixing
and perhaps homogenization of single-base alternatives across the var-
ious copies of a duplicon (Fig. 1a; MSV2 pattern).
There is considerable evidence that gene conversion18,19 and copy
number variation20,21 are active in subsets of duplicons. To evaluate the
generality of these processes, we assessed sequences adjacent to 16 dis-
covered MSVs (in nine duplicons) and two control SNPs for copy-num-
ber variation using multiplex ligation-dependent probe amplification
(MLPA)22,23. We used another six control sequences for normalization.
No CHM had more than about ten copies of any interrogated sequence
(Supplementary Fig. 1 online), and there was considerable evidence for
copy-number variation in 50% (8 of 16) of cases (Table 3).
Furthermore, sequences close to MSVs with a larger number of different
allele ratios (as assessed by DASH) tended to report greater copy-num-
ber variability (Supplementary Fig. 2 online). Thus, MSVs are a conse-
quence (at least in part) of widespread duplicon copy-number variation.
This interpretation is supported by Fosmid end-mapping data (E.E.E.,
unpublished results) and studies of copy-number differences related to
disease6,20,21,24. Only some closely spaced markers showed correlated
MLPA ratios (Fig. 3), however, indicating that there is substantial
within-duplicon heterogeneity in this phenomenon.
Counting SNPs and MSVs together, at least two-thirds of predicted
duplicon SNPs in public databases are polymorphic rather than PSVs.
The one-third of these that are MSVs produce genotype patterns in
diploid samples very similar to those of SNPs, other than having (some-
times subtle) allele ratio variability in heterozygotes. Genotyping tech-
nologies will need to detect this allele ratio variability to reliably
identify MSVs. This raises a concern regarding whole-genome amplifi-
cation procedures, which may distort these allele ratios. In pooled
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Figure 2 Summarized genotyping results. (a) Marker results. Individual CHM
data, along with a single line summary (Real) of marker classification based
on data from the CHMs and the normal individuals. Purely qualitative
genotyping methods used on normal DNA could misinterpret SNPs in
duplicons as PSVs and MSVs as SNPs (Apparent), and only sometimes will
HWE considerations resolve the latter (HWD). Dup, duplicon. Regions A–T are
as described in Table 1. (b) Duplicon results. Whereas SNPs in duplicons are
the largest category in the >98% similar (presumably recent) duplicons, PSVs
are the biggest group in the <98% similar (presumably older) duplicons.MSVs
have a similar representation in these two duplicon classes. PSVs can thus be
viewed as a genetic remnant of duplicon sequence variation, representing the
path duplicons follow towards sequence divergence and uniqueness.
Table 2  Identification of genomic structures by analysis of DASH genotypes for CHMs and normal DNA
Genetic structure Material Number of alleles Genotypes Het. allele ratios Constraints
SNP DNA 1 or 2 M, H, m Fixed ratio –
CHM 1 or 2 M, m – –
SNP in duplication DNA 1 or 2 M, H 2 different ratios One DNA H ratio must match CHM ratio
CHM 1 or 2 M, H Fixed ratio
PSV DNA 2 H Fixed ratio Same H ratio in DNA and CHM
CHM 2 H Fixed ratio
MSV DNA 1 or 2 M, H, m Variable ratio –
CHM 1 or 2 M, H, m Variable ratio –
Samples are either homozygous with respect to one allele (M or m) or apparently heterozygous (H). Single-locus SNPs produce consistent homozygous and heterozygous signals in
normal individuals, and no heterozygotes in CHMs. For a true SNP present in one copy of a duplicon (SNP in duplicon), one of the alleles is additionally represented at the other
duplicon version(s), generating a heterozygote signal in one or more CHM. In normal DNA, these completely lack one homozygote pattern and generate two distinctive heterozygote
patterns with different allele ratios. PSVs render heterozygote signals of identical allele ratios in all tested samples. MSVs produce two or more heterozygote types in CHMs, three







































L E T T E R S
DNAs, because individual allele ratio information is lost, it will be
impossible to identify MSVs. To detect MSVs in routine practice,
CHMs or haploid genomes could be included in upstream assay valida-
tion routines. Mendelian inheritance tests might assist but will not be
effective for MSVs involving intrachromosomal duplicons.
Consideration of Hardy-Weinberg equilibrium (HWE) may help, but
analysis will not be fool-proof if the ‘single allele’ and ‘two allele’ hap-
loid signals for MSVs are consistent with HWE in the overall popula-
tion. Beyond MSVs, SNPs residing in one copy of a duplicon may also
be mis-scored, because the additional signal component from the non-
polymorphic duplicon would make one of the two homozygotes
appear to be a heterozygote.
How duplicon markers might be scored disregarding heterozygote
allele ratio differences (which many methods tend to do) and without
using CHMs is an important question. To explore this, we re-exam-
ined our total data set, ignoring these two pieces of evidence. This
analysis incorrectly indicated an abundance of PSVs in duplicons (Fig.
2a; consistent with previous interpretations3,7,8), with only half of the
apparent SNPs that were truly MSVs deviating from HWE (32 chro-
mosomes; P < 0.01). Consistent with this, as of April 2004, four of the
MSV markers we report are classified as experimentally validated
SNPs with genotype data in dbSNP. Additionally, one PSV is described
in current HapMap data, where it is listed as a monomorphic SNP.
In light of these considerations, we reviewed recent genotyping data
from our production facility, which uses DASH. We considered almost
800 markers from different studies that used various SNP selection cri-
teria, leaving 45 targets in duplicons. The initial validation (assessing
16–96 control individuals and considering HWE), identified 15
monomorphic single-allele signals and classified the remaining 30
markers as follows: 12 (40%) unique SNPs, 8 (27%) SNPs in one copy
of a duplicon, 4 (13%) PSVs and 6 (20%) MSVs. Five of the unique
SNPs had been used for production genotyping of 1,600–2,000 indi-
viduals, and only after observing several tens of heterozygote-like sig-
nals did it become clear that two of these were actually MSVs and
another was a SNP in a duplicon. For the two MSVs, if samples that
reported two alleles had been scored as heterozygotes (regardless of
allele ratios), then the total genotype data were in complete HWE (P =
0.115 and 0.357).
In conclusion, our study identifies MSVs as a new form of genome
polymorphism. Careful laboratory practice should often recognize
MSVs as aberrant markers, and MSVs may underlie the considerable
fraction of markers that fail HWE. But some MSVs are probably being
interpreted and used as unique SNPs, and HWE will not always iden-
tify these, even if large sample numbers are used. More generally,
MSVs (or rather duplicon copy-number variation and duplicon gene
864 VOLUME 36 | NUMBER 8 | AUGUST 2004 NATURE GENETICS
Figure 3 MLPA data for eight CHMs across three consecutive loci. These
span 3.4 kb on chromosome 16 (Table 1). The graph shows mean ± 2 s.e.m.
values across replicate experiments. For all three probes, CHMs 1 and 2
have ratios ∼ 50% higher than those of CHMs 3–6 (a 3:2 relative copy-
number difference). CHMs 7 and 8 are harder to classify because of a wider
spread between replicates, but they seem to overlap mostly with CHMs 1
and 2. This result is in full agreement with observed genotyping data, in that
the MLPA ratios correlate with the observed DASH heterozygote classes.


























Table 3  MLPA analysis of 16 MSVs and two single-copy reference sequences
Normalized MLPA ratios (triplicate means)
Nearest Dup. Copy-number
rs ID region CHM1 CHM2 CHM3 CHM4 CHM5 CHM6 CHM7 CHM8 s.d. variation
– Unique – 0.87 1.12 1.11 0.85 0.93 1.03 0.92 0.11 No
– Unique 0.93 0.89 1.1 1.09 0.93 0.98 1.03 1.06 0.08 No
394595 B 1.16 1.05 0.97 0.63 0.91 1.01 – 1.04 0.18 Yes
2910545 C 1.13 1.01 1.01 1.00 0.94 0.93 0.93 1.04 0.07 No
1057729 D 1.28 1.22 0.85 0.85 0.77 0.86 1.17 1.02 0.2 Yes
2868008 D 1.28 1.17 0.83 0.92 0.73 0.89 – 0.96 0.19 Yes
2868007 D 1.35 1.18 0.89 0.78 0.74 0.93 1.00 1.14 0.21 Yes
2690641 E 1.04 0.94 1.09 1.16 0.88 0.91 – 0.82 0.12 No
505235 F 1.03 1.02 1.04 0.98 0.96 0.96 0.94 1.06 0.04 No
1836885 H 1.01 0.98 0.94 0.96 1.11 0.93 0.92 1.16 0.09 No
964055 I 1.05 1.18 0.95 1.01 1.01 1.18 0.72 – 0.16 Yes
2939843 I 1.04 1.05 0.92 1.11 1.07 0.94 0.85 1.03 0.09 No
2684043 J 1.15 1.1 1.02 1.16 0.79 0.97 0.92 0.89 0.13 No
2740736 J 1.17 1.1 1.21 1.24 0.7 0.82 1.03 0.74 0.22 Yes
2740083 J 1.03 1.1 1.01 1.11 0.91 0.89 0.97 0.98 0.08 No
746659 J 1.37 1.3 1.00 – 0.73 0.83 0.95 0.78 0.25 Yes
296349 K 0.99 1.00 1.12 1.06 0.89 1.02 0.81 1.1 0.1 No
380880 K 0.75 1.26 1.05 0.86 1.00 1.08 0.93 1.08 0.15 Yes
Half of the MSV sequences show substantial evidence of copy-number variation. The remainder, including the two reference sequences, either have a fixed number of sequence







































L E T T E R S
conversion processes) might underlie some common phenotypic dif-
ferences between individuals. We therefore suggest that MSVs should
be specifically targeted for evaluation in disease and pharmacoge-
nomics research.
METHODS
In silico detection of SNP and duplicate region overlap. Duplicon regions
were as previously defined3, derived from alignments of sequence fragments
from the National Center for Biotechnology Information (NCBI) human
genome assembly2 combined with sequence read depth analysis of WSSD from
the Celera human genome assembly1. We downloaded duplication sequence
and June 2002 NCBI assembly locations from the human paralogy database.
We used the most complete SNP list available with June 2002 NCBI assembly
locations (dbSNP25 build 112; 2,337,575 SNPs) and updated the annotation
with data from dbSNP build 119. We downloaded gene lists from Ensembl26.
We loaded the locations into a MySQL database and identified overlaps of chro-
mosomal locations through SQL queries issued from a set of Perl scripts. Total
counts were nonredundant so that each SNP was counted only once in our
analysis, even if it mapped to multiple genome locations (duplicon paralogs).
We searched for any dbSNP annotations that might uniquely characterize
duplicon SNPs. We tested the following factors: (i) validation (by cluster, ‘SNP
discovered by at least two different methods’; by two hit–two allele, ‘SNP must
be observed twice, in two different DNA samples which must have produced
two alleles’; by frequency, ‘allele frequency data available for SNP’); (ii) source
(which discovery effort generated the SNP); and (iii) frequency of minor allele.
Map weight was excluded from consideration, as these SNPs are, by definition,
in repetitive sequence, and for any SNP in a duplicon with a map weight <2, the
map weight is due to the difference in alignment methods and scoring thresh-
olds between duplicon detection and SNP mapping.
DASH. We carried out DASH experiments, designed with DFold27 software,
using standard protocols as previously described14. Oligonucleotide sequences
for all assays are available on request. We carried out PCR reactions in 20-µl
volumes, containing 25–250 pg µl–1 of genomic DNA. We used DASH software
(Thermo Hybaid) to visualize denaturation events by plotting the negative
derivative of the fluorescence versus temperature profile. Genotypes were
scored manually and blindly. We reviewed independent duplicate experiments
for 25% of assays as a control for assay reproducibility and found scoring to be
consistent across runs. We assessed deviation from HWE for individual mark-
ers using the χ2 statistic (P < 0.01). We excluded 32% of assays across all regions
from analysis; 3.2% (5 of 157) assays produced no PCR product, and 29% (13
of 45) of those in nonduplicon regions (control regions plus falsely predicted
duplicons with support only from the public assembly) and 18% (20 of 112) of
those in real duplicons gave no indication of polymorphism. These percentages
were evenly distributed between different sources of SNPs (data not shown)
and are consistent with what is generally found for public database SNPs28.
Further, 4.4% (2 of 45) of assays in nonduplicon regions and 8.9% (10 of 112)
of those in real duplicons were of low quality, and many gave three distinct
allele signals. This is probably due to additional but uncharacterized sequence
variants in the probe hybridization region at positions other than that being
tested. This left 107 informative polymorphic assays covering all tested regions.
Complete genotyping information is available on request.
The number of tested DNA samples affects the certainty of classification.
Also, misclassifications may arise if a PCR does not amplify multiple duplicon
copies with similar or equal efficiency. We cannot estimate the cumulative size
of these biases, but both will tend to cause an overestimation of the number of
PSVs at the expense of MSVs and suggest monomorphic sites over SNPs, SNPs
over SNPs in duplicons and SNPs in duplicons over MSVs. Therefore, our PSV
estimate must be considered a maximum, and our MSV estimate a minimum.
MLPA. We designed MLPA probes based on consensus sequences derived from
global alignments of duplicated segments. Probes were localized in regions
immediately flanking MSV variants identified by the DASH experiment. To
avoid allelic discrimination and ensure specificity, no polymorphism or
sequence differences between duplicon copies were allowed within 6 bp on
either side of the ligation site (sequences available on request). The specific
priming sequences in the 5′ ends of the half-probes allowed multiplex amplifi-
cation with either the MLPA primers23 or the MAPH primers29. Resulting PCR
products had a minimal size difference of 2 bp, with the products ranging in
size from 80 bp to 125 bp. The forward primer of each pair was fluorescently
labeled (MLPAF-FAM or MAPHF-HEX), allowing probes to be distinguished
also on the basis of color. Each color set included three control probes from
known single-copy regions, for normalization purposes, and we added two
other single-copy probes to one of the sets as controls for copy-number varia-
tion. All oligonucleotides were combined in a single mix at a final concentra-
tion of 4 fmol µl–1.
We carried out the MLPA reaction essentially as described23. We heated 100
ng of DNA at 98 °C for 5 min. After cooling to 25 °C, we added 1.5 µl of probe
mix and 1.5 µl of SALSA hybridization buffer to each sample, denatured them
at 95 °C for 2 min and then hybridized them for 16 h at 60 °C. Ligation was
done at 54 °C by adding 32 µl of ligation mix. After 10–15 min, we stopped the
reaction by heat inactivation at 95 °C for 5 min. We carried out PCR amplifica-
tion for 30 cycles in a final volume of 25 µl. In addition to the reagents
described23, we added MAPH-F and MAPH-R to each PCR reaction to a final
concentration of 100 nM. From each PCR reaction, we mixed 1–2 µl of product
with 10 µl (Hi Di) of formamide and 0.1 µl of ROX 500 size standard (Applied
Biosystems) in a 96-well plate. We separated products by capillary elec-
trophoresis on the ABI 3700 DNA sequencer (Applied Biosystems).
MLPA data analysis. We retrieved peak data using GeneScan (Applied
Biosystems) and exported it to Excel (Microsoft) and SPSS 10 (SPSS) for fur-
ther analysis. We obtained signals for 84% (16 of 19) of designed assays. We
obtained a ratio for each of the working probes by dividing the height of the
corresponding peak by the sum of the heights of three control peaks of the
same color. We did three replicate experiments across all CHM samples, calcu-
lated the average value of the three ratios and discarded the results if the s.d.
was >20%. This eliminated 6 of 144 measurements (4.2%). We then normal-
ized the data for each probe around 1.0 by dividing by the average of the
remaining values.
URLs. The Human Paralogy Server is available at http://humanparalogy.gene.
cwru.edu/. The NCBI dbSNP is available at http://www.ncbi.nlm.nih.gov/SNP/.
The International HapMap Project is available at  http://www.hapmap.org/.
Note: Supplementary information is available on the Nature Genetics website.
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The work presented in this thesis describes the further development and application of two 
techniques for the detection of copy number changes in genomic DNA, namely Multiplex 
Amplifiable Probe Hybridization (MAPH) and Multiplex Ligation-dependent Probe 
Amplification (MLPA).  Both techniques allow the quantitative analysis of up to 50 loci in a 
single reaction. 
The initial work involved analysis of the DMD gene, mutations in which cause Duchenne and 
Becker Muscular Dystrophy (DMD/BMD). MAPH was used for the detection of deletions and 
duplications in Duchenne Muscular Dystrophy patients (Chapter 2.1). Using this approach several 
small duplications and deletions were identified. It is especially noteworthy that a duplication of 
exon 2 was described for the first time, yet is the single most common duplication found.  A 
further investigation of duplications in the DMD gene, using both MAPH and MLPA, is 
described in chapter 2.2.  Among several novel duplications found were several non-contiguous 
duplications and triplications, as well as a duplication that lead to a deletion at the mRNA level. 
Such cases emphasize the importance of screening all exons within the gene for rearrangements, 
and show that the reading-frame rule used for the prediction of disease progression has to be used 
with caution when duplications are involved. 
Although detecting the causative mutation is obviously critical for the patient, determining the 
carrier status of relatives is also important. This is made considerably easier when the mutation to 
look for has already been identified in the patient. We took advantage of this in developing a 
rapid approach for testing female relatives of affected patients (Chapter 2.3).  
There are many other forms of muscular dystrophy known. Among these are the recessive forms 
of the limb-girdle muscular dystrophies. In contrast to DMD/BMD, the mutation spectra of these 
diseases show that small mutations affecting only one or a few nucleotides are almost exclusively 
the cause of the disease. There are, however, situations when mutations can not be found at all, or 
only in one allele. In one such patient a single exon deletion was found in the sarcoglycan gamma 
(SGCG) gene. The same deletion had been described in two patients from another country, and 
breakpoint analysis showed the identical, complex rearrangement. The fact that this mutation 
segregated with the same haplotype in the three, unrelated individuals strengthened the argument 
for a common ancestor (Chapter 3). 
Although MAPH is ideally suited for the analysis of exonic deletions and duplications, it can also 
be applied to the detection of larger rearrangements. Such changes, known to be involved in 
developmental delay, were investigated in a cohort of patients with mental retardation. Along 
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with the expected changes involving the subtelomeric regions, several interstitial rearrangements 
were found (Chapter 4). The discovery of affected regions in these patients will hopefully lead to 
the identification of the genes responsible for the development delay. 
Given the relative simplicity of the assay, MLPA is becoming the technique of choice in 
diagnostic settings. A drawback of the technique, however, is the costly and time-consuming 
cloning required for generating probes. To circumvent this we developed a two color method 
using synthetic oligonucleotides only, and tested it by screening the EXT1 and EXT2 genes, 
involved in Hereditary Multiple Exostoses (HME). Using this we showed that partial gene 
deletions do occur in both genes, and account for 5-8% of all HME cases (Chapter 5.1). The same 
approach was also used to detect a deletion in the EP300 gene in a patient with Rubinstein-Taybi 
Syndrome (RSTS), showing for the first time that mutations in this gene also cause the disease 
(Chapter 5.2).  This simple manner of probe development should facilitate quantitative analysis of 
other genes in the future. 
It is known that ~5% of the genome is composed of duplicons, which are highly similar 
sequences present in more than one copy. These are difficult to characterize by sequencing, and 
complicate Single Nucleotide Polymorphism (SNP) analysis. A number of apparently SNP-
containing loci within these regions were analyzed by MLPA, which showed for several of the 
cases that differences seen between samples were the result of variations in copy number 
(Chapter 6). These multisite variants (MSVs) may appear as SNPs unless correctly analyzed, and 
application of techniques such as MLPA will be necessary to provide a clearer picture of the 
contribution of MSVs to genomic variation. Techniques such as MAPH and MLPA are therefore 
not only applicable to the search for intragenic deletions and duplications in disease, but also to 






Het onderzoek dat in dit proefschrift uiteengezet wordt beschrijft de verdere ontwikkeling en toepassing 
van twee technieken voor het detecteren van veranderingen in kopie aantal in genomisch DNA, namelijk 
Multiplex Amplifiable Probe Hybridisation (MAPH) and Multiplex Ligation-dependent Probe 
Amplification (MLPA). Beide technieken maken het mogelijk tot 50 loci kwantitatief te analyseren in één 
enkele reactie.  
Aanvankelijk richtte het onderzoek zich op de analyse van het DMD gen, waarin mutaties Duchenne en 
Becker spierdystrofie (DMD/BMD) veroorzaken. MAPH werd gebruikt voor de detectie van deleties en 
duplicaties in DMD patiënten (Hoofdstuk 2.1). Met deze aanpak werden meerdere kleine deleties en 
duplicaties gevonden. Het is vooral opmerkelijk dat voor het eerst een duplicatie van exon 2 werd 
gevonden terwijl dit de meest voorkomende duplicatie bleek te zijn. Een diepgaand onderzoek naar 
duplicaties in het DMD gen, gebruik makend van zowel MAPH als MLPA, is beschreven in hoofdstuk 
2.2. Onder de verschillende nieuwe duplicaties die werden gevonden bevonden zich ook enkele niet-
aaneengesloten duplicaties en triplicaties, als ook een duplicatie die leidt tot een deletie in het mRNA. 
Zulke gevallen benadrukken het belang van het screenen van alle exonen in het gen voor 
herrangschikkingen, en tonen aan dat de leesraam regel voor het voorspellen van ziekte verloop 
voorzichtig gebruikt moet worden wanneer het duplicaties betreft. 
Hoewel het detecteren van de onderliggende mutatie uiteraard essentieel is voor de patiënt, is het bepalen 
van eventueel dragerschap van familieleden ook zeer belangrijk  Dit is een stuk eenvoudiger indien de 
mutatie waarnaar gezocht moet worden in de patiënt reeds is gevonden. We hebben hiervan gebruik 
gemaakt voor het ontwikkelen van een snelle aanpak voor het testen van vrouwelijke familieleden van 
aangedane patiënten (Hoofdstuk 2.3). 
Er zijn vele andere vormen van spierdystrofie bekend. Hieronder bevinden zich de recessieve vormen van 
limb-girdle spierdystrofieën. In tegenstelling tot DMD/BMD, tonen de mutatie spectra dat kleine mutaties 
van één of enkele nucleotiden vrijwel de enige oorzaken zijn van deze ziekten. Er zijn echter gevallen 
waarbij geen enkele mutatie gevonden kan worden, of in slechts één van de twee allelen. In één zo’n 
patiënt werd een deletie gevonden van een heel exon in het sarcoglycan gamma (SGCG) gen. Dezelfde 
deletie was eerder beschreven in twee patiënten uit een ander land, en breukpunt analyse toonde dezelfde, 
complexe herrangschikking. Het feit dat deze mutatie overerft met hetzelfde haplotype in deze drie niet-
verwante individuen versterkt het argument voor het bestaan van een gezamenlijke voorouder (Hoofdstuk 
3). 
Hoewel MAPH bij uitstek geschikt is voor de analyse van exon deleties en duplicaties, kan het ook 
gebruikt worden voor het detecteren van grotere herrangschikkingen. Zulke veranderingen die een rol 
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spelen in vertraging van de ontwikkeling werden onderzocht in een group patiënten met mentale 
retardatie. Naast de verwachtte veranderingen van de subtelomere gebieden werden verschillende 
herrangschikkingen in de gebieden daartussen gevonden (Hoofdstuk 4). Het ontdekken van aangedane 
gebieden in deze patiënten leidt hopelijk tot de identificatie van genen die verantwoordelijk zijn voor de 
ontwikkelings achterstand. Dankzij de relatieve eenvoud van de analyse wordt MLPA de techniek van 
keuze  in de diagnostiek. Een nadeel van de MLPA techniek is echter dat het kloneren van de benodigde 
probes duur en tijdrovend is. Om dit te omzeilen hebben we een twee kleuren methode ontwikkeld waarbij 
we alleen gebruik maken van synthetische oligonucleotides, deze methode hebben we uitgeprobeerd door 
de EXT1 en EXT2 genen te screenen die een rol spelen bij Erfelijke Multiple Exostosen (HME). Hiermee 
hebben we aangetoond dat gedeeltelijke gen deleties in beide genen voorkomen, en verantwoordelijk zijn 
voor 5-8 % van alle HME gevallen (Hoofdstuk 5.1). Dezelfde methode werd ook gebruikt om een deletie 
in het EP300 gen in een patiënt met Rubinstein-Taybi Syndroom (RSTS) aan te tonen, hiermee voor het 
eerst aantonend dat mutaties in dit gen ook deze ziekte veroorzaken (Hoofdstuk 5.2).  Deze eenvoudige 
methode van probes maken zou de kwantitatieve analyse van andere genen in de toekomst moeten 
vereenvoudigen. Het is bekend dat ~5 % van het genoom bestaat uit duplicons, dit zijn sterk 
overeenkomstige sequenties die in meer dan één kopie aanwezig zijn. Deze zijn moeilijk te analyseren 
door middel van sequencen en bemoeilijken Single Nucleotide Polymorphism (SNP) analyses. Een aantal 
schijnbaar SNP bevattende plaatsen in deze gebieden werden geanalyseerd met MLPA, waarmee werd 
aangetoond dat in meerdere gevallen de verschillende patronen tussen monsters te wijten waren aan 
verschillen in kopie aantal (Hoofdstuk 6). Deze ‘multisite variants’ (MSVs) kunnen zich voordoen als 
SNPs tenzij ze correct worden geanalyseerd, waarbij toepassing van een techniek zoals MLPA 
noodzakelijk is om een beter beeld te krijgen van de bijdrage van MSVs aan genoom variatie.  
Technieken zoals MAPH en MLPA zijn daarom niet alleen geschikt voor het zoeken naar deleties en 
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